

US 20210395372A1

(19) United States (12) Patent Application Publication (10) Pub. No.: US 2021/0395372 A1

VIGNA et al.

(54) ANTI-MET FAB-FC FOR THE TREATMENT **OF A TUMOR AND/OR METASTASIS**

- (71) Applicant: METIS PRECISION MEDICINE SB S.R.L., Torino (IT)
- (72) Inventors: Elisa VIGNA, Villarbasse (Torino) (IT); Cristina BASILICO, Pavarolo (Torino) (IT); Tiziana CREPALDI, Torino (IT); Paolo Maria COMOGLIO, Arignano (Torino) (IT)
- (21) Appl. No.: 17/283,482
- (22) PCT Filed: Oct. 7, 2019
- (86) PCT No.: PCT/EP2019/077116 § 371 (c)(1), Apr. 7, 2021 (2) Date:

(30)**Foreign Application Priority Data**

Oct. 9, 2018 (IT) 102018000009282

Dec. 23, 2021 (43) **Pub. Date:**

Publication Classification


(51)	Int. Cl.	
Č,	C07K 16/28	(2006.01)
	A61P 35/00	(2006.01)
	A61P 35/04	(2006.01)
	C07K 16/46	(2006.01)

(52) U.S. Cl. CPC C07K 16/2863 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); C07K 16/462 (2013.01); A61P 35/04 (2018.01)


(57)ABSTRACT


An anti-Met antibody fragment comprising a single antigen binding arm and an Fc region, wherein the antigen binding arm is defined by the variable regions having amino acid sequences as set forth in SEQ ID No.: 7, 8 and wherein the anti-Met antibody fragment is useful in the treatment of a tumor and/or metastasis.

Specification includes a Sequence Listing.



-Fig.





0.94

0.94

hOA-DN30-cl04H08 0.686 ± 0.149 0.967 ± 0.035

hOA-DN30-cl03H08 0.859 ± 0.196 0.557 ± 0.021

A

R square	0,97	66'0	66'0	0,99	
Bmax (AU)	1.303 ± 0.029	2.189 ± 0.017	0.568 ± 0.012	2.041 ± 0.025	
(Mn) by	0.262 ± 0.037	0.325 ± 0.016	35.99±2.381	0.273 ± 0.021	
	Human	Rat	Mouse	Monkey	







Fig. 2/cont





C

Patent Application Publication








Fig. 3

hOA-DN30- cl03E08 (200 nM)







hOA-DN30- cl03H08 (200 nM)



hOA-DN30- cl03G05 (200 nM)



CTRL








MvDN30 (200 nM)


DN30 mAb (200 nM)

HGF (8 ng/ml)









0.91

115726±311.2

1

0.94

52310±7.68

0.95

2381±1.31


hOA-DN30-cl03G05

hOA-DN30-cl03F04

hOA-DN30-cl03H08

hOA-DN30-cl04H08

N/A*





hOA-DN30-cl03E08

GTL-16

14.97% 4.92%

Patent Application Publication









Fig. 7/cont




HGF+ hOA-DN30-cl03E08 + DecoyMET^{K842E}

HGF + hOA-DN30-cl03E08

CTRL

HGF









Fig. 10


















Seq. ID N°7: VL-cl03E08 humanized
METDTILLWVLLLWVPGSTGDIVLTQSPDSLAVSLGQRATINCKASQ SVDYDGGSY MSWFQQKPGQPPKLL
IYAASNLESGVPARFSGSGSGTDFTLTISSLQAEDVATYYCQQSYEDPLTFGGGTKVEIK
Seq. ID N°8: VH-cl03E08 humanized
MGWSYIILFLVATATDGHSQVQLQQSGAEVKKPGASVKLSCKAS GYTFTSYW IHWVRQAPGQGLEWIGE IN
PSSGRT NYNEKFKNRVTVTVDKSTSTAYMELSSLTSEDSAVYYC ASRGY WGQGTTLTVSS
Seq. ID N°9: human CL
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSST
LTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
Seq. ID N°10: human CH1

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTV

PSSSLGTQTYICNVNHKPSNTKVDKKV

Seq. ID N°11: First Fc (Knob mutation)
E PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAK
TKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKN
QVSL w CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
HYTQKSLSLSPGK
Seq. ID N°12: Second Fc (Hole mutations)
MGWSYIILFLVATATDGHSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVK
FNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ
VYTLPPSRDELTKNQVSL S CAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFL V SKLTVDKSRWQQG

NVFSCSVMHEALHNHYTQKSLSLSPGK

Seq. ID N°14: DecoyMet mutation K842E -TAGS

LNEEDLQKVAEYKTGPVLEHPDCFPCQDCSSKANLSGGVWKDNINMALVVDTYYDDQLISCGSVNRGTCQRH RRLKETKDGFMFLTDQSY1DVLPEFRDSYP1KYVHAFESNNF1YFLTVQRETLDAQTFHTR1IRFCS1NSGL HSYMEMPLECILTEKRKKRSTKKEVFNILQAAYVSKPGAQLARQIGASLNDDILFGVFAQSKPDSAEPMDRS AMCAFPIKYVNDFFNKIVNKNNVRCLQHFYGPNHEHCFNRTLLRNSSGCEARRDEYRTEFTTALQRVDLFMG QFSEVLLTSISTFIKGDLTIANLGTSEGRFMQVVVSRSGPSTPHVNFLLDSHPVSPEVIVEHTLNQNGYTLV GGTRLTICGWDFGFRRNNKFDLKKTRVLLGNESCTLTLSESTMNTLKCTVGPAMNKHFNMSIIISNGHGTTQ Y S T F S Y V D P V I T S I S P K Y G P M A G G T L T L T G N Y L N S G N S R H I S I G G K T C T L K S V S N S I L E C Y T P A Q T I S T E F RSNSEIICCTTPSLQQLNLQLPLKTKAFFMLDGILSKYFDLIYVHNPVFEPFEKPVMISMGNENVLEIKGND IDPEAVKGEVLKVGNKSCENTHLHSEAVLCTVPNDLLKLNSELNTEWKQAISSTVLGKVIVQPDQNFTASGA MKAPAVLAPGILVLLFTLVQRSNGECKEALAKSEMNVNMKYQLPNFTAETPIQNVILHEHHIFLGATNYIYV VFPHNHTADIQSEVHCIFSPQIEEPSQCPDCVVSALGAKVLSSVKDRFINFFVGNTINSSYFPDHPLHSISV ITGKKITKIPLNGLGCRHFQSCSQCLSAPPFVQCGWCHDKCVRSEECLSGTWTQQICLPAIYKVFPNSAPLE AVKLKIDLANRETSIFSYREDPIVYEIHPTKSFISGGSTITGVGKNLNSVSVPRMVINVHEAGRNFTVACQH AWSHPQFEKGAAWSHPQFEKGAAWSHPQFEKGAAHHHHH

ANTI-MET FAB-FC FOR THE TREATMENT OF A TUMOR AND/OR METASTASIS

FIELD OF THE INVENTION

[0001] The present disclosure concerns a novel antibodyderived therapeutic agent for the treatment of a tumor and/or metastasis.

BACKGROUND

[0002] Cancer is a genetic disease in which somatic endogenous genes undergo mutations. Only a handful of genes-known as oncogenes and tumor suppression genes-are altered in cancer cells and drive tumorigenesis. The activated oncogenes are accelerators and the inactivated tumor suppressor genes are missing brakes for cancer cell growth. Subsequent to the discovery of cancer-causing mutated genes, a new concept emerged for oncogenes: the "oncogene addiction", which indicates that a cancer cell, despite its abundance of genetic alterations, is still dependent on a single oncogenic protein for its sustained proliferation or survival. Therefore, new therapeutic inroads were undertaken to develop "target therapy" to cure cancer. In the last 20 years, pharmacological targeting of proteins encoded by cancer-causing mutated genes-through chemical drugs or antibodies-has represented the forefront armamentarium to eliminate the mutated cells and combat cancer disease. Target therapies promise to be more effective than conventional cytotoxic chemotherapies, often with fewer side effects. However, only the patients bearing in their tumors the altered specific target gene are likely to benefit from target therapy. Thus, personalized medicine is required in parallel to assess the druggable genetic lesions through comprehensive genomic profiling of the patient tumor.

[0003] The MET oncogene encodes for a unique receptor tyrosine kinase endowed with pleiotropic functions. When genetically altered (by point mutations, gene fusion, translocation, and/or amplification), MET initiates transformation of the cells by virtue of its ability to activate the invasive growth program. Thus, MET genetic lesions leading to constitutive Met kinase hyperactivation initiate and maintain the transformed phenotype ("MET addiction")¹.

[0004] MET genetic lesions occur in most solid tumors with an overall frequency of 1-4% and are able to upregulate its kinase activity¹. Point mutations are concentrated in domains critical for Hepatocyte Growth Factor (HGF) ligand binding or receptor signalling (SEMA domain, juxtamembrane domain, and catalytic domain). Most recently, next-generation sequencing revealed exon 14 splice site mutations in 3% of non-small cell lung cancers², which lead to exon skipping and deletion of the juxtamembrane region of the MET transcript, where a serine residue (Ser985) negatively regulates the Met kinase activity³ and a tyrosine residue (Tyr1003) is required for Met internalization and degradation⁴.

[0005] In the "invasive growth" program elicited by MET, the proliferative response is coupled with migration, survival, extracellular matrix degradation, and induction of cell polarity⁵. These biological responses are strived by cells to adapt to adverse conditions and/or escape to find a more convenient environment. In a hostile context, Met is over-expressed—via transcriptional upregulation—by a variety of stimuli such as hypoxia, inflammatory cytokines, pro-angiogenic factors, mitogens and even HGF itself. Lastly,

Met is overexpressed in conditions of radiation-induced DNA damage and contributes to resistance to radiotherapy by promoting activation of DNA repair and evasion of programmed cell death of cancer cells.

[0006] Several Met-targeting molecules have been developed to erase the hyperactive Met signalling in a selective, robust, and highly effective manner. These drugs include: HGF antagonists (either blocking antibodies or decoys), mAbs targeting the Met receptor, and chemical tyrosine kinase inhibitors (TKIs). Anti-Met mAbs potentially represent a major step in the battle against the cancers driven by MET. Nowadays, four anti-Met mAbs have entered early clinical trials: MetMab (Onartuzumab, Roche), LY2875358 (Emibetuzumab, Eli Lilly & Company), ARGX-111 (Argenx), SAIT301 (Samsung) and Sym015 (Symphogen A/S), a mixture of two antibodies. They act by blocking HGF binding to MET in a competitive fashion (Onartuzumab, ARGX-111) and/or downregulating MET (Emibetuzumab, SAIT301, Sym015).

[0007] The murine DN30 mAb (disclosed in WO 2007/ 090807) is an IgG2A which binds the extracellular domain of the human Met receptor and induces only some of the Met-triggered biological effects⁶. It partially activates receptor phosphorylation due to its bivalent nature which allows simultaneous binding to two distinct antigen molecules, resulting in stabilization of receptor complexes in a fashion similar to that achieved by natural ligands. This unwanted partial agonistic activity on Met was not observed in the monovalent DN30 Fab fragment (MvDN30)⁷. Conversion of the bivalent DN30 parental antibody into the monovalent Fab fragment unleashes the therapeutic potential of the DN30 anti-Met antibody, leading to a full antagonist molecule. However, the short half-life of the Fab, due to its low molecular weight, is a severe limitation for the deployment in therapy. The present inventors thus developed new engineered molecules called DCD (Dual Constant Domain Fab) characterized by the duplication of the constant domains present in the DN30 Fab: DCD-1, in which the duplication was done in tandem, and DCD-2, in which the constant domains of the light and heavy chain were reciprocally swapped (disclosed in WO 2014/108829). Both the new recombinant molecules show biochemical properties in vitro comparable to the original Fab, acting as full Met antagonists. In vivo, upon systemic administration, the new recombinant molecules reduce Met-addicted tumor growth. DCD-1 and DCD-2 show a pharmacokinetic profile improved over the original DN30 Fab, nevertheless none of two reach the behavior comparable to the mAb of origin⁸. [0008] It has been previously reported that conversion from bivalent to a monovalent form of an antibody can be reached also by deleting-trough a molecular engineering approach-one of the two antibody arms (disclosed in WO 2005/063816). Data reported an improvement in the in vivo stability of the molecule, mainly due to the activity of the Fc domain, which binds the Fc receptor expressed in the organs.

SUMMARY OF THE INVENTION

[0009] The object of this disclosure is to provide a novel anti-tumor agent derived from a monoclonal antibody useful in the treatment of oncologic patients, namely the DN30 monoclonal antibody.

[0010] According to the invention, the above object is achieved thanks to the subject matter recalled specifically in

the ensuing claims, which are understood as forming an integral part of this disclosure.

[0011] The present invention concerns an anti-Met antibody fragment comprising a single antigen binding arm and an Fc region, wherein the Fc region comprises a complex of a first and a second Fc polypeptide. The antibody fragment comprises:

[0012] (i) a first polypeptide comprising one humanized light chain variable (VL) domain, and one human light chain constant (CL) domain, wherein the humanized light chain variable (VL) domain is fused to the human light chain constant (CL) domain in the N- to C-term direction, and wherein the humanized light chain variable (VL) domain contains three complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID No.: 1, 2 and 3, and wherein the humanized VL domain has an amino acid sequence as set forth in SEQ ID No.: 7;

[0013] (ii) a second polypeptide comprising one humanized heavy chain variable (VH) domain, one human heavy chain constant CH1 domain and the first Fc polypeptide, wherein the first Fc polypeptide comprises one human hinge region, one human constant CH2 domain and one human constant CH3 domain, wherein the humanized heavy chain variable (VH) domain is fused to the human heavy chain constant CH1 domain, that is fused to the human hinge region, that is fused to the human constant CH2 domain, that is fused to the human constant CH3 domain in the N- to C-term direction, and wherein the humanized heavy chain variable (VH) domain contains three complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID No.: 4, 5 and 6, and wherein the humanized VH domain has an amino acid sequence as set forth in SEQ ID No.: 8;

[0014] (iii) a third polypeptide comprising the second human Fc polypeptide, wherein the second human Fc polypeptide comprises one hinge region, one human constant CH2 domain and one human constant CH3 domain, wherein the hinge region is fused to the human CH2 constant domain that is fused to the human CH3 constant domain in the N- to C-term direction, wherein the hinge region is truncated at the N-terminus.

[0015] The improved therapeutic properties of the above described antibody fragment are dependent from the structure of the variable regions, and are not simply due to the monovalent form of the antibody and/or the presence of the Fc region.

[0016] The present invention also concerns a product comprising, in a single bottle or in two bottles, (a) the anti-Met antibody fragment as defined above, and a pharmaceutically acceptable vehicle, and (b) an extracellular portion of human Met and a pharmaceutically acceptable vehicle, wherein the extracellular portion of human Met is capable of binding to Hepatocyte Growth Factor (HGF) in a stable manner and contains at least one amino acid mutation within the epitope recognized by the anti-Met antibody fragment to prevent binding of the anti-Met antibody fragment thereto.

BRIEF DESCRIPTION OF THE DRAWINGS

[0017] The invention will now be described in detail, purely by way of an illustrative and non-limiting example and, with reference to the accompanying drawings, wherein: [0018] FIG. 1: Schematic representation of the DN30 antibody and its monovalent derivatives. (A) the original

murine bivalent mAb; (B) MvDN30, the chimeric Fab; (C) chOA-DN30, the chimeric monovalent 'One-Arm' antibody; (D) hOA-DN30, the humanized monovalent 'One-Arm' antibody; (E) The OA-DN30 antibodies were subjected to SDS-PAGE under reducing and not reducing conditions. The gel was stained with Gel Code blue.

[0019] FIG. 2: Binding to Met of the monovalent DN30derived molecules. (A) ELISA binding analysis of MvDN30, chOA-DN30, hOA-DN30 antibodies (liquid phase) to a human Met-Fc chimera (solid phase). (B) ELISA binding analysis of hOA-DN30-cl03E08 (liquid phase) to Met-Fc chimera (solid phase); Met of human, murine, rat, monkey origin were included in the assay. Binding was revealed using anti-human k chain antibodies. O.D.: Optical Density; AU: arbitrary units. Each point is the mean of triplicate values; bars represent standard deviations. Tables below the graphs report Kd values, binding maximum values (Bmax), and the fitting score (R^2) . (C) Flow-cytometer analysis of hOA-DN30-cl03E08 binding to Met expressed at the surface of a panel of cell lines derived from different species (EBC-1, human lung cancer; C2C12 mouse muscle myoblasts; H9C2 rat cardiac myoblasts; MDCK dog kidney cells; Cos-7 monkey kidney cells). The new molecules bind to human Met-Fc with high affinity; the antibody cross-reacts with human, rat, dog, and monkey Met.

[0020] FIG. **3**: Agonistic activity of the monovalent DN30-derived molecules. Scatter assay. HPAF-II cells were incubated for 24 hrs with the indicated concentration of HGF (Met ligand), DN30 mAb (partial agonist), MvDN30 (full antagonist) and the chimeric or humanized One-Arm antibodies. All the DN30-derived monovalent molecules do not induce cell scattering, a Met-mediated biological response.

[0021] FIG. 4: Met shedding and down-regulation in cells treated by the monovalent DN30-derived molecules. A549 cells were incubated for 48 hrs in serum free medium with the indicated increasing concentration of MvDN30, chOA-DN30, or hOA-DN30 derivatives. Total Met levels were determined by Western blot analysis of cell extracts using anti-Met antibodies. The detected bands correspond to the mature form of the receptor (p145 Met). As a loading control, the filter was probed with an unrelated protein (vinculin). Met shedding was determined by Western blot analysis of conditioned medium using anti-Met antibodies. The detected bands correspond to the shed extracellular domain of the receptor (p80 Met ectodomain). The table reports pixel intensity quantification of each western blot band normalized on the corresponding vinculin signal, as measured by densitometry with ImageJ software. All the monovalent One-Arm antibodies downregulate Met and induce Met shedding.

[0022] FIG. **5**: Inhibition of Met-activation by the monovalent DN30-derived molecules. GTL-16 (MET-addicted cells carrying a constitutively active Met due to receptor over-expression sustained by MET gene amplification) were incubated for 24 hrs in serum free medium plus hOA-DN30 or chOA-DN30 antibodies (1000 or 250 nM). Met activation was determined in total cell lysates by Western blotting with anti-Met antibodies specific for the phosphorylated Tyr^{1234/} 1235 Met residues, the major phosphorylation site. The same blot was re-probed with anti-Met antibodies. To control protein loading, the filter was also probed with anti-vinculin antibodies. Chimeric and humanized One-Arm antibodies inhibit Met phosphorylation. **[0023]** FIG. 6: Vitality of MET-addicted cells treated with the monovalent DN30-derived molecules. GTL-16 human gastric carcinoma cells were plated in 96 well plates in 10% FCS medium. After 24 hrs, cells were treated with increasing concentrations of MvDN30, chOA-DN30, or hOA-DN30 antibodies for a further 72 hrs. Number of cells was evaluated by Cell titer-glo. The plot represents the percentage of alive cells with respect to untreated control. Each point is the mean of triplicate values. The table reports the calculated IC₅₀ values and the fitting score (\mathbb{R}^2). One-Arm molecules inhibit cell growth of MET-addicted cells.

[0024] FIG. 7: Proliferation and death of MET-addicted cells induced by treatment with the monovalent DN30derived molecules. (A) Proliferation assay: GTL-16 human gastric carcinoma cells were plated in 6 well plates in 10% FCS medium. After 24 hrs, cells were treated with a fixed concentration (1 µM) of MvDN30, chOA-DN30, or hOA-DN30-cl03E08 for a further 48 hrs. EdU (10n µM) was then added to the culture medium for a further 2 hrs. Percentage of cells in S phase was determined by cytofluorimeter analysis following the procedure of the ClicK-iT EdU Flow Cytometry assay. The plots represent the cells negative and positive for the APC staining (EdU+, S phase cells). Table reports percentage of cells in S phase. (B) Cytotoxicity Assay: GTL-16 human gastric carcinoma cells were plated in 96 well plates in 10% FCS medium. After 24 hrs, cells were treated with increasing concentrations of MvDN30, chOA-DN30, or hOA-DN30-cl03E08 for a further 48 hrs. Cell cytotoxicity was evaluated by Cell-Tox green assay. The graphs represent the increment of cytotoxicity respect to untreated control. Each point is the mean of triplicate values. The table reports the calculated EC_{50} values, and the fitting score (R²). One-Arm molecule efficiently block proliferation and induce cytotoxicity in MET-addicted cells.

[0025] FIG. **8**: HGF-induced cell motility in cells treated with hOA-DN30-cl03E08. HPAF-II cells were pre-treated for 18 hrs with the indicated concentrations of hOA-DN30-cl03E08 alone or in combination with DecoyMet^{K842E} (same amount as hOA-DN30-cl03E08) and then incubated for 24 hrs with HGF (6.25 ng/ml). hOA-DN30-cl03E08 inhibits HGF-induced cell motility; the combination with DecoyMet^{K842E} more efficiently counteracts the cell response.

[0026] FIG. 9: Invasion of cells treated with hOA-DN30cl03E08. HPAF-II cells were plated in the upper chamber of transwell filters coated with matrigel in serum free medium with 0.5 μ M of hOA-DN30-cl03E08 alone or in combination with 1 μ M of DecoyMet^{K842E}. Medium with HGF (25 ng/ml) was added in the lower chamber. After 24 hrs, cells that migrated on the lower part of the filter were evaluated by staining and microscope observation. hOA-DN30cl03E08 inhibits HGF-induced cell invasion; the combination with DecoyMet^{K842E} blocks the biological response.

[0027] FIG. **10**: Modulation of PD-L1 expression by hOA-DN30-cl03E08. GTL-16 cells were treated with 50 ng/ml of IFN-gamma alone or in combination with 250 nM of hOA-DN30-cl03E08. After 48 hrs, cells were lysed; PD-L1 expression and Met activation on total protein extracts were evaluated by Western blot. As a loading control, filters were probed with anti-GAPDH antibodies.

[0028] FIG. **11**: Pharmacokinetic profile in vivo of MvDN30, DN30 mAb, and hOA-DN30-cl03E08. Immunodeficient mice were injected intravenously with a single dose $(100 \ \mu g)$ of MvDN30, DN30 mAb, or hOA-DN30. Peripheral blood was collected at different time points. Serum concentrations of the therapeutic molecules were measured by ELISA. Graph represents the amount of circulating molecules as a function of time. Samples are in triplicate; bars represent standard deviations.

[0029] FIG. 12: Inhibition of MET-addicted tumor growth in vivo by treatment with the monovalent DN30 derivatives. 1×10^{6} GTL-16 MET-addicted gastric carcinoma cells were inoculated in the flank of immune-deficient NOD-SCID mice. When the tumors reached an average volume of 68.4 ± 5.4 mm³, mice were randomized in 4 homogeneous groups and treated with 30 mg/kg of MvDN30, chOA-DN30, or hOA-DN30-cl03E08 by intravenous injection 2 times per week. As a control, a group was treated with the same volume of PBS (Vehicle). Tumor growth was monitored periodically with a caliper. After 15 days, mice were sacrificed. (A) Kinetics of tumor growth; (B) Tumor volumes at the end of the experiment reported as percentage of the untreated group. hOA-DN30-cl03E08 inhibits METaddicted tumor growth more efficiently than the chOA-DN30.

[0030] FIG. **13**: Dose-response inhibition of MET-addicted tumor growth in vivo by hOA-DN30-cl03E08 treatment. 1×10^6 GTL-16 MET-addicted gastric carcinoma cells were inoculated in the flank of immunodeficient NOD-SCID mice. After 8 days, the tumors reached an average volume of 80.7±2 mm³ and the mice were randomized in 5 homogeneous groups and treated with increasing concentrations of hOA-DN30-cl03E08 by intravenous injection. As a control, a group was treated with the same volume of PBS (Vehicle). Tumor growth was monitored periodically with a caliper. After 17 days, mice were sacrificed, and the tumors were excised and weighted. (A) kinetics of tumor growth; (B) Tumor weights. hOA-DN30-cl03E08 inhibits MET-addicted tumor growth with a dose-response profile.

[0031] FIG. 14: Amino acid sequences of VL, VH, CL and CH1 domains of chOA-DN30 and hOA-DN30-cl03E08 antibodies. The Complementary Determining Regions sequences are highlighted by a bold, underlined character. [0032] FIG. 15: Amino acid sequences of the first and the second Fc polypeptides of OA-DN30. The amino acid mutations within the CH3 domains of the first and second Fc polypeptides—necessary for generating the knob and the hole, respectively,—are highlighted by a bold, underlined character.

[0033] FIG. **16**: Amino acid sequence of the mutated form of DecoyMet. The amino acid mutation K842E is highlighted by a bold, underlined character.

DETAILED DESCRIPTION OF THE INVENTION

[0034] In the following description, numerous specific details are given to provide a thorough understanding of the embodiments. The embodiments can be practiced without one or more of the specific details, or with other methods, components, materials, etc. In other instances, well-known structures, materials, or operations are not shown or described in detail to avoid obscuring aspects of the embodiments.

[0035] Reference throughout this specification to "one embodiment" or "an embodiment" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the phrases "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments.

[0036] The headings provided herein are for convenience only and do not interpret the scope or meaning of the embodiments.

[0037] The instant disclosure concerns a novel therapeutic agent for the treatment of a tumor and/or metastasis.

[0038] It is estimated that more than 200,000 patients per year are "MET-addicted", and Met inhibition may potentially result in remission of the disease. Considering that mutations accumulate with aging and over the next 20 years the ageing population will increase, the burden of cancer is expected to rise and to have a high impact on global healthcare resources for patients' management. Genetic alterations responsible for "MET-addiction" have been found in gastric, oesophageal, colorectal, renal, and lung carcinoma, melanoma, and brain tumors (see COSMIC database: www.sanger.ac.uk). Moreover, selection of MET genetic lesions has been found as an acquired mechanism of resistance to a number of other targeted therapies in colorectal and non-small cell lung cancer (NSCLC)⁹.

[0039] The role of Met in metastasis is also associated with the ability of Met in helping cells to adapt to a harsh environment. The metastatic capabilities driven by Met not only depend on genetic and epigenetic alterations, but also on paracrine secretion of HGF by tumor stromal tissue which is composed by a large variety of cell types, including fibroblasts, resident epithelial cells, pericytes, myofibroblasts, vascular and lympho-vascular endothelial cells, and infiltrating cells of the immune system.

[0040] Met is nowadays recognized as a cancer-specific target for: (i) personalized treatment of tumors with MET mutations/amplifications ('addicted to MET'); (ii) for prevention/reversion of Met-driven primary and secondary resistance to other targeted cancer therapies; and (iii) for prevention/reversion of Met-driven invasive/metastatic phenotype¹.

[0041] The DN30 inhibitory activity lies on its ability to promote the physiological activity of the metalloprotease ADAM-10 acting at the cell surface¹⁰, which releases from the plasma membrane the intact extracellular portion of the receptor (Met-shedding), followed by the rapid degradation of the Met intracellular kinase domain¹¹. As a consequence of these processes, Met is physically removed from the cell surface and the extracellular domain acts as soluble 'decoy', preventing ligand binding by sequestering HGF. Thus, the advantage of DN30 is to inhibit both HGF-dependent and HGF-independent activation of Met¹².

[0042] As compared with other anti-Met antibodies, DN30 blocks the receptor functions by a unique mechanism that rise to different and synergic activities: (i) removal of Met from the cell surface by 'shedding' of the ectodomain; (ii) sequestration of the HGF ligand; (iii) inhibition of the homoor hetero-dimerization of Met receptor at the membrane; (iv) stimulation of receptor degradation. Thus, DN30 offers the opportunity to kill two birds with one stone, allowing optimal blockade of the Met pathway, as it can potentially act not only on cancer cells but also on the tumor microen-vironment (HGF-driven biological responses of endothelial cells, fibroblasts, and macrophages). **[0043]** The present invention relies on the idea that, to reach the highest therapeutic potential against a tumor by means of an anti-Met antibody, it is mandatory to apply a molecule that: i) is not eliciting, even also in part, intracellular responses evoked upon Met activation, i.e. is not an agonist or a partial agonist; ii) impairs Met activation through a mechanism of action different from ligand (HGF) displacement; iii) has a favorable pharmacokinetic profile, suitable for deployment in the clinic; iv) reasonably does not exert immune-response in humans. To fulfill all the above considerations, the inventors converted the murine DN30 antibody—that blocks Met activation by a shedding mechanism—into a fully humanized, monovalent and highly stable molecule, by formatting it in the "One-Arm" form, named in the following as "hOA-DN30".

[0044] In an embodiment, the present invention concerns an anti-Met antibody fragment comprising a single antigen binding arm and an Fc region, wherein the Fc region comprises a complex of a first and a second Fc polypeptide. The antibody fragment comprises, preferably consists of:

[0045] (i) a first polypeptide comprising, preferably consisting of, one humanized light chain variable (VL) domain, and one human light chain constant (CL) domain, wherein the humanized light chain variable (VL) domain is fused to the human light chain constant (CL) domain in the N- to C-term direction, and wherein the humanized light chain variable (VL) domain contains three complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID No.: 1, 2 and 3, and wherein the humanized light chain variable (VL) domain has an amino acid sequence as set forth in SEQ ID No.: 7;

[0046] (ii) a second polypeptide comprising one humanized heavy chain variable (VH) domain, one human heavy chain constant CH1 domain and the first Fc polypeptide, wherein the first Fc polypeptide comprises one human hinge region, one human constant CH2 domain and one human constant CH3 domain, wherein the humanized heavy chain variable (VH) domain is fused to the human heavy chain constant CH1 domain, that is fused to the human hinge region, that is fused to the human constant CH2 domain, that is fused to the human constant CH3 domain in the N- to C-term direction, and wherein the humanized heavy chain variable (VH) domain contains three complementary determining regions (CDRs) having the amino acid sequences set forth in SEQ ID No.: 4, 5 and 6, and wherein the humanized heavy chain variable (VH) domain has an amino acid sequence as set forth in SEQ ID No.: 8;

[0047] (iii) a third polypeptide comprising, preferably consisting of, the second human Fc polypeptide, wherein the second human Fc polypeptide comprises, preferably consists of, one human hinge region, one human constant CH2 domain and one human constant CH3 domain, wherein the hinge region is fused to the human CH3 constant domain, that is fused to the human CH3 constant domain in the N- to C-term direction, wherein the hinge region is truncated at the N-terminus.

[0048] In one embodiment, the human light chain constant (CL) domain is a human light kappa type domain.

[0049] In one embodiment, the human hinge region and the human constant domains CH1, CH2 and CH3 are from a human IgG1.

[0050] In one embodiment, the two Fc polypeptides are linked through intermolecular disulfide bonds at the hinge region.

[0051] In one embodiment, the first Fc polypeptide and the second Fc polypeptide meet at an interface, and one between the first and the second Fc polypeptide comprises a knob at the interface, and the other between the first and the second Fc polypeptide comprises a hole at the interface, wherein the knob is positionable into the hole.

[0052] In a preferred embodiment, one between the first and the second Fc polypeptide comprises a mutated CH3 constant domain, wherein the mutated CH3 constant domain carries an amino acid mutation at position 389, wherein the original amino acid at position 389 has been mutated to import an amino acid having a larger side chain volume than the original amino acid, so as to create a knob at the interface between the Fc polypeptides; and wherein the other between the first and the second Fc polypeptide comprises a mutated CH3 constant domain, wherein the mutated CH3 constant domain carries three amino acid mutations at positions 389, 391 and 438, wherein the original amino acids have been mutated to import amino acids having smaller side chain volumes than the original amino acids, so as to create a hole at the interface between the Fc polypeptides, wherein the knob is positionable into the hole, and wherein the amino acid numbering is according to the EU numbering scheme of Kabat (pp. 688-696 in Sequences of proteins of immunological interest, 5th ed., Vol. 1, 1991; NIH, Bethesda, Md.). [0053] In a still preferred embodiment, the original amino acids at positions 389, 391 and 438 are threonine, leucine and tyrosine respectively; and wherein in one between the first and the second Fc polypeptide the threonine in position 389 has been mutated to tryptophan; and wherein in the other between the first and the second Fc polypeptide the threonine at position 389 has been mutated to serine, the leucine at position 391 has been mutated to alanine and the tyrosine at position 438 has been mutated to valine.

[0054] In a preferred embodiment, the human light chain constant (CL) domain has an amino acid sequence as set forth in SEQ ID No.: 9 and the human heavy chain constant CH1 domain has an amino acid sequence as set forth in SEQ ID No.: 10.

[0055] In a preferred embodiment, the first human Fc polypeptide has an amino acid sequence as set forth in SEQ ID No.: 11, and the second human Fc polypeptide has an amino acid sequence as set forth in SEQ ID No.: 12.

[0056] In an embodiment, the present invention concerns an isolated nucleic acid encoding the anti-Met antibody fragment as disclosed above.

[0057] In an embodiment, the present invention concerns a composition comprising two or more recombinant nucleic acids which collectively encode the anti-Met antibody fragment as disclosed above.

[0058] The anti-Met antibody fragment disclosed herein when bound to Met induces shedding of the extracellular domain of Met. The anti-Met antibody fragment when bound to Met does not exert an agonistic activity towards Met. The anti-Met antibody fragment when bound to Met inhibits Met phosphorylation. The anti-Met antibody fragment when bound to Met further blocks proliferation and induces cytotoxicity in MET-addicted cells. The anti-Met antibody fragment when bound to Met further inhibits cell motility and cell invasion induced by Hepatocyte Growth Factor (HGF). The aforementioned properties of the anti-Met antibody fragment with anti-tumor and/or anti-metastasis activity.

[0059] The expression "antigen binding arm", as used herein, refers to a component part of an antibody fragment of the invention that has an ability to bind specifically a target molecule of interest. The antigen binding arm is a complex of variable domain sequences (VL and VH), including the CDRs and the Frame Regions of an immuno-globulin light and heavy chain, and constant domain sequences (CL and CH) of an immunoglobulin light and heavy chain.

[0060] "Humanized" forms of non-human (e.g., murine) antibodies are non-natural recombinant antibodies that contain minimal amino acid residues derived from non-human immunoglobulin. For the most part, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a hypervariable region of the recipient (i.e. the Complementarity Determining Regions—CDRs) are replaced by residues from a hypervariable region of a non-human species (donor antibody) having the desired specificity, affinity, and properties. In some instances, framework region (FR) residues of the human immunoglobulin can be replaced by corresponding non-human residues.

[0061] Furthermore, humanized antibodies may comprise residues that are not found in the recipient antibody or in the donor antibody. These modifications are made to further refine antibody performance. In general, the humanized antibody will comprise two variable domains, in which all or substantially all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the Frame residues (FRs) are those of a human immunoglobulin sequence. The humanized antibody also comprises a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin. For further details, see¹³⁻¹⁵. See also the following review articles and references cited therein:¹⁶⁻¹⁸.

[0062] The term "Fc region", as used herein, generally refers to a dimer complex comprising the C-terminal polypeptide sequences of an immunoglobulin heavy chain, wherein a C-terminal polypeptide sequence is that which is obtainable by papain digestion of an intact antibody. The Fc region may comprise native or variant Fc sequences. Although the boundaries of the Fc sequence of an immunoglobulin heavy chain might vary, the human IgG1 heavy chain Fc sequence is usually defined to stretch from an amino acid residue included between Asp 234 and Thr 238, to the carboxyl terminus of the Fc sequence according to the EU numbering scheme of Kabat. The Fc sequence of an immunoglobulin generally comprises one hinge region, two constant domains, a CH2 domain and a CH3 domain, and optionally comprises a CH4 domain. By "Fc polypeptide" herein is meant one of the polypeptides that make up an Fc region. The Fc region increases stability of the antibody fragment compared to a Fab molecule comprising an antigen binding arm.

[0063] The "hinge region", "hinge sequence", and variations thereof, as used herein, includes the meaning known in the art, which is illustrated in, for example, Janeway et al., Immuno Biology: the immune system in health and disease, (Elsevier Science Ltd., NY) (4th ed., 1999) and in^{19,20}.

[0064] The phrase "truncated hinge region", as used herein, refers to a polypeptide comprising parts, but not all, of a hinge sequence. The truncated hinge region is capable of linkage to the "first" Fc polypeptide. If the wild type hinge sequence is not present, the remaining sequence in the "second" Fc polypeptide would comprise a component that

is capable of linkage to the "first" Fc polypeptide. For example, said component can be a modified residue or an added cysteine residue capable of forming a disulfide linkage.

[0065] A "knob" refers to at least one amino acid side chain which projects from the interface of a first Fc polypeptide and is therefore positionable in a compensatory hole in the adjacent interface (i.e. the interface of a second Fc polypeptide) so as to stabilize the heteromultimer, and thereby favor heteromultimer formation over homomultimer formation, for example. The knob may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, a nucleic acid encoding the interface of the first polypeptide is altered to encode the knob. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the interface of the first polypeptide is replaced with nucleic acid encoding at least one "import" amino acid residue which has a larger side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue. The upper limit for the number of original residues which are replaced is the total number of residues in the interface of the first polypeptide.

[0066] A "hole" refers to at least one amino acid side chain which is recessed from the interface of a second Fc polypeptide and therefore accommodates a corresponding knob on the adjacent interface of a first Fc polypeptide. The hole may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). Normally, nucleic acid encoding the interface of the second polypeptide is altered to encode the hole. To achieve this, the nucleic acid encoding at least one "original" amino acid residue in the interface of the second polypeptide is replaced with nucleic acid encoding at least one "import" amino acid residue which has a smaller side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue. The upper limit for the number of original residues which are replaced is the total number of residues in the interface of the second polypeptide.

[0067] The knob is "positionable" into the hole which means that the spatial location of the knob and hole on the interface of a first Fc polypeptide and second Fc polypeptide respectively and the sizes of the knob and hole are such that the knob can be located into the hole without significantly perturbing the normal association of the first and second polypeptides at the interface. Since knobs do not typically extend perpendicularly from the axis of the interface and have preferred conformations, the alignment of a knob with a corresponding hole relies on modeling the knob/hole pair based upon a three-dimensional structure such as that obtained by X-ray crystallography or nuclear magnetic resonance (NMR). This can be achieved using widely accepted techniques in the art.

[0068] The expression "non-agonist activity" of the anti-Met antibody fragment as used herein refers to the anti-Met antibody fragment that does not exert any activity that elicits, even also in part, cellular responses evoked upon Met activation. The non-agonistic activity of the anti-Met antibody fragment can be measured by the evaluation of the Met level of phosphorylation by conventional techniques such as western blot, immunofluorescence, immunohistochemistry, ELISA, cytofluorimeter analysis or any other method that includes the use of an antibody that recognizes specifically Met, or the Met residues $Tyr^{1234-1235}$ if phosphorylated (i.e. the major phosphorylation site of Met^{21}), or the Met residues $Tyr^{1349/1356}$ if phosphorylated (i.e. the docking site of Met^{22}) upon incubation of the cells with the said non-agonist antibody. As an alternative, the evaluation of cellular biological responses upon antibody treatment compared to the responses induced by HGF treatment can be applied.

[0069] The present invention further concerns a product comprising, in a single bottle or in two bottles, (a) the anti-Met antibody fragment as disclosed herein, and a pharmaceutically acceptable vehicle, and (b) an extracellular portion of human Met and a pharmaceutically acceptable vehicle, wherein the extracellular portion of human Met is capable of binding to Hepatocyte Growth Factor (HGF) in a stable manner and contains at least one amino acid mutation within the epitope recognized by the anti-Met antibody fragment to prevent binding of the anti-Met antibody fragment thereto.

[0070] In an embodiment, the extracellular portion of human Met contains SEMA, PSI, IPT-1, IPT-2, IPT-3 and IPT-4 domains.

[0071] In a preferred embodiment, the extracellular portion of human Met has an amino acid sequence as set forth in SEQ ID No.: 13, wherein at least one of the amino acids between position 797 and position 875 of SEQ ID No.: 13 is mutated in order to prevent binding of the anti-Met antibody fragment thereto.

[0072] In a more preferred embodiment, the extracellular portion of human Met has the amino acid sequence set forth in SEQ ID No.: 14.

[0073] The present description also concerns a nucleic acid molecule encoding the extracellular portion of human Met capable of binding to Hepatocyte Growth Factor (HGF) in a stable manner and containing at least one amino acid mutation within the epitope recognized by the anti-Met antibody fragment to prevent binding of the anti-Met antibody fragment thereto, preferably the extracellular portion of human Met having the amino acid sequence set forth in SEQ ID No.: 14.

[0074] As used herein, the expression "the extracellular portion of human Met is capable of binding to human HGF in a stable manner" means that the extracellular portion of human Met binds to HGF with a calculated Kd not higher than 100 nM.

[0075] The expression "the extracellular portion of human Met contains at least one amino acid mutation at the epitope recognized by the anti-Met antibody fragment", as used herein, means the presence of one or more mutations (i.e. amino acid substitutions and/or deletions and/or insertions) within the extra-cellular portion of Met, able to induce a modification within the extra-cellular portion of Met that prevents the engagement of the above region by the anti-Met antibody variable domains. The skilled man in view of his common general knowledge (represented i.a. by the possibility to generate a cDNA including a single nucleotide change in a given DNA sequence using specific primers during DNA duplication; see Maniatis T. Molecular cloning: A laboratory manual Cold Spring Harbor Laboratory, 1982) does not need further details about the realization of a mutated form of the extracellular portion of human Met retaining the ability to bind to human HGF but not to the anti-Met antibody fragment. The present invention must not therefore be interpreted as encompassing only the mutated

extra-cellular portion of human Met as disclosed herein (i.e. SEQ ID No.: 14), since the skilled man in view of the common general knowledge can produce further mutated versions of the extra-cellular portion of human Met having SEQ ID No.: 13 that prevent the bind of the anti-Met antibody thereto.

[0076] The terms "SEMA", "PSI", "IPT-1", "IPT-2", "IPT-3" and "IPT-4" refer to the Met domains constituting the extracellular region of Met. Such domain names belong to the common general knowledge of a skilled man as represented i.a. by^{23,24}. SEMA domain is a protein interacting module in common with semaphorins and plexins encompassing the region comprised between amino acids 25-516 of Met (SEQ ID No.: 13); PSI is a domain in common with Plexins, Semaphorins, and Integrins encompassing the region comprised between amino acids 519-561 of Met (SEQ ID No.: 13); the IPT domain-repeated four times-is a region Immunoglobulin-like in common with Plexins and Transcription factors, encompassing the region comprised between amino acids 563-934 of MET (SEQ ID No.: 13). In detail, IPT repeat 1 covers the amino acid positions 563-656 of SEQ ID No.: 13, IPT repeat 2 covers the amino acid positions 657-740 of SEQ ID No.: 13, IPT repeat 3 covers the amino acid positions 741-837 of SEQ ID No.: 13, IPT repeat 4 covers the amino acid positions 838-934 of SEQ ID No.: 13.

[0077] The present invention further concerns the therapeutic use of the anti-Met antibody fragment as disclosed herein, optionally in combination with an extracellular portion of human Met as disclosed herein, for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein the patient carries genetic alterations of the MET gene.

[0078] The present invention further concerns the therapeutic use of the anti-Met antibody fragment as disclosed herein in combination with an extracellular portion of human Met as disclosed herein for use in the treatment of a patient suffering from a tumor and/or metastasis, wherein the patient carries a wild-type MET gene.

[0079] In one aspect, the invention provides a method of treating a tumor and/or metastasis in a subject, said method comprising administration to the subject of an effective amount of the anti-Met antibody fragment, optionally in combination with an extracellular portion of human Met, whereby said condition is treated.

[0080] In one aspect, the invention provides a method of inhibiting the growth of a cell that expresses Met, said method comprising contacting said cell with the anti-Met antibody fragment disclosed herein, optionally in combination with an extracellular portion of human Met of the invention, thereby causing an inhibition of growth of said cell.

[0081] In one aspect, the invention provides a method of therapeutically treating a mammal having a cancerous tumor and/or metastasis, said method comprising administration to said mammal of an effective amount of the anti-Met antibody fragment disclosed herein, optionally in combination with an extracellular portion of human Met, thereby effectively treating said mammal.

[0082] In one aspect, the invention provides a method for treating a cell proliferative disorder, said method comprising administration to a subject in need of such treatment of an effective amount of the anti-Met antibody fragment object of the present disclosure, optionally in combination with an

extracellular portion of human Met, thereby effectively treating or preventing said cell proliferative disorder.

[0083] In one aspect, the invention provides a method of therapeutically treating a tumor and/or metastasis in a mammal, wherein the growth of said tumor is at least in part dependent upon a growth potentiating effect of the Met/HGF system, as the consequence of either an increase in cell proliferation, a protection from apoptosis, or both. Said method comprises contacting a tumor cell with an effective amount of the anti-Met antibody fragment, optionally in combination with an effective amount of an extracellular portion of human Met of the invention, thereby effectively treating said tumor and/or metastasis.

[0084] The tumor, that can be effectively treated with the anti-Met antibody, optionally in combination with an extracellular portion of human Met, is selected from breast, colorectal, lung, colon, pancreatic, prostate, ovarian, cervical, central nervous system, renal, hepatocellular, bladder, gastric, head and neck tumor cell, papillary carcinoma (e.g. the thyroid gland), melanoma, lymphoma, myeloma, glioma/glioblastoma (e.g. anaplastic astrocytoma, multiforme glioblastoma, anaplastic oligodendroglioma, anaplastic oligodendroastrocytoma), leukemia cell, sarcoma, rhabdomyosarcoma, or a tumor from a Cancer of Unknown Primary origin (CUP).

[0085] In one embodiment, a cell that is therapeutically targeted in a method of the invention is a hyperproliferative and/or hyperplastic cell. In one embodiment, a cell that is targeted in a method of the invention is a dysplastic cell. In yet another embodiment, a cell that is targeted in a method of the invention is a method of the invention is a Meterpressing cell belonging to the microenvironment sustaining the tumor and/or the metastasis.

[0086] The present inventors demonstrated that the One-Arm structure, obtained by selected point mutations of the CH3 domain and resulting in efficient Fc heterodimerization, originates an antibody into a monovalent form.

[0087] Monovalency is essential to avoid the eventual agonistic activity of the DN30 due to the bivalent native structure of the antibody.

[0088] Unexpectedly and surprisingly the present inventors discovered that one of the humanized One-Arm format of the DN30 (i.e. hOA-DN30-cl03E08) displays strong inhibitory properties in vitro and in vivo.

[0089] In vitro hOA-DN30-cl03E08 shows a superior activity as compared to the corresponding chimeric form (named in the following as "chOA-DN30") and to all the other humanized One-Arm derivatives herein disclosed (named "hOA-DN30 antibodies") (see Material and Methods section for a detailed description of all the One-Arm antibodies derived from DN30). Unexpectedly hOA-DN30cl03E08 binds to Met with a higher affinity as compared to the other OA-DN30 antibodies tested, either chimeric or human. Unpredictably, the inventors found that the shedding response is potentiated by increasing the affinity of the DN30 antibody for Met. Consequently, the inhibition of Met activation, measured as amount of phosphorylated Met receptors, was stronger. These activities translate into a repression of Met-mediated biological responses. Impairment of MET-addicted tumor cell growth occurs at very low dose; the hOA-DN30-cl03E08 IC₅₀ is the lowest among all those measured for the OA-DN30 antibodies included in the analysis, either chimeric or human. A better inhibition of tumor cell growth can be due to a more extensive block of cell proliferation, and/or to a more pronounced increment of cytotoxicity.

[0090] The hOA-DN30-cl03E08 shows improved therapeutic potential also in vivo. This is expected if the comparison is done with MvDN30, a molecule that, due to its low molecular weight, is subjected to high kidney clearance. The poor pharmacokinetic properties of MvDN30 considerably affect the performance of the molecule in the in vivo experimental models.

[0091] One can consider that reaching a molecular weight higher than the cut-off of renal clearance is per se sufficient to elicit the best therapeutic response, but this is not the case. In fact, the results obtained with the DCD-1 and DCD-2 derivatives of the DN30 mAb—recombinant molecules with increased size with respect to MvDN30—clearly show that the pharmacokinetic profile is only partially improved and the therapeutic response is limited to a reduction of the tumor growth rate⁸.

[0092] The superior activity of the hOA-DN30-cl03E08 can in part be due to the presence of the Fc region that generates differences in the tissue/organ distribution of the antibody due to the binding to the Fc Receptor, thus providing a highly favourable pharmacokinetic profile.

[0093] The positive aspects related to the in vivo stability due to the presence of the Fc region have been already discussed and disclosed during Onartuzumab application. This is an anti-Met antibody designed in the One-Arm format²⁵. Nevertheless this antibody is produced in bacteria, thus is not glycosylated. Consequently, it lacks the ability to activate Antibody Dependent Cellular Cytotoxicity (ADCC) and/or Complement Dependent cytotoxicity (CDC). On the contrary, hOA-DN30-cl03E08 is produced in mammalian cells and therefore, it must be considered fully able to elicit Fc effector functions.

[0094] hOA-DN30-cl03E08 is different from Onartuzumab also for the mechanism of action. While the first antibody induces Met receptor shedding, wiping out Met from the cell surface and sponging HGF in the extracellular environment, the second one competes with HGF for Met binding. As result, hOA-DN30 inhibits Met independently from the mechanisms that sustain the aberrant activation of the onco-receptor, while Onartuzumab is effective only in the cases of ligand-dependent activation.

[0095] The presence of the Fc region cannot be responsible of the notable improvement of the therapeutic response in vivo obtained by the hOA-DN30-cl03E08, as this domain is present in all the humanized and chimeric One-Arm antibody tested. What the humanized and the chimeric One-Arm antibodies do not share are the variable regions, in which lies the binding site of the antibodies. In particular, the DN30 CDRs-identical in all the derivatives-are inserted in the frame regions. These parts of the antibody, even if not directly involved in the formation of the binding pocket, include particular amino acids, called Vernier residues²⁶, that could influence the final conformation of the CDR structures and therefore could determine the final affinity of the antibody for the antigen. The DN30 CDRs in combination with the frame sequences, i.e. the sequences of the heavy and light variable domains, of the cl03E08 originate an anti-Met antibody with a stronger affinity probably because the sequence combination generates a binding pocket fitting better with the corresponding epitope on the Met receptor. A more robust interaction between the antibody and Met further implements the shedding of the receptor and the consequent impairment of Met-mediated biological responses. This, conjugated with the improved plasma stability due to the One-Arm format, gives rise to an antibody—i.e. the cl03E08—with unexpected superior activity against MET-addicted/driven cancers.

[0096] Data reported in Basilico et al.²⁷ show that concomitant targeting of both HGF and Met gives rise to a higher therapeutic robustness in the treatment of tumors and/or metastasis. The experimental data witnessed herein unexpectedly show that inhibition of the MET/HGF axis by means of hOA-DN30 in combination with DecoyMet^{K842E} is superior to the one obtained upon the application of MvDN30 in combination with DecoyMet^{K842E}. In fact,

comparing the results obtained in the invasion assay (here reported in FIG. 9) with the ones published in Basilico et al.²⁷, hOA-DN30 abrogates the HGF-driven invasion of cancer cells, while a residual activity is still present if MvDN30 is part of the combination.

[0097] Cancer cells without MET genetic alterations exploit the 'physiological' program triggered by the MET oncogene as an 'expedient' to boost the malignant phenotype and to unleash the invasive metastatic phenotype in response to stress conditions such as hypoxia, ionizing radiation or chemotherapy. 'Expedience' requires stimulation of wild-type MET by its ligand HGF. The data provided herein show that, in conditions of MET 'expedience', a concomitant intervention hitting both sides of the MET/ HGF axis results in improved inhibitory activity. The hOA-DN30-cl03E08 induces the physical removal of MET from the cell surface by 'shedding' of the ectodomain. The latter is released in the extracellular environment and acts as 'decoy' for HGF. Exogenous supply of recombinant DecoyMet reinforces the HGF-sequestering activity of the endogenous DecoyMet generated by hOA-DN30-cl03E08. of hOA-DN30-cl03E08 The combination and $DecoyMet^{K842E}$ acts simultaneously on Met-expressing cancer cells and on HGF-secreting tumor stroma. This allows optimal blockade of the HGF-driven Met signalling and thus represents a reliable therapeutic option for a large cohort of patients carrying tumors expressing wild-type MET that rely on MET for sustaining the invasive/metastatic phenotype.

[0098] The proteins disclosed herein (i.a. the humanized anti-Met antibody and the extracellular portion of human Met) can be easily manufactured either in the form of proteins or in the form of nucleic acid molecules encoding the proteins by a skilled man in view of the common general knowledge of the field related to the recombinant DNA technology, as represented i.a. by Maniatis T. Molecular cloning: A laboratory manual Cold Spring Harbor Laboratory (1982). For example, the following standard procedure can be followed: (i) synthesis of the corresponding cDNA sequences, (ii) insertion of the cDNAs into a plasmid suitable for expression in mammalian by conventional recombinant DNA methods, (iii) transient or stable cotransfection with the above mentioned plasmids of a mammalian cell line, (iv) collection of the culture supernatant, (v) purification by affinity chromatography of the recombinant protein.

[0099] Therapeutic compositions comprising the active ingredient(s) of the instant invention, i.e. the humanized anti-Met antibody fragment alone or in combination with an extracellular portion of human Met, can be prepared with physiologically acceptable carriers, excipients, or stabilizers

(Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed., 1980), in the form of aqueous solutions, lyophilized, or other dried formulations. Acceptable carriers, excipients, or stabilizers are nontoxic to recipients at the dosages and concentrations employed, and include buffers; antioxidants; preservatives; low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids; monosaccharides, disaccharides, and other carbohydrates; chelating agents; sugars; salt-forming counter-ions; metal complexes and/or nonionic surfactants. The formulations may also contain other active compound(s) as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect the therapeutic activity of hOA-DN30 alone or in combination with the extracellular portion of human Met. Such molecules are suitably present in combination in amounts that are effective for the purpose intended.

[0100] The active ingredient(s) may also be entrapped in microcapsules prepared by means of techniques disclosed i.a. in Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980).

[0101] Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the active ingredients of the invention, which matrices are in the form of shaped articles, e.g. films, or microcapsule.

[0102] The active ingredient(s) of the invention can be used either alone or in combination with another antibody, small molecule tyrosine kinase inhibitors, chemotherapeutic agent(s) (including cocktails of chemotherapeutic agents), other cytotoxic agent(s), anti-angiogenic agent(s), cytokines, and/or growth inhibitory agent(s). Such combined therapies noted above include combined administration (where the two or more agents are included in the same or separate formulations), and separate administration, in which case, administration of hOA-DN30 can occur prior to, and/or following, administration of the adjunct therapy or therapies.

[0103] The active ingredient(s) of the present invention (and adjunct therapeutic agent(s)) is(are) administered by any suitable means, including parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. The active ingredient(s) of the instant invention can be suitably administered by pulse infusion, particularly with declining doses of the active ingredients. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.

[0104] The active ingredient(s) of the invention will be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The active ingredient(s) of the invention need not be, but may optionally be, formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents

depends on the amount of active ingredient(s) of the invention present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as used hereinbefore or about from 1 to 99% of the heretofore employed dosages.

[0105] For the treatment of disease, the appropriate dosage of the active ingredient(s) of the invention (when used alone or in combination with other agent(s) such as chemotherapeutic agent(s)) will depend on the type of disease to be treated, the severity and course of the disease, whether the active ingredients are administered for preventive or therapeutic purposes, the patient's clinical history and response to the active ingredients of the invention are duly taken into consideration, and at the discretion of the attending physician.

[0106] hOA-DN30 is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 mg/kg to 30 mg/kg of antibody is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dose might range from about 1 µg/kg to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody fragment would be in the range from about 0.05 mg/kg to about 20 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, e.g. about six doses of the antibody). An initial higher loading dose, followed by one or more lower doses may be administered. An exemplary dosing regimen comprises administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the antibody. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays. With respect to the combination therapy, the extracellular portion of human Met is preferably delivered at the same time of hOA-DN30 and dosed in proportion to hOA-DN30, preferentially but not limited to, the molar ratio 1:1 hOA-DN30:DecoyMet^{K842E}, depending on the type and severity of the disease.

Results

Generation of the Chimeric and Humanized One-Arm Formats of the DN30 Antibody.

[0107] Through classical molecular biology techniques, the present inventors substituted the constant domains of the DN30 mAb heavy and light chains with constant domains derived from human immunoglobulins. The light chain constant domain was substituted with the human kappa type domain, (the one more represented in the natural human antibodies), while the heavy chain constant domains were substituted with the homologous domains derived from the human IgG1 (the one that can induce ADCC/CDC).

[0108] Humanization of the DN30 mouse antibody has been done by Fair Journey Biologics using a phage display library approach. They started from the identification of

deviating FR (frame) residues and the analysis of the closest human V germline, chosen from germlines with identical canonical fold combination for CDR1-CDR2, using available tools and databases: abYsistool from Dr. Andrew Martin at UCL plus, http://www.bioc.uzh.ch/plueckthun/antibody/ and http://www2.mrc-lmb.cam.ac.uk/vbase/. Upon generation of phage display libraries-in which randomization of the VH and VL region has been performed-four affinity-driven phage display rounds of selection have been done. At the end of the process, the DN30 humanized variants with the highest human identity and homology were selected. Variable regions were linked through classical molecular biology techniques to the constant domain sequences derived from human immunoglobulins, i.e. human kappa light chain and IgG1 heavy chain constant domains.

[0109] To format the chimeric and the humanized antibodies into the One-Arm single chain form, specific amino acid modifications have been inserted in the CH3 region to produce the 'knob into hole' structure^{28,29}; one CH3 domain carries the knob mutation: ³⁸⁹T→W, the other CH3 domain carries the hole mutations: ³⁸⁹T→S; ³⁹¹L→A; ⁴³⁸Y→V. cDNAs encoding for the chimeric or humanized light chains, the chimeric or humanized heavy chains (mutated in the CH3 domain) and the human Fc domain (mutated in the CH3 domain) were cloned into expression plasmids and then expressed into eukaryotic cells. Assembled One-Arm antibodies were purified from cell culture supernatants by affinity chromatography and gel filtration. FIG. **1** shows a schematic drawing of the DN30 derivatives and the SDS-Page separation under not reducing and reducing condition of the purified recombinant OA-DN30 molecules.

DN30 One-Arm Antibodies Recognize Met with High Affinity.

[0110] Purified One-Arm forms of the chimeric or humanized DN30 antibodies were analysed for binding to the Met receptor by an ELISA assay. As reference, the chimeric DN30 Fab (MvDN30)¹² was included in the analysis. The assay was assembled to include Met-Fc in solid phase and the DN30 derivatives in liquid phase. Binding was revealed using anti-human k chain antibodies. Data showed that both the chimeric and the humanized antibodies bind to Met, the hOA-DN30-cl03E08 showing the highest affinity (FIG. **2**A). Analysis of hOA-DN30-cl03E08 Cross-Reactivity with Non-Human Met Receptors.

[0111] The present inventors analysed the species cross reactivity of the hOA-DN30-cl03E08 performing: (i) an ELISA assay with purified Met extracellular domains of human, mouse, rat, and monkey origin (FIG. 2B); (ii) a flow-cytometer analysis of antibody binding to surface Met expressed by cells of human, mouse, rat, dog and monkey origin (FIG. 2C). Results of the experiments showed that hOA-DN30-cl03E08 binds Met of human, rat, dog, monkey origin, while the interaction with mouse Met was very weak.

DN30 One-Arm Antibodies do not Exert Agonistic Properties.

[0112] The present inventors tested whether the new DN30 derivatives could display Met agonistic activity in a highly sensitive assay, the scatter assay. HPAF-II human pancreatic carcinoma cells, which represent a standard system for determining cell motility in response to HGF stimulation, were stimulated for 24 hrs with increasing concentrations of the antibody. As a positive control, HGF and

bivalent DN30 mAb were included in the assay. While cells stimulated with the positive controls were clearly scattered, the phenotype of the cells treated with all the monovalent DN30 derivatives (MvDN30, chOA-DN30, and hOA-DN30 antibodies) was indistinguishable from the untreated ones (FIG. **3**).

hOA-DN30 Potently Induces Met 'Shedding'.

[0113] The present inventors also investigated whether hOA-DN30 maintained the ability to promote receptor shedding and downregulation. A549 cells were incubated with increasing concentrations of chOA-DN30 and hOA-DN30 antibodies. As a reference, MvDN30 was included in the assay. After 48 hours, Met ectodomains released in the conditioned medium were scored by immunoblotting using a monoclonal antibody directed against the extracellular portion of Met. Total cellular levels of Met were also determined on cell lysates using the same antibody. This analysis revealed that all the OA-DN30 antibodies induced Met shedding, resulting in the release of soluble Met ectodomains in the extracellular space and physically removing Met from the cell surface (FIG. 4). Unexpectedly, the activity of the hOA-DN30-cl03E08 was superior as compared with all the other DN30 derivatives included in the test.

hOA-DN30-cl03E08 Strongly Inhibits Met Phosphorylation.

[0114] The present inventors investigated if the chOA-DN30 and the hOA-DN30 antibodies inhibited Met phosphorylation in cells derived from human carcinomas, i.e. GTL-16. These cells have a constitutive active Met as the consequence of receptor over-expression due to gene amplification. Met activation was determined by immunoblotting with anti-phosphoMet antibodies. As shown in FIG. **5**, all the molecules impaired Met phosphorylation/activation, with a dose-response modality. hOA-DN30-cl03E08, inducing the strongest impairment of Met levels in the cells, was the DN30 derivative more active.

hOA-DN30-cl03E08 Powerfully Inhibits MET-Addicted Cell Growth.

[0115] Cell growth (viability) can be impaired by a Metinhibitor only in MET-addicted cells, which rely on Metsignalling for proliferation/survival. To test the activity of the DN30 derivatives, exponentially growing GTL-16 cells (MET-addicted human gastric carcinoma cells) were incubated with increasing concentrations of chOA-DN30 or hOA-DN30 antibodies. MvDN30 was included in the assay as a positive control. After 72 hours, cell viability was determined using a luminescence-based ATP assay. All the DN30 derivatives inhibited MET-addicted cell growth in a dose-dependent manner (FIG. **6**). hOA-DN30-cl03E08 showed the highest inhibition, being the IC₅₀ 2.5 folds lower as compared to MvDN30, 5.4 folds lower as compared to the chOA-DN30, and at least 5.2 folds lower as compared to the other hOA-DN30 antibodies (see table in FIG. **6**).

hOA-DN30-cl03E08 is Highly Effective in Blocking Proliferation and in Inducing Cytotoxicity in MET-Addicted Cells.

[0116] To further analyze the mechanisms underlining the inhibition of MET-addicted cell growth exerted by the DN30 derivatives, the inventors evaluated cell proliferation and cell cytotoxicity, comparing MvDN30, chOA-DN30, and hOA-DN30-cl03E08. GTL-16 cells were incubated with a single dose (1 μ M) of the DN30 derivatives and cell proliferation was assessed by measuring the incorporation of

EdU—a thymidine analogous—by the cells during the S phase of the cell cycle, with the ClickIT Edu flow cytometry assay. MvDN30 was included in the assay as a positive control. This analysis revealed that DN30 derivatives affected proliferation, as the percentage of treated cells in S-phase was dramatically reduced as compared with control. In particular, the most effective molecule was hOA-DN30-cl03E08, where only 4.9% of cells were still proliferating (84.2% reduction versus control). The proliferating cells in the population treated with chOA-DN30 were the 14.97% (52% reduction versus control) (FIG. 7A).

[0117] To test if DN30 derivatives induced only a block of proliferation or if they caused also cytotoxicity, exponentially growing MET-addicted GTL-16 cells were incubated with increasing concentrations of chOA-DN30 or hOA-DN30-cl03E08. MvDN30 was included in the assay as a positive control. After 72 hours, cytotoxicity was determined adding CellToxTM Green dye to the cells and measuring the fluorescence of the cells that is directly proportional to the number of dead cells. All the DN30 derivatives induced cytotoxicity in GTL-16 cells in a dose-dependent manner (FIG. 7B). hOA-DN30-cl03E08 showed the highest induction, being the EC₅₀ 1.3 and 6.1 folds lower as compared to MvDN30 and chOA-DN30, respectively.

hOA-DN30-cl03E08 Inhibits HGF-Induced Cell Motility, Alone and in Combination with DecoyMet.

[0118] The present inventors tested the ability of hOA-DN30-cl03E08 to inhibit HGF-dependent cell motility of HPAF-II human pancreatic carcinoma cells. Cells were incubated or not with HGF and treated with increasing dose of hOA-DN30-cl03E08. After 24 hrs, cell colonies were stained and analysed. In this assay, hOA-DN30-cl03E08 strongly reduced HGF-dependent cell scattering (FIG. **8**).

[0119] In the above cellular system it has been reported that a more effective inhibition of the HGF-induced biological response can be achieved by blocking concomitantly the ligand (HGF) and the receptor $(Met)^{27}$. The present inventors thus tested if hOA-DN30-cl03E08 in combination with DecoyMet^{K842E} induced a higher therapeutic response. DecoyMet^{K842E} is a recombinant soluble receptor encompassing the whole extracellular region of Met carrying a mutation that abolishes the interaction with DN30; it binds HGF with high affinity and inhibits ligand-driven biological activities by sponging and neutralizing HGF and by forming heterodimers with intact Met receptors still present on the cell surface, rendering them inactive. With equimolar amount of the two molecules in combination, the effective dose completely reverting the scattered phenotype was 4 times lower than the dose of hOA-DN30-cl03E08 alone able to eliciting a similar cell phenotype (FIG. 8).

hOA-DN30-cl03E08 Inhibit HGF-Induced Cell Invasion, Alone and in Combination with DecovMet.

[0120] The present inventors tested the ability of hOA-DN30-cl03E08 to inhibit HGF-dependent cell invasion of HPAF-II cells. Cells were seeded in the upper chambers of transwell filters coated with matrigel in serum free medium with hOA-DN30-cl03E08 (0.5 μ M) alone or in combination with DecoyMet^{K842E} (1 μ M). The lower chambers were filled with medium containing HGF (25 ng/ml). After 24 hrs, cells migrating on the lower part of the filter were evaluated by staining and microscope observation. In this assay, hOA-DN30-cl03E08 strongly reduced HGF-dependent cell invasion; the cell response was almost abolished by the combination hOA-DN30-cl03E08 and DecoyMet^{K842E} (FIG. 9).

hOA-DN30-cl03E08 Revokes Interferon-Gamma Induction of Pd-L1 Expression.

[0121] Programmed cell death ligand 1 (PD-L1) and programmed cell death receptor 1 (PD-1) are key modulatory molecules, known as immune-checkpoints, that play a central role at the interface between immune response and tumor microenvironment³⁰. They may significantly impair the ability of the immune system to control tumor progression. The expression of PD-L1 by tumor cells is inducible and interferon gamma (IFNgamma) is the most potent inducer³¹.

[0122] The present inventors analyzed if inhibition of Met by hOA-DN30-cl03E08 could modulate the IFNgamma pathway and consequently PD-L1 regulation (FIG. **10**). MET-addicted GTL-16 cells were treated with INFgamma for 48 hrs and analyzed for IFNgamma-inducible PD-L1 expression. In an unstimulated condition, PD-L1 was not detectable, while upon exposure to IFNgamma, it was consistently up-regulated. Treatment with hOA-DN30-Cl03E08 for 48 hrs significantly impaired the upregulation of PD-L1 induced by IFNgamma.

hOA-DN30-cl03E08 Shows a Favorable Pharmacokinetic Profile In Vivo.

[0123] The present inventors studied the pharmacokinetic properties of hOA-DN30-Cl03E08, in comparison with MvDN30 and the chimeric DN30 mAb. A single dose of the above mentioned molecules were delivered by intravenous injection to immunodeficient mice. Peripheral blood from the treated mice was collected at different time points after the delivery. The circulating concentrations of the studied molecules were determined by ELISA performed on serum samples. hOA-DN30-cl03E08 circulating levels were comparable to the ones measured for the mAb, and always higher than MvDN30 (FIG. **11**).

hOA-DN30-cl03E08 Impairs Growth of MET-Addicted Tumors In Vivo

[0124] The ability of DN30-derivatives to inhibit tumor growth in vivo was tested on a MET-addicted model. 1×10^6 GTL-16 cells were sub-cutaneously injected in the flank of NOD-SCID mice. After 1 week, mice carrying palpable tumors were randomized in 4 homogenous treatment groups: Vehicle (n=6), MvDN30 (n=6), hOA-DN30-cl03E08 (n=5), chOA-DN30 (n=5). Antibodies were delivered by intravenous injection twice/week at 30 mg/Kg; to administer the same amount of molecules, MvDN30 was delivered following the same schedule at 15 mg/kg, as the molecular weight of the One-arm antibodies are double with respect to MvDN30 (i.e. around 100 KDa for OA-DN30 formats and around 50 KDa for MvDN30). MvDN30 was not effectiveas expected from its short plasma half-life-while both the One-Arm derivatives inhibited tumor growth (FIG. 12A) (P=0.0007 and 0.05 for hOA-DN30-cl03E08 and for chOA-DN30 respectively versus vehicle). Surprisingly hOA-DN30-cl03E08 was exceedingly more effective than chOA-DN30: the treated masses were, in the case of hOA-DN30cl03E08, 87.8% and, in the case of chOA-DN30, 52.9% smaller than controls (FIG. 12B) (P=0.009 for hOA-DN30cl03E08 versus chOA-DN30). The present inventors further analyzed the inhibitory activity of the hOA-DN30-cl03E08 performing a dose response experiment. Maintaining the experimental conditions described above, mice were randomized in 5 homogenous groups and treated by i.v. injection three times/week with different doses of hOA-DN30cl03E08. Doses of 10, 30, and 60 mg/kg were highly

effective in blocking tumor growth, while treatment with 3.3 mg/kg was not statistically different from controls (FIG. 13).

Material and Methods

Cell Culture

[0125] A549 human lung adenocarcinoma cells, HPAF-II human pancreatic adenocarcinoma cells, C2C12 mouse muscle myoblasts, H9C2 (2-1) rat cardiac myoblasts, MDCK dog kidney cells, and Cos-7 monkey kidney cells were obtained from ATCC/LGC Standards S.r.l. (Sesto San Giovanni, Italy); GTL-16 cell line is a clone derived from MKN-45 cells (human gastric carcinoma cells available by the Japanese Collection of Research Bioresources, Osaka, Japan) that differs in MET gene copy number from the parental cell line³². GTL-16 cell line is available by Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC) Italy, with accession number ICLC PD 08003. EBC-1, human lung cancer, were from Japanese Collection of Research Bioresources). DN30 hybridoma is available by Advanced Biotechnology Center (ABC), Interlab Cell Line Collection (ICLC) Italy, with accession number ICLC PD 05006.

[0126] All the cells were cultured as suggested by the supplier. All cell cultures were tested for *Mycoplasma* contamination.

Generation of the Chimeric and Human One-Arm Form of the DN30 Antibody.

[0127] For the chimeric DN30 antibody: three separate cDNAs encoding respectively the light chain (VL-CL), the heavy chain (VH-CH1-cH2-CH3), and the Fc domain (CH2-CH3) have been generated by gene synthesis. Variable regions (mouse sequences) were from the DN30 antibody (SEQ ID: 15 and 16); constant regions of human origin derived from human immunoglobulins, in particular the light chain includes the human kappa type constant domain (GenBank sequence ID #: DI165992), and the heavy chain includes the human IgG1 constant domains (GenBank sequences, the heavy chain includes a His-TAG (SEQ ID: 38, 39) and the Fc includes a strep-TAG (SEQ ID: 40, 41).

[0128] For the humanized DN30 antibody: Humanization by germ line screening of the DN30 mouse antibody has been done by Fair Journey Biologics using a phage display library approach. They started from the identification of deviating FR (frame) residues and the analysis of the closest human V germline, chosen from germlines with identical canonical fold combination for CDR1-CDR2, using available tools and databases: abYsistool from Dr. Andrew Martin at UCL plus, http://www.bioc.uzh.ch/plueckthun/antibody/ and http://www2.mrc-lmb.cam.ac.uk/vbase/. Upon generation of phage display libraries-in which randomization of the VH and VL region has been performed-four affinity-driven phage display rounds of selection have been done. At the end of the process, five different DN30 humanized variants with the highest human identity and homology were selected, namely clones 03E08, 03G05, 03F04, 03H08 and 04H08. Variable regions were linked through classical molecular biology techniques to the constant domain sequences derived from human immunoglobulins, i.e. human kappa light chain and IgG1 heavy chain constant domains.

[0129] For formatting the chimeric and the humanized antibodies into the One-Arm form (chOA-DN30 and hOA-DN30 antibodies): specific amino acid modifications have been inserted in the CH3 region to produce the 'knob into hole' structure^{28,29}. 'Knobs-into-holes' was demonstrated to be an effective design strategy for enhancing the formation of heterodimers over homodimers. The strategy is based on the domain interface remodeling, introducing sterically complementary mutations in the CH3 region of the antibody Fc fragment, the most extensive site of protein-protein interaction between the H chains of human IgG molecules. One chain, the VH-CH1-CH2-CH3 polypeptide, includes the ${}^{389}T \rightarrow W$ (Knob mutation), in which a small amino acid is substituted by a larger one; conversely, the other chain, the CH2-CH3 polypeptide, includes the replacement of large residues with smaller ones: ${}^{389}T \rightarrow S$; ${}^{391}L \rightarrow A$; ${}^{438Y} \rightarrow V$ (Hole mutations). These mutations were selected upon optimization by phage display technology³³, in which residues 389, 391 and 438, that are in proximity to the knob on the partner CH3 domain, were randomly substituted. Knobsinto-holes engineering facilitates the assembly of a heterodimer, including the three different amino acid chains (VL-CL+VH-CH1-CH2-CH3+CH2-CH3) in place of homodimers i.e. the bona fide antibody (VL-CL+VH-CH1-CH2-CH3)₂ or the Fc domain only (CH2-CH3)₂.

[0130] At the N-terminal, the CH2-CH3 polypeptide includes a sequence corresponding to a truncated human Hinge region. The deletion is necessary to exclude the cysteine at position 233 according to the EU numbering scheme of Kabat that is involved in the formation of an inter-chain disulfide bond with the cysteine at the C-terminal position of the light chain constant domain (CL). Moreover, to allow the CH2-CH3 polypeptide to enter the RER/Golgi pathway of protein synthesis—as light (VL-CL) and heavy chains (VH-CH1-CH2-CH3) of the antibody do—at the N-terminus, before the truncated Hinge region, a sequence corresponding to the signal peptide of the DN30 Heavy chain is included.

[0131] The chimeric anti-Met antibody fragment (chOA-DN30) disclosed herein is made of:

[0132] (i) a light chain variable domain having the amino acid sequence set forth in SEQ ID No.: 15;

[0133] (ii) a heavy chain variable domain having the amino acid sequence set forth in SEQ ID No.: 16;

[0134] (iii) a human light chain constant (CL) domain having the amino acid sequence set forth in SEQ ID No.: 9; [0135] (iv) a human heavy chain constant CH1 domain having the amino acid sequence set forth in SEQ ID No.: 10; [0136] (v) a first human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 11; and

[0137] (vi) a second human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 12.

[0138] The humanized anti-Met antibody fragment (hOA-DN30-cl03E08) object of the present disclosure is made of: **[0139]** (i) a humanized light chain variable domain having the amino acid sequence set forth in SEQ ID No.: 7;

[0140] (ii) a humanized heavy chain variable domain having the amino acid sequence set forth in SEQ ID No.: 8; **[0141]** (iii) a human light chain constant (CL) domain having the amino acid sequence set forth in SEQ ID No.: 9;

[0142] (iv) a human heavy chain constant CH1 domain having the amino acid sequence set forth in SEQ ID No.: 10; **[0143]** (v) a first human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 11; and

[0144] (vi) a second human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 12.

[0145] The humanized anti-Met antibody fragment (hOA-DN30-cl03G05) is made of:

[0146] (i) a humanized light chain variable domain having the amino acid sequence set forth in SEQ ID No.: 17;

[0147] (ii) a humanized heavy chain variable domain having the amino acid sequence set forth in SEQ ID No.: 18; [0148] (iii) a human light chain constant (CL) domain having the amino acid sequence set forth in SEQ ID No.: 9; [0149] (iv) a human heavy chain constant CH1 domain having the amino acid sequence set forth in SEQ ID No.: 10; [0150] (v) a first human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 11; and

[0151] (vi) a second human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 12.

[0152] The humanized anti-Met antibody fragment (hOA-DN30-cl03F04) is made of:

[0153] (i) a humanized light chain variable domain having the amino acid sequence set forth in SEQ ID No.: 19;

[0154] (ii) a humanized heavy chain variable domain having the amino acid sequence set forth in SEQ ID No.: 20; [0155] (iii) a human light chain constant (CL) domain having the amino acid sequence set forth in SEQ ID No.: 9; [0156] (iv) a human heavy chain constant CH1 domain having the amino acid sequence set forth in SEQ ID No.: 10; [0157] (v) a first human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 11; and

[0158] (vi) a second human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 12.

[0159] The humanized anti-Met antibody fragment (hOA-DN30-cl03H08) object of the present disclosure is made of: **[0160]** (i) a humanized light chain variable domain having the amino acid sequence set forth in SEQ ID No.: 21;

[0161] (ii) a humanized heavy chain variable domain having the amino acid sequence set forth in SEQ ID No.: 22; [0162] (iii) a human light chain constant (CL) domain having the amino acid sequence set forth in SEQ ID No.: 9; [0163] (iv) a human heavy chain constant CH1 domain having the amino acid sequence set forth in SEQ ID No.: 10; [0164] (v) a first human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 11; and

[0165] (vi) a second human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 12.

[0166] The humanized anti-Met antibody fragment (hOA-DN30-cl04H08) object of the present disclosure is made of: **[0167]** (i) a humanized light chain variable domain having the amino acid sequence set forth in SEQ ID No.: 23;

[0168] (ii) a humanized heavy chain variable domain having the amino acid sequence set forth in SEQ ID No.: 24; [0169] (iii) a human light chain constant (CL) domain having the amino acid sequence set forth in SEQ ID No.: 9; [0170] (iv) a human heavy chain constant CH1 domain having the amino acid sequence set forth in SEQ ID No.: 10; [0171] (v) a first human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 11; and

[0172] (vi) a second human Fc polypeptide having the amino acid sequence set forth in SEQ ID No.: 12.

Expression and Purification of Chimeric and Human One Arm Antibodies

[0173] The cDNAs encoding the above described light chains (nucleotide sequence set forth in SEQ ID No.: 25, 26, 27, 28, 29 for the humanized light chains and SEQ ID No.: 30 for the chimeric light chain), heavy chains (nucleotide sequence set forth in SEO ID No.: 31, 32, 33, 34, 35 for the humanized heavy chain and SEQ ID No.: 36 for the chimeric heavy chain) and Fc (nucleotide sequence set forth in SEQ ID No.: 37) were cloned into commonly available expression vectors (e.g. pcDNA3.1 plasmids cat. #V79020 Invitrogen Corporation, Camarillo, Calif.) and used to transfect ExpiCHO-S cells (cat. #: A29127, ThermoFisher Scientific). The vector ratio was optimized to maximize the output of the desired 97.5 kDa heterodimer (the OA-Ab) and to minimize the presence of any 150 kDa bivalent homodimer (bona fide Mab). The optimal ratio was: 1:1:2 respectively for Light chain, Heavy chain full size ("knob" vector) and Fc ("hole" vector). This condition resulted in the least amount of homodimer present, with the heterodimer being approximately 85% of the total protein. Transient expression was powered by ExpiFectamine[™] CHO transfection reagent (cat. #A29130, ThermoFisher Scientific). Supernatants were harvested after 9 days of production. The OA-DN30 antibodies were purified using a Hitrap MabSelect Sure column (cat. #GE29-0491-04, Sigma Aldrich) on an ÄKTA Pure 25 chromatography system. The OA-DN30 antibodies were subsequently eluted using 0.1 M citrate buffer at pH 3.0. Eluted fractions were collected and neutralized with 1M Tris-HCl pH 9.0 (at a ratio of 0.15 ml per ml of eluted protein). The OA-DN30 antibodies were further purified on a 1×PBS (pH 7.4)-equilibrated Superdex 200 26/600 size exclusion column (cat. #GE28-9893-36, Sigma Aldrich) on a GE AKTA Prime Liquid Chromatography System (GE Healthcare Life Sciences), where fractions containing the OA-Ab were separated from homodimeric fractions (mAb or Fc). Preparative SEC fractions containing the OA-DN30 antibodies were pooled and analyzed by SDS-PAGE to ascertain the purity. The pooled fractions were also tested for endotoxin levels. The final pooled fractions from the preparative SEC purifications, showing the absence of any bivalent homodimer, and the presence of a small amount (<5%) of a smaller \approx 70 kDa band, which corresponds to the Knob-Knob Fc homodimer.

[0174] Generation, Expression, and Purification of Mutated Met Ectodomain

[0175] cDNA sequence of human MET ectodomain (DecoyMet) carrying a single amino acid substitution was synthetically generated starting from the human Met ectodomain sequence as disclosed in GenBank at deposit number X54559, and using the QuickChange II Site-Directed Mutagenesis Kit (cat. #200524 Agilent Technologies, Santa Clara, Calif.), following the instruction of the manufacturer. The procedure requires the design of sense and antisense oligonucleotides, that include the desired point mutation. The following oligos has been employed:

mutation K842E:

sn. 5'-gtacataatcctgtgtttgagccttttgaaaagccagtg-3';

(SEQ ID No.: 43)

(SEO ID No.: 42)

as. 5'-cactggcttttcaaaaggctcaaacacaggattatgtac-3'.

[0176] Engineered soluble receptor was produced by transient transfection of HEK-293T cells with pcDNA3.1 plasmids (cat. #V79020 Invitrogen Corporation, Camarillo, Calif.) expressing cDNA encoding for DecoyMet mutant. Transfected cells were starved for three days and cell culture supernatants containing the soluble receptor were collected. Purification of the recombinant proteins was done by affinity chromatography using HisTrap HP columns (cat. #17524701 GE Healthcare, Freiburg, Germany) according to manufacturer's instructions. Large-scale protein production and purification was performed by U-Protein Express BV (Utrecht, The Netherlands).

[0177] The variant of human DecoyMet (DecoyMET^{K842E}) has the amino acid sequences set forth in SEQ ID No.: 14.

Analysis of the Purified Proteins by SDS-PAGE+Blue Coomassie

[0178] Purified OA-DN30 antibodies (1 μ g) were separated into a 4-12% acrylamide gradient gel by SDS-PAGE in the presence of in the absence of β -mercapto ethanol following standard methods. Molecular weight markers (cat. #1610374, Bio-Rad) were included in the analysis. Polypeptides separated into the gel were revealed by Gel Code Blue Stain reagent (cat. #24590, Thermo Fisher Scientific).

ELISA Binding Assays

[0179] For analysis of the interaction between Met and the DN30 derivatives, purified Met-Fc chimeras (cat #. 358-MT-100 R&D Systems, 100 ng/well) were immobilized on ELISA plates. After saturation with 0.5% BSA incubated 1 hr at 37° C., increasing concentrations of the antibodies (MvDN30, chOA-DN30 or hOA-DN30 antibodies, 0-500 nM prepared in PBS-BSA 0.5%—Tween 0.1%)) were added in liquid phase. Binding was revealed using HRP-conjugated anti-human k chain antibody (cat. #A7164, Sigma-Aldrich) followed by incubation with TMB (cat. #T8665, Sigma Aldrich). Colorimetric assay was quantified by the multi-label plate reader VICTOR-X4 (Perkin Elmer Instruments INC., Whaltman, Mass.). Data were analyzed and fit using Prism software (GraphPad).

[0180] For ELISA binding analysis of hOA-DN30cl03E08 (liquid phase) to Met-Fc chimera (solid phase) derived from different species, Met of human (cat #. 358-MT-100 R&D Systems), murine (cat. #50622-M02H, Sino Biological), rat (cat. #80004-R02H, Sino Biological), and monkey (cat. #90304-C02H, Sino Biological) origin were included in the assay. The procedure was same as the one described above.

Flow-Cytometer Binding Analysis

[0181] For hOA-DN30-cl03E08 binding to Met expressed at the surface of cells, 2×10^5 EBC-1, C2C12, H9C2, MDCK, or Cos-7 cells were treated with StemProTM AccutaseTM Cell Dissociation Reagent (cat. #A1110501, ThermoFisher Scientific) collected and incubated for 1 hour at 4° C. in PBS-2% FCS. Antibody staining was performed by incubating the cells for 30 min at 4° C. with 10 µg/ml of hOA-DN30-cl03E08 in PBS-2% BSA. After 6 washes with PBS-2% BSA, cells were incubated with anti-human IgG-APC (cat. #109-606-088 Jackson Immuno Research) diluted 1:100 for 30 min at 4° C. and then washed to removed unbound antibodies. Cells were co-stained with DAPI (3 µl

of 1 µg/ml working solution, Sigma-Aldrich, cat. #10236276001) for 5 min at 4° C. and analyzed for Met expression by Summit 4.3 software (Dako). The fluorescence signal derived from the isotype control (anti human APC IgG) was set as a threshold ($0 < MFI < 10^{1}$). Cells were considered positive for Met expression if the Mean Fluorescence Intensity (MFI) was higher than the threshold ($MFI > 10^{1}$).

Analysis of Met Shedding

[0182] Sub-confluent A549 monolayers were washed twice with PBS and then incubated in serum-free medium with increasing concentrations (37, 111, 333, 1000 nM) of DN-30 derivatives. After 48 hours, conditioned medium was collected and cells were lysed with Laemmli Buffer. Met protein levels were determined in 15 µg of total cellular proteins by Western blot using anti-Met antibodies (3D4, cat. #08-1366 Invitrogen Corporation); as a loading control, filters were probed also with anti-vinculin antibodies (clone hVIN-1, cat. #V9131 Sigma Life Science). Met ectodomain levels were determined in 15 µl of cell culture supernatant by Western blotting using an anti-human HGFR/Met antibody directed against the extracellular domain of the receptor (cat. #AF276, R&D Systems). Anti-mouse IgG1 HRP-conjugated secondary antibodies (cat. #JI115035003, Jackson ImmunoResearch) and the ECL System (cat. #W1015, Promega) were used for protein detection. Western Blot bands were quantified using ImageJ software.

MET Phosphorylation Assays

[0183] Serum-starved GTL-16 cells were incubated for 24 h with DN30 derivatives (1000 or 250 nM). Total cellular lysates were analyzed by Western blot using the following primary antibodies: anti-Met phospho-Tyr^{1234/1235} (D26, cat. #3077 Cell Signaling Technology); anti-Met (3D4, cat. #08-1366 Invitrogen Corporation); and anti-vinculin (clone hVIN-1, cat. #V9131 Sigma Life Science). Anti-mouse IgG1 and anti-rabbit IgG (cat. #JI111035003) HRP-conjugated secondary antibodies and the ECL System were used for protein detection. Western Blot bands were quantified using ImageJ software.

In Vitro Biological Assays

[0184] For cell scattering assays, HPAF-II cells (8000/ well) were seeded in 96-well plates in complete culture medium. To analyze the agonistic activity of the antibodies, after 24 hrs, HGF (8 ng/ml, positive control, cat. #294-HG-025, R&D Systems) or the antibodies (DN30 mAb, MvDN30, chOA-DN30, hOA-DN30 antibodies, all at the concentration of 200 nM), were added to the culture medium. To analyze the inhibitory activity, increasing concentrations (0-4 µM) of hOA-DN30-cl03E08, alone or in 1:1 combination with DecoyMet^{K842E}, were added. After an additional time of 24 hrs, cells were stimulated with 6.25 ng/ml HGF for 24 hrs. Cells were then fixed with 11% glutaraldehyde (cat. #340855 Sigma-Aldrich), stained with 0.1% Crystal Violet (cat. #C3886 Sigma-Aldrich) and analyzed by microscope observation (Microscope Leica DM2000). Images were captured with QICAM Fast 1394 color digital Camera (QImaging).

[0185] For cell invasion assays, HPAF-II cells $(1.5 \times 10^{5/7})$ well) were suspended in serum-free culture medium in the presence of 0.5 μ M hOA-DN30-cl03E08 alone or in com-

bination with 1 μ M DecoyMet^{K842E}, and seeded on the upper compartment of transwell chambers pre-coated with 30 μ g/well of Matrigel Matrix (cat. #354234, Corning Inc.). Culture medium supplemented with 2% FBS and 6.25 ng/ml HGF was added to the lower compartment of the chambers. After 24 hrs, cells on the upper side of the transwell filters were mechanically removed, while cells migrated through the membrane were fixed with 11% glutaraldehyde and stained with 0.1% Crystal Violet. Cell invasion was quantified with Image-J software.

[0186] For vitality assay, GTL-16 cells were seeded 2000 cells/well in a 96 well plate in 10% FBS culture medium. After 24 hrs, medium was replaced with a fresh one with 10% FBS plus the molecules to be tested (increasing concentrations—from 0 to 10 μ M). Cell viability was evaluated after 72 hrs using the CellTiter-Glo (cat. #G7573 Promega Corp), according to the manufacturer's instructions. Chemo-luminescence was detected with VICTOR X4.

[0187] For proliferation assay, 350000 GTL-16 cells were plated in 6 well plates in 10% FCS medium. After 24 hrs, cells were treated with a fixed concentration (1 μ M) of DN30 derivatives for further 48 hrs. Then, 10 μ M EdU (cat. #A10044, Thermo Fisher) was added to the culture medium for a further 2 hrs. The % of cells in S phase was determined by cytofluorimeter analysis following the procedure of the Click-iTTM EdU Alexa FluorTM 488 Flow Cytometry Assay (cat. #C10425, Thermo Fisher).

[0188] For cytotoxicity assay, 2000 GTL-16 cells were plated in 96 well plates in 10% FCS medium. After 24 hrs, cells were treated with increasing concentrations of the DN30 derivatives for a further 48 hrs. Cell cytotoxicity was evaluated by Cell-ToxTM Green cytotoxicity assay (cat. #G8741, Promega) following manufacturer's instructions.

PD-L1 Expression Analysis

[0189] Sub-confluent GTI-16 cells were treated with 50 ng/ml of IFNy-1b (Miltenyi Biotec, cat. #130-096-484) for 48 hours (replaced every 24 hours) in combination with 250 nM hOA-DN30-cl03E08. Monolayers were then lysed in Laemmli buffer and 45 µg of total proteins were subjected to 8% SDS-PAGE gel. Proteins were transferred from the gel onto iBlot Transfer nitrocellulose membranes (Life technologies, cat. #IB23001) following standard methods. PD-L1 expression was detected by anti-PD-L1 antibody (E1L3N, cat. #13684, Cell Signaling Technology). P-Met levels were checked by anti-MET phospho-Tyr1234/1235 (D26) antibodies. As loading control, filters were probed with anti-GAPDH (D4C6R, cat. #97166 Cell Signaling Technology). Secondary HRP-conjugated goat anti-mouse IgG (cat. #JI115035003) or anti-rabbit IgG (cat. #JI111035144) (both from Jackson ImmunoResearch) and the ECL System were used for protein detection.

In Vivo Experiments

[0190] All animal procedures were performed according to protocols approved by Ethical Committee for animal experimentation of the Fondazione Piemontese per la Ricerca sul Cancro and by Italian Ministry of Health. NOD-SCID mice were purchased from Charles River (Calco, Italy).

[0191] For pharmacokinetic analysis NOD-SCID mice were injected intravenously with a single dose $(100 \ \mu\text{g})$ of hOA-DN30-cl03E08. Peripheral blood was collected at different time points: 10', 30', 1 hr, 4 hrs, 8 hrs, 24 hrs, 48 hrs, 72 hrs, 120 hrs. Serum concentrations of the therapeutic molecules were measured by ELISA as described above in the binding assay section, interpolating the absorbance values of the samples on the linear part of a standard curve obtained by serial dilutions of the different purified molecules. Each time point was the average value of 4 mice.

[0192] For tumor growth analysis 1×10^6 GTL-16 cells were inoculated in the flank of NOD-SCID mice. Tumor growth was monitored by caliper measurement twice weekly. Tumor volume was calculated using the formula: $V=4/3\pi(x/2)(y/2)(z/2)$, where x, y and z are height, width and depth of the tumor mass. When the tumors reached a volume of 70-100 mm³ (approximately one week after cell injection) mice were randomized in homogeneous groups. In one case, 4 groups were generated (PBS-vehicle, MvDN30, chOA-DN30, hOA-DN30-cl03E08; all the antibodies 30 mg/kg, 2 times per week); in the other case, 5 groups were generated (PBS-vehicle, hOA-DN30-cl03E08 60 mg/kg, 30 mg/kg, 10 mg/kg, 3.3 mg/kg; all the doses 3 times per week). Molecules were administered by intravenous injection. At the end of the experiments (15 or 17 days of treatment) mice were sacrificed, tumors were excised and weighted.

Statistical Analysis

[0193] Average and standard deviation (SD) were calculated using Microsoft Office Excel 2010 software (Microsoft Corporation). To calculate K_d values, data from ELISA assays were analyzed and fitted according to nonlinear regression, one site binding hyperbola curve, using Graph-Pad Prism software (GraphPad Software). To calculate IC₅₀ and EC₅₀ values, data were analyzed and fitted according to nonlinear regression, sigmoidal dose-response curve, using GraphPad Prism software. All experiments were repeated at least two times. Figures show one representative experiment.

Budapest Treaty for the Recognition of Deposit of Microorganisms for Patent Purposes

International Form

[0194]

METIS PRECISION MEDICINE SB S.r.l.	Duplicate
Via Magenta 35	Declaration of viability
Torino	issued under Rule 10.2
Italy	By the Deposit International Authority
	specified below
I. Depositor	II. Identification of the microorganism
	(hybridoma or cell line)

-continued

Accession number assigned by the Deposit
International Authority:
PD 08003
Date of deposit or transfer:
16 April 2008
under point II has been controlled
enced microorganism resulted
U
Signature of the Legal Representative
of the Deposit International Authority or of an
authorized officer:
Dr. Carlo Castelli
The liquidator
*

¹Fill in only if the information was requested and if the test result was negative Form BP/9 (single page)

Budapest Treaty for the Recognition of Deposit of Microorganisms for Patent Purposes

oncogenic deletion of met in lung cancer. *Cancer Res* 2006; 66(1): 283-289; doi 10.1158/0008-5472.CAN-05-2749.

International Form

[0198] 3. Gandino L, Longati P, Medico E, Prat M, Comoglio P M. Phosphorylation of serine 985 negatively regu-

[0195]

Istituto per la Ricerca e la Cura del Cancro Receipt of original deposit (IRCC) Issued under Rule 7.1 Div. Oncologia Molecolare By the Deposit International Authority specified below Strada provinciale 142 10060 CANDIOLO (Torino) I. Identification of the microorganism (hybridoma or cell line) Identifying reference provided Accession number assigned by the Deposit by depositor: International Authority: PD 05006 DN-30 II. Scientific description and/or proposed taxonomic designation The identified hybridoma under point I. was accompanied by \sqrt{a} scientific description a proposed taxonomic description III. Receipt and acceptance This Deposit International Authority accepts the hybridoma identified under point I., received on December 29, 2005 (date of original deposit) IV. Receipt of requested conversion The cell line identified under point I. has been received by this Deposit International Authority (date of original deposit) on A request of converting the original deposit in a deposit under the provisions of the Budapest Treaty has been received on (date of request of conversion) V. Deposit International Authority Name: Signature of the Legal Representative Centro di Biotecnologie Avanzate (CBA) of the Deposit International Authority or of an Interlab Cell Line Collection authorized officer: Address: Dr. Paolo Rolleri L.go R. Benzi, 10 CBA President 16132 GENOVA - ITALY

Form BP/4 (single page)

REFERENCES

- **[0196]** 1. Comoglio P M, Trusolino L, Boccaccio C. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy. *Nat Rev Cancer* 2018; 18(6): 341-358; doi 10.1038/s41568-018-0002-y.
- [0197] 2. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N et al. Somatic mutations lead to an

lates the hepatocyte growth factor receptor kinase. *J Biol Chem* 1994; 269(3): 1815-1820.

[0199] 4. Petrelli A, Gilestro G F, Lanzardo S, Comoglio P M, Migone N, Giordano S. The endophilin-CIN85-Cbl complex mediates ligand-dependent downregulation of c-Met. *Nature* 2002; 416(6877): 187-190; doi 10.1038/ 416187a.

- **[0200]** 5. Trusolino L, Bertotti A, Comoglio P M. MET signalling: principles and functions in development, organ regeneration and cancer. *Nat Rev Mol Cell Biol* 2010; 11(12): 834-848; doi 10.1038/nrm3012.
- [0201] 6. Prat M, Crepaldi T, Pennacchietti S, Bussolino F, Comoglio P M. Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. *J Cell Sci* 1998; 111 (Pt 2): 237-247.
- [0202] 7. Pacchiana G, Chiriaco C, Stella M C, Petronzelli F, De Santis R, Galluzzo M et al. Monovalency unleashes the full therapeutic potential of the DN-30 anti-Met antibody. *J Biol Chem* 2010; 285(46): 36149-36157; e-pub ahead of print 2010/09/10; doi 10.1074/jbc.M110. 134031.
- [0203] 8. Cignetto S, Modica C, Chiriaco C, Fontani L, Milla P. Michieli P et al. Dual Constant Domain-Fab: A novel strategy to improve half-life and potency of a Met therapeutic antibody. *Mol Oncol* 2016; 10(6): 938-948; e-pub ahead of print 2016/03/28; doi 10.1016/j.molonc. 2016.03.004.
- [0204] 9. Wang Q, Yang S, Wang K, Sun S Y. MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer. *J Hematol Oncol* 2019; 12(1): 63; e-pub ahead of print 2019/06/21; doi 10.1186/s13045-019-0759-9.
- [0205] 10. Schelter F, Kobuch J, Moss M L, Becherer J D, Comoglio P M, Boccaccio C et al. A disintegrin and metalloproteinase-10 (ADAM-10) mediates DN30 antibody-induced shedding of the met surface receptor. *J Biol Chem* 2010; 285(34): 26335-26340; doi 10.1074/jbc. M110.106435.
- [0206] 11. Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V et al. Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. *Mol Biol Cell* 2009; 20(9): 2495-2507; doi 10.1091/mbc.E08-09-0969.
- [0207] 12. Vigna E, Chiriaco C, Cignetto S, Fontani L, Basilico C, Petronzelli F et al. Inhibition of ligandindependent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30. *Mol Oncol* 2015; 9(9): 1760-1772; doi 10.1016/j. molonc.2015.05.007.
- [0208] 13. Jones P T, Dear P H, Foote J, Neuberger M S, Winter G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. *Nature* 1986; 321(6069): 522-525; doi 10.1038/ 321522a0.
- [0209] 14. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. *Nature* 1988; 332(6162): 323-327; doi 10.1038/332323a0.
- [0210] 15. Presta L G. Antibody engineering. Curr Opin Biotechnol 1992; 3(4): 394-398.
- [0211] 16. Vaswani S K, Hamilton R G. Humanized antibodies as potential therapeutic drugs. *Ann Allergy Asthma Immunol* 1998; 81(2): 105-115; quiz 115-106, 119; doi 10.1016/S1081-1206(10)62794-9.
- [0212] 17. Hurle M R, Gross M. Protein engineering techniques for antibody humanization. *Curr Opin Biotechnol* 1994; 5(4): 428-433.
- [0213] 18. Harris W J. Production of humanized monoclonal antibodies for in vivo imaging and therapy. *Biochem Soc Trans* 1995; 23(4): 1035-1038.
- **[0214]** 19. Bloom J W, Madanat M S, Marriott D, Wong T, Chan S Y. Intrachain disulfide bond in the core hinge

region of human IgG4. *Protein Sci* 1997; 6(2): 407-415; doi 10.1002/pro.5560060217.

- [0215] 20. Humphreys D P, Chapman A P, Reeks D G, Lang V, Stephens P E. Formation of dimeric Fabs in *Escherichia coli*: effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions. *J Immunol Methods* 1997; 209(2): 193-202.
- [0216] 21. Ferracini R, Longati P, Naldini L, Vigna E, Comoglio P M. Identification of the major autophosphorylation site of the Met/hepatocyte growth factor receptor tyrosine kinase. *J Biol Chem* 1991; 266(29): 19558-19564.
- [0217] 22. Ponzetto C, Bardelli A, Zhen Z, Maina F, dalla Zonca P. Giordano S et al. A multifunctional docking site mediates signaling and transformation by the hepatocyte growth factor/scatter factor receptor family. *Cell* 1994; 77(2): 261-271.
- **[0218]** 23. Gherardi E, Love C A, Esnouf R M, Jones E Y. The sema domain. *Curr Opin Struct Biol* 2004; 14(6): 669-678; doi 10.1016/j.sbi.2004.10.010.
- **[0219]** 24. Bork P, Doerks T, Springer T A, Snel B. Domains in plexins: links to integrins and transcription factors. *Trends Biochem Sci* 1999; 24(7): 261-263.
- **[0220]** 25. Merchant M, Ma X, Maun H R, Zheng Z, Peng J, Romero M et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. *Proc Natl Acad Sci USA* 2013; 110(32): E2987-2996; doi 10.1073/ pnas.1302725110.
- [0221] 26. Makabe K, Nakanishi T, Tsumoto K, Tanaka Y, Kondo H, Umetsu M et al. Thermodynamic consequences of mutations in vernier zone residues of a humanized anti-human epidermal growth factor receptor murine antibody, 528. *J Biol Chem* 2008; 283(2): 1156-1166; e-pub ahead of print 2007/10/17; doi 10.1074/jbc.M706190200.
- [0222] 27. Basilico C, Modica C, Maione F, Vigna E, Comoglio P M. Targeting the MET oncogene by concomitant inhibition of receptor and ligand via an antibody-"decoy" strategy. *Int J Cancer* 2018; e-pub ahead of print 2018/04/25; doi 10.1002/ijc.31550.
- [0223] 28. Ridgway J B, Presta L G, Carter P. 'Knobsinto-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. *Protein Eng* 1996; 9(7): 617-621.
- [0224] 29. Zhu Z, Presta L G, Zapata G, Carter P. Remodeling domain interfaces to enhance heterodimer formation. *Protein Sci* 1997; 6(4): 781-788; doi 10.1002/pro. 5560060404.
- [0225] 30. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. *Nat Rev Immunol* 2008; 8(6): 467-477; doi 10.1038/nri2326.
- [0226] 31. Garcia-Diaz A, Shin D S, Moreno B H, Saco J, Escuin-Ordinas H, Rodriguez G A et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression. *Cell Rep* 2017; 19(6): 1189-1201; doi 10.1016/j.celrep.2017.04.031.
- [0227] 32. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, Comoglio P M et al. Karyotypic analysis of gastric carcinoma cell lines carrying an amplified c-met oncogene. *Cancer Genet Cytogenet* 1992; 64(2): 170-173.
- **[0228]** 33. Atwell S, Ridgway J B, Wells J A, Carter P. Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. *J Mol Biol* 1997; 270(1): 26-35; doi 10.1006/jmbi.1997.1116.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 43 <210> SEQ ID NO 1 <211> LENGTH: 10 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: VL-CDR1 <400> SEQUENCE: 1 Gln Ser Val Asp Tyr Asp Gly Gly Ser Tyr 1 5 10 <210> SEQ ID NO 2 <211> LENGTH: 3 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: VL-CDR2 <400> SEQUENCE: 2 Ala Ala Ser 1 <210> SEQ ID NO 3 <211> LENGTH: 9 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: VL-CDR3 <400> SEQUENCE: 3 Gln Gln Ser Tyr Glu Asp Pro Leu Thr 1 5 <210> SEQ ID NO 4 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: VH-CDR1 <400> SEQUENCE: 4 Gly Tyr Thr Phe Thr Ser Tyr Trp 1 5 <210> SEQ ID NO 5 <211> LENGTH: 8 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: VH-CDR2 <400> SEQUENCE: 5 Ile Asn Pro Ser Ser Gly Arg Thr 1 5 <210> SEQ ID NO 6 <211> LENGTH: 5 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE:

<223> OTHER INFORMATION: VH-CDR3 <400> SEQUENCE: 6 Ala Ser Arg Gly Tyr 1 <210> SEQ ID NO 7 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL-cl03E08 <400> SEQUENCE: 7 Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Trp Val Pro 5 10 15 1 Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Asp Ser Leu Ala 25 30 20 Val Ser Leu Gly Gln Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser 35 40 45 Val Asp Tyr Asp Gly Gly Ser Tyr Met Ser Trp Phe Gln Gln Lys Pro 50 55 60 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser 65 70 75 80 Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95 Leu Thr Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Tyr Cys 110 100 105 Gln Gln Ser Tyr Glu Asp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 115 120 125 Glu Ile Lys 130 <210> SEQ ID NO 8 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH-cl03E08 <400> SEQUENCE: 8 Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp 5 10 1 Gly His Ser Gln Val Gln Leu Gln Gln Ser Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 40 45 35 Thr Ser Tyr Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Glu Ile Asn Pro Ser Ser Gly Arg Thr Asn Tyr Asn 65 70 75 80 Glu Lys Phe Lys Asn Arg Val Thr Val Thr Val Asp Lys Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Ala Ser Arg Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr

20

-continued	

<pre>211 > LENOTH: 107 2213 > TUPE: PET 2313 > ORGANISM: Homo sepiens 4400> SEQUENCE: 9 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 15 Sin Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 Pro Yarg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 50 Pro Yar Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 65 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 Pro Sec UP No 10 211 > LENNTH: 98 Pro Val Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 213 > ORGANISM: Homo sepiens 4400> SEQUENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 Phe Pro Gly Thr Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 40 Ser Ser Val Val Thr Val Ser Ser Ser Ser Leu Gly Thr Gln Thr 5 Py Tile Cys Asn Val Ann His Lys Pro Ser Ser Leu Gly Thr Gln Thr 5 Pry Tile Cys Asn Val Ann His Lys Pro Ser Ser Leu Gly Thr Gln Thr 5 Pry Tile Cys Asn Val Ann His Lys Fro (Knob mutation) 4 4 Callo> SEQUENCE: 11 Super Cys Asn Lys Thr First Fr (Knob mutation) 4 4 4 Callo> SEQUENCE: 11 Super Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 Callo Sequence: 11 Call Pro Ser Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr First Fr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Pro Ser Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr Pro Ser Ser Lys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr Pro Ser Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser Cys Asn Lys Thr Pro Ser Cys Pro Pro Cys Pro Ala 1 Call Pro Lys Ser</pre>											_	COII	tin	led	
130 210 SEQ ID NO 9 2112 EMRONENT: NOT 212 STORE PAT 212 STORE PAT 213 SOCRADIUM: Homo sequents 4400 SEQUENCE: 9 And Let Lyp Ser Gly Thr Ala Ser Val Phe 11e Phe Pro Pro Ser App Glu 10 21 Fr Pro Arg Glu Ala Lyp Val Gln Tpr Lyp Val App Am Ala Leu Gln 35 36 Gly Ann Ser Gln Glu Ser Val Thr Glu Gln App Ser Lyp App Ser 50 For Yar Arg Glu Ala Lyp Val Gln Tpr Lyp Val App Am Ala Leu Gln 35 37 Fr Pro Arg Glu Ala Lyp Val Gln Thr Glu Gln App Ser Lyp App Ser 50 For Yar Pro Arg Glu Ala Lyp Glu Val Thr Glu Gln Gly Leu Ser 50 For Val Thr Lyp Ger Phe Am Arg Gly Glu Val Thr His Gln Gly Leu Ser Ser 50 50 For Val Thr Lyp Ger Phe Am Arg Gly Glu Cyr 100 105 52 54 54 54 55 For Di No 10 51 54 54 55 For Thr Ser Lyp Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lyp 10 55 56 Thr Ser Gly Gly Thr Ala Ala Leu Gly Cyp Leu Val Lyp App Tyr 10 56 57 Thr Ser Lyp Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lyp 10 56 57 Thr Ser Gly Gly Thr Ala Ala Leu Gly Cyp Leu Val Lyp App Tyr 20 58 59 For Glu Pro Val Thr Val Ser Trp Ann Ser Gly Ala Leu Thr Ser 50 50 50 For Glu Pro Val Thr Val Ser Trp Ann Ser Gly La Leu Thr Ser 50 50 50 For Glu Pro Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 50 50 50 51 52 52 54 54 54 55 56 57 50 57 57 58 59 59 59 59 59 50 50 50 50 50 50 50 50 50 50		115	_		_		120	_	_	_	_	125	_	_	_
Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Aen Ala Leu Gln 35 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Cys Lys Asp Ser 50 55 57 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 57 70 70 70 70 70 70 75 75 75 77 78 79 70 70 70 75 70 75 77 70 70 75 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 70 75 75 75 75 75 70 75 75 75 75 75 75 75 75 75 75															
AND SEQUENCE: 9 Arg Thr Val Ala Ala Pro Ser Val Phe 10 Pho Pro Ser Asp Glu 10 10 Pro Arg Glu Ala Lyo Val Gln Trp Lyo Val Asp Asn Ala Leu Gln 35 40 40 40 40 40 40 40 40 40 40	<211> L <212> T	ENGTH YPE :	H: 10 PRT	07											
Arg Thr Val Ala Ala Pro Ser Val Phe11ePhePro Pro Ser Asp Glu111010102011Gln Leu Lye Ser Gly Thr Ala Ser Val Val Qu Cye Leu Leu Aen Aen Phe 202020Tyr Pro Arg Glu Ala Lye Val Gln Trp Lye Val Asp Aen Ala Leu Gln 4030Ser Gly Aen Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lye Asp Ser 5055Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lye Ala Asp Tyr Glu 7010070Val Thr Lye Ser Phe Aen Arg Gly Glu Cye 1002010 SEQ ID NO 10 2112 LENGTH: 982120 TPE: PRT 2123 CTPE: PRT2130 ORGANISM: Homo sapiene4000 SEQUENCE: 10Ala Ser Thr Lye Gly Pro Ser Val Phe 20Ala Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cye Leu Val Lye Asp Tyr 20Phe Pro Glu Pro Val Thr Val Ser Trp Aen Ser Gly Leu Tyr Ser 400Ser Stor For Cy Asp Val Asp His Lye Pro Ser Ser Leu Gly Thr Gln Thr 20Tyr ILe Cye Asn Val Asn His Lye Pro Ser Ser Leu Gly Thr Gln Thr 802010 SEQ ID NO 11 2012 TPTE: PRT2010 SEQ UENCE: 112010 SEQ UENCE: 11Clu Pro Lye Ser Cye Asp Lye Thr His Thr Cye Pro Pro Cye Pro Ala 20202 FERTURE: 202 SEQUENCE: 11Clu Pro Lye Ser Cye Asp Lye Thr His Thr Cye Pro Pro Cye Pro Ala 10210 Pro Lye Ser Cye Asp Lye Thr His Thr Cye Pro Pro Cye Pro Ala 10211 Pro Lye Ser Cye Asp Lye Thr His Thr Cye Pro Pro Cye Pro Ala 10212 Preve 213 Preve214 Prove 214215215216216217218219					o saj	pien	5								
1 5 10 15 Gln Leu Lye Ser Gly Thr Ala Ser Val Val Qal Cys Leu Leu Aan Aon Phe 20 Tyr Pro Arg Glu Ala Lye Val Gln Trp Lye Val Aep Aan Ala Leu Gln 35 Ser Gly Aon Ser Gln Glu Ser Val Thr Glu Gln Aep Ser Lye Aep Ser 50 50 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 95 Pro Val Thr Lye Ser Phe Asn Arg Gly Glu Cys 105 C210 > SEQ TD NO 10 C210 > SEQ UENCE: 10 Ala Ser Thr Lye Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 10 Fro Glu Pro Val Thr Val Ser Trp Aen Ser Gly Ala Leu Thr Ser 20 Phe Pro Gly Or Val Thr Val Ser Trp Aen Ser Gly Ala Leu Thr Ser 50 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 60 Cys Lys Asn Val Thr Val Ser Ser Ser Ser Lys 10 Cys Lus Ser Ser Val Val Thr Val Ser Ser Ser Lys 10 Fro Ser Ser Val Val Thr Val Ser Ser Gly Ala Leu Thr Ser 40 10 10 10 10 10 10 10 10 10 1					Deve	G		Dl	T] -	Dl	Deve	D	<i>a</i>	7	G]
202530Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Aan Ala Leu Gln 4545Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 5055Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 7080Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 9590Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys90200 > SEQ ID NO 10 211> LENGTH: 98212> TPE: PRT 212> Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 10Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 10Ala Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Leu Gly Thr Gln Thr 85Py His Lys Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 8561777070717575757575757575757575757575757575767778797970707071757575757575767677787979707575 <t< td=""><td>1</td><td></td><td></td><td>5</td><td></td><td></td><td></td><td></td><td>10</td><td></td><td></td><td></td><td></td><td>15</td><td></td></t<>	1			5					10					15	
35 40 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Ang Ser Lys Asp Ser 50 55 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 70 70 11 Lys Ser De Asn Arg Gly Glu Cys 100 10 20 105 2010 SEQ UENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 30 SEQUENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 40 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 Cys Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Lug Jys 10 15 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 55 Cys Val 20 58 Cys Val 210 58 210 10 11 210 59 210 58 210 58 210 58 210 10 11 210 58 211 5 212 58 213 58 214 58 215 215 215 215 215 215 216 216 216 217 218 219 210 58 219 219 210 210 58 219 210 210 58 210 10 211 210 58 210 58 210 10 211 211 212 58 213 58 213 214 215 215 215 215 215 215 215 215	Gln Leu	Lys		Gly	Thr	Ala	Ser		Val	Сүз	Leu	Leu		Asn	Phe
50 55 60 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 70 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 95 90 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 91 <210> SEQ ID NO 10 105 <211> LEMOTH: 98 93 <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 10 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 50 Fry Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Lang Hap Lys 90 Ser Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 Cys Val <210> SEQ ID NO 11 <211> LENOTH: 232 <212> OTHER INFORMATION: First Fc (Knob mutation) <400> SEQUENCE: 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 15	Tyr Pro	-	Glu	Ala	ГЛа	Val		Trp	Гла	Val	Asp		Ala	Leu	Gln
65 70 75 80 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 105 2110 > LEMCTH: 98 100 2210 > SEQ ID NO 10 <2111 > LEMCTH: 98 <2112 > LTYPE: PRT <2113 > URGANISM: Homo sapiens <400 > SEQUENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gln Ser Ser Gly Leu Tyr Ser 65 55 Clu Pro Val Thr Val Ser Trp Asn Ser Gly Leu Tyr Ser 60 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Leu Gly Thr Gln Thr 70 75 10 90 11 5 12 90 13 90 14 15	-	Asn	Ser	Gln	Glu		Val	Thr	Glu	Gln	_	Ser	Lys	Asp	Ser
90 95 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 100 10 (211> LENGTH: 98 (212> TYPE: PRT (213> ORGANISM: Homo sapiens (400> SEQUENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 40 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 50 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 10 10 11 (210> SEQ ID NO 11 (210> SEQ ID NO 11 (210> SEQ ID NO 11 (210> SEQ ID NO 11 (210> FEATURE: (223> OTHER INFORMATION: First Fc (Knob mutation) (400> SEQUENCE: 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 10 15 15 10 15 15 10 15 15 10 15 15 15 15 15 15 15 15 15 15	-	Ser	Leu	Ser		Thr	Leu	Thr	Leu		Lys	Ala	Asp	Tyr	
100 105 (210) SEQ ID NO 10 (211) LENGTH: 98 (212) TYPE: PET (213) ORGANISM: Homo sapiens (400) SEQUENCE: 10 Ala ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 20 20 20 20 25 20 20 20 25 20 20 20 20 25 20	Lys His	Lys	Val	-	Ala	Суз	Glu	Val		His	Gln	Gly	Leu		Ser
<pre><211> LENGTH: 98 <212> TYPE: PRT <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys 1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 55 5 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 90 95 Lys Val </pre>	Pro Val	Thr	-	Ser	Phe	Asn	Arg	_	Glu	Суз					
1 5 10 15 Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 30 Asp Tyr 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 Gly Ala Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 60 5 Gly Val His Thr Phe Pro Ala Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 80 Thr 80 70 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 80 Thr 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 95 90 Lys Val Seq ID NO 11 <210 > SEQ ID NO 11 <211 > LENGTH: 232 <212 > TYPE: PRT <213 > ORGANISM: artificial <220 > FEATURE: <211 > LUP TO Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 15	<211> L <212> T	ENGTH YPE :	H: 98 PRT	3	s sat	oien:	3								
Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 20 20 21 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 20 21 Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 45 20 22 22 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 22 22 22 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 22 22 22 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 90 20 29 29 Lys Val 2210 > SEQ ID NO 11 2212 > TYPE: PRT 2213 > ORGANISM: artificial $2200 > FEATURE:2223 > OTHER INFORMATION: First Fc (Knob mutation)400 > SEQUENCE: 11Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala10$ 15	<211> L <212> T <213> O	ENGTH YPE : RGANI	I: 98 PRT SM:	Homo	s saj	pien:	3								
202530Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35Gly Ala Lieu Thr Ser 40Ser Gly Leu Tyr Ser 60Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 80Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Thr Lys Val Asp Lys 85Ser Ser Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 90210> SEQ ID NO 11 <211> LENGTH: 232 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: First Fc (Knob mutation)<400> SEQUENCE: 11Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1011Star Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 10	<211> L <212> T <213> O <400> S Ala Ser	ENGTH YPE : RGANJ EQUEN	I: 98 PRT SM: NCE:	Homo 10 Gly	_	-		Phe		Leu	Ala	Pro	Ser		Гуз
35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 80 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Ser Jule Cly Thr Gln Thr 85 Ser Val Ser Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 90 Ser Val Asp Lys 95 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 Ser Val Val Ser Val Val Asp Lys 90 Ser Val Val Asp Lys 95 c210> SEQ ID NO 11 <211> LENGTH: 232 Ser Pro Cys Pro Tor Cys Pro Ala 10 Ser Val Val c210> SEQ ID NO 11 <221> TYPE: PRT Ser Val Val Ser Val Val c210> SEQ ID NO 11 <211> CRGNISM: artificial Ser Val Val c210> SEQ ID NO 11 <211> ORGANISM: artificial Ser Val Val c210> SEQUENCE: 11 Ser Val Val c400> SEQUENCE: 11 Ser Val Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 10 Ser Val Pro Ala	<211> L <212> T <213> O <400> S Ala Ser 1	ENGTH YPE : RGANJ EQUEN Thr	I: 98 PRT SM: NCE: Lys	Homo 10 Gly 5	Pro	Ser	Val		10					15	
50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 80 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val 85 90 95 <210> SEQ ID NO 11 90 95 <211> LENGTH: 232 232 212 <212> TYPE: PT 233> ORGANISM: artificial <220> FEATURE: 223> OTHER INFORMATION: First Fc (Knob mutation) <400> SEQUENCE: 11 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 10 1 5 10 15	<211> L <212> T <213> O <400> S Ala Ser 1	ENGTH YPE : RGANJ EQUEN Thr	H: 98 PRT SM: ICE: Lys Gly	Homo 10 Gly 5	Pro	Ser	Val	Leu	10				Lys	15	
65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 90 95 95 Lys Val 210> SEQ ID NO 11 91 91 <210> SEQ ID NO 11 232 91 95 <211> LENGTH: 232 2212> TYPE: PRT 91 91 <213> ORGANISM: artificial 220> FEATURE: 91 91 <223> OTHER INFORMATION: First Fc (Knob mutation) 400> SEQUENCE: 11 10 15	<211> L <212> T <213> O <400> S Ala Ser 1 Ser Thr	ENGTH YPE: RGANJ EQUEN Thr Ser Glu	I: 98 PRT SM: ICE: Lys Gly 20	Homo 10 Gly 5 Gly	Pro Thr	Ser Ala	Val Ala Ser	Leu 25	10 Gly	Суз	Leu	Val Ala	Lуз 30	15 Asp	Tyr
85 90 95 Lys Val <210> SEQ ID NO 11 <211> LENGTH: 232 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: First Fc (Knob mutation) <400> SEQUENCE: 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15	<211> L <212> T <213> O <400> S Ala Ser 1 Ser Thr Phe Pro Gly Val	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35	I: 98 PRT SM: ICE: Lys Gly 20 Pro	Homo 10 Gly 5 Gly Val	Pro Thr Thr	Ser Ala Val Ala	Val Ala Ser 40	Leu 25 Trp	10 Gly Asn	Cys Ser	Leu Gly Ser	Val Ala 45	Lys 30 Leu	15 Asp Thr	Tyr Ser
<pre><210> SEQ ID NO 11 <211> LENGTH: 232 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: First Fc (Knob mutation) <400> SEQUENCE: 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15</pre>	<pre><211> L <212> T <213> 0 <400> S Ala Ser 1 Ser Thr Phe Pro Gly Val 50 Leu Ser</pre>	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35 His	I: 96 PRT SM: UCE: Lys Gly 20 Pro Thr	Homo 10 Gly 5 Gly Val Phe	Pro Thr Thr Pro Thr	Ser Ala Val Ala 55	Val Ala Ser 40 Val	Leu 25 Trp Leu	10 Gly Asn Gln	Cys Ser Ser Ser	Leu Gly Ser 60	Val Ala 45 Gly	Lys 30 Leu Leu	15 Asp Thr Tyr	Tyr Ser Ser Thr
<pre><211> LENGTH: 232 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: First Fc (Knob mutation) <400> SEQUENCE: 11 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15</pre>	<pre><211> L <211> Z <212> T <213> 0 <400> S Ala Ser 1 Ser Thr Phe Pro Gly Val 50 Leu Ser 55</pre>	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35 His Ser	H: 96 PRT SM: ICE: Lys Gly 20 Pro Thr Val	Homo 10 Gly 5 Gly Val Phe Val Val	Pro Thr Thr Pro Thr 70	Ser Ala Val Ala 55 Val	Val Ala Ser 40 Val Pro	Leu 25 Trp Leu Ser	10 Gly Asn Gln Ser Ser	Cys Ser Ser Ser 75	Leu Gly Ser 60 Leu	Val Ala 45 Gly Gly	Lys 30 Leu Leu Thr	15 Asp Thr Tyr Gln Asp	Tyr Ser Ser Thr 80
Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15	<pre><211> L <212> T <213> O <400> S Ala Ser 1 Ser Thr Phe Pro 3ly Val 50 Leu Ser 55 Fyr Ile</pre>	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35 His Ser Cys	H: 96 PRT SM: ICE: Lys Gly 20 Pro Thr Val	Homo 10 Gly 5 Gly Val Phe Val Val	Pro Thr Thr Pro Thr 70	Ser Ala Val Ala 55 Val	Val Ala Ser 40 Val Pro	Leu 25 Trp Leu Ser	10 Gly Asn Gln Ser Ser	Cys Ser Ser Ser 75	Leu Gly Ser 60 Leu	Val Ala 45 Gly Gly	Lys 30 Leu Leu Thr	15 Asp Thr Tyr Gln Asp	Tyr Ser Ser Thr 80
1 5 10 15	<pre><211> L <212> T <212> T <213> O <400> S Ala Ser 1 Ser Thr Phe Pro Gly Val 50 Leu Ser 55 Fyr Ile Lys Val <210> S <211> L <212> T <212> T <212> T <212> F</pre>	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35 His Ser Cys EQ II ENGTH YPE: RGANJ EATUF	I: 96 PRT SM: SM: Lys Gly 20 Pro Thr Val Asn Val Asn SSM: SM: SM:	Homo 10 Gly 5 Gly Val Phe Val 85 11 32 art:	Pro Thr Thr Pro Thr 70 Asn	Ser Ala Val Ala 55 Val His	Val Ala Ser 40 Val Pro Lys	Leu 25 Trp Leu Ser Pro	10 Gly Asn Gln Ser 90	Cys Ser Ser Ser 75 Asn	Leu Gly Ser 60 Leu Thr	Val Ala 45 Gly Gly Lys	Lys 30 Leu Leu Thr	15 Asp Thr Tyr Gln Asp	Tyr Ser Ser Thr 80
	<pre><211> L <212> T <212> T <213> O <400> S Ala Ser 1 Ser Thr Phe Pro Gly Val 50 Leu Ser 55 Tyr Ile <210> S <211> L <210> S <211> L <212> T <213> O <220> S <221> O</pre>	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35 His Ser Cys EQ II ENGTH YPE: RGANJ	I: 96 PRT SM: CE: Lys Gly 20 Pro Thr Val Asn Val Asn I: 2: PRT :SM: INF(Homo 10 Gly 5 Gly Val Val Val Val 85 11 32 art: DRMA:	Pro Thr Thr Pro Thr 70 Asn	Ser Ala Val Ala 55 Val His	Val Ala Ser 40 Val Pro Lys	Leu 25 Trp Leu Ser Pro	10 Gly Asn Gln Ser 90	Cys Ser Ser Ser 75 Asn	Leu Gly Ser 60 Leu Thr	Val Ala 45 Gly Gly Lys	Lys 30 Leu Leu Thr	15 Asp Thr Tyr Gln Asp	Tyr Ser Ser Thr 80
	<pre><211> L <212> T <212> T <213> O <400> S Ala Ser I Ser Thr Phe Pro Gly Val 50 Leu Ser 55 Fyr Ile Lys Val <210> S <210> S <211> L <212> T <213> O <220> F <223> O <400> S Glu Pro</pre>	ENGTH YPE: RGANJ EQUEN Thr Ser Glu 35 His Ser Cys EQ II ENGTH YPE: RGANJ EATUR THER EQUEN	I: 96 PRT SM: CE: Lys Gly 20 Pro Thr Val Asn Val Asn O NO I: 2: SM: SM: INF(ICE:	Homod 10 Gly 5 Gly Val Phe Val 85 11 32 art: DRMA: 11	Pro Thr Thr Pro Thr 70 Asn ific:	Ser Ala Val Ala 55 Val His	Val Ala Ser 40 Val Pro Lys	Leu 25 Leu Ser Pro	10 Gly Asn Gln Ser 90 Xnob	Cys Ser Ser 75 Asn muta	Leu Gly Ser 60 Leu Thr	Val Ala 45 Gly Lys	Lys 30 Leu Leu Thr Val	15 Asp Thr Tyr Gln Asp 95	Tyr Ser Ser Thr 80 Lys

-cont:	inued
--------	-------

			20					25					30		
Lys .	Asp	Thr 35	Leu	Met	Ile	Ser	Arg 40	Thr	Pro	Glu	Val	Thr 45	Суз	Val	Val
Val .	Asp 50	Val	Ser	His	Glu	Asp 55	Pro	Glu	Val	Lys	Phe 60	Asn	Trp	Tyr	Val
Asp 65	Gly	Val	Glu	Val	His 70	Asn	Ala	Lys	Thr	Lys 75	Pro	Arg	Glu	Glu	Gln 80
Tyr .	Asn	Ser	Thr	Tyr 85	Arg	Val	Val	Ser	Val 90	Leu	Thr	Val	Leu	His 95	Gln
Asp	Trp	Leu	Asn 100	Gly	ГЛа	Glu	Tyr	Lys 105	Суз	Lys	Val	Ser	Asn 110	Lys	Ala
Leu	Pro	Ala 115	Pro	Ile	Glu	Гла	Thr 120	Ile	Ser	Гла	Ala	Lys 125	Gly	Gln	Pro
Arg	Glu 130	Pro	Gln	Val	Tyr	Thr 135	Leu	Pro	Pro	Ser	Arg 140	Asp	Glu	Leu	Thr
Lys . 145	Asn	Gln	Val	Ser	Leu 150	Trp	Сүз	Leu	Val	Lys 155	Gly	Phe	Tyr	Pro	Ser 160
Asp	Ile	Ala	Val	Glu 165	Trp	Glu	Ser	Asn	Gly 170	Gln	Pro	Glu	Asn	Asn 175	Tyr
Lys	Thr	Thr	Pro 180	Pro	Val	Leu	Asp	Ser 185	Asp	Gly	Ser	Phe	Phe 190	Leu	Tyr
Ser	Lys	Leu 195	Thr	Val	Asp	Lys	Ser 200	Arg	Trp	Gln	Gln	Gly 205	Asn	Val	Phe
Ser	Cys 210	Ser	Val	Met	His	Glu 215	Ala	Leu	His	Asn	His 220	Tyr	Thr	Gln	Lys
Ser 225	Leu	Ser	Leu	Ser	Pro 230	Gly	Lys								
<210 <211 <212 <213 <220	> LH > TY > OH > FH	ENGTI (PE : RGAN] EATUI	H: 24 PRT ISM: RE:	46 art:											
<223					LION	: Seo	cond	FC	(HOI6	e mut	tatio	ons)			
Met 1		_			Ile	Ile	Leu	Phe	Leu 10	Val	Ala	Thr	Ala	Thr 15	Asp
Gly :	His	Ser	Asp 20	Lys	Thr	His	Thr	Суз 25	Pro	Pro	Сүз	Pro	Ala 30	Pro	Glu
Leu	Leu	Gly 35	Gly	Pro	Ser	Val	Phe 40	Leu	Phe	Pro	Pro	Lys 45	Pro	Lys	Asp
Thr	Leu 50	Met	Ile	Ser	Arg	Thr 55	Pro	Glu	Val	Thr	Суз 60	Val	Val	Val	Азр
Val 65	Ser	His	Glu	Asp	Pro 70	Glu	Val	Lys	Phe	Asn 75	Trp	Tyr	Val	Asp	Gly 80
Val	Glu	Val	His	Asn 85	Ala	Гла	Thr	Гла	Pro 90	Arg	Glu	Glu	Gln	Tyr 95	Asn
Ser	Thr	Tyr	Arg 100	Val	Val	Ser	Val	Leu 105	Thr	Val	Leu	His	Gln 110	Asp	Trp
Leu .	Asn	Gly 115	Lys	Glu	Tyr	Lys	Cys 120	Lys	Val	Ser	Asn	Lys 125	Ala	Leu	Pro
Ala	Pro	Ile	Glu	ГЛа	Thr	Ile	Ser	ГЛа	Ala	Lys	Gly	Gln	Pro	Arg	Glu

Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Ser Cys Ala Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Val Ser Lys 195 200 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys <210> SEQ ID NO 13 <211> LENGTH: 976 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Decoy Met wt-TAGs <400> SEOUENCE: 13 Met Lys Ala Pro Ala Val Leu Ala Pro Gly Ile Leu Val Leu Leu Phe Thr Leu Val Gln Arg Ser Asn Gly Glu Cys Lys Glu Ala Leu Ala Lys Ser Glu Met Asn Val Asn Met Lys Tyr Gln Leu Pro Asn Phe Thr Ala Glu Thr Pro Ile Gln Asn Val Ile Leu His Glu His His Ile Phe Leu Gly Ala Thr Asn Tyr Ile Tyr Val Leu Asn Glu Glu Asp Leu Gln Lys Val Ala Glu Tyr Lys Thr Gly Pro Val Leu Glu His Pro Asp Cys Phe Pro Cys Gln Asp Cys Ser Ser Lys Ala Asn Leu Ser Gly Gly Val Trp Lys Asp Asn Ile Asn Met Ala Leu Val Val Asp Thr Tyr Tyr Asp Asp Gln Leu Ile Ser Cys Gly Ser Val Asn Arg Gly Thr Cys Gln Arg His Val Phe Pro His Asn His Thr Ala Asp Ile Gln Ser Glu Val His Cys Ile Phe Ser Pro Gln Ile Glu Glu Pro Ser Gln Cys Pro Asp Cys Val Val Ser Ala Leu Gly Ala Lys Val Leu Ser Ser Val Lys Asp Arg Phe Ile Asn Phe Phe Val Gly Asn Thr Ile Asn Ser Ser Tyr Phe Pro Asp His Pro Leu His Ser Ile Ser Val Arg Arg Leu Lys Glu Thr Lys Asp Gly Phe Met Phe Leu Thr Asp Gln Ser Tyr Ile Asp Val Leu Pro Glu

-continued

225					230					235					240
Phe	Arg	Asp	Ser	Tyr 245	Pro	Ile	Lys	Tyr	Val 250	His	Ala	Phe	Glu	Ser 255	Asn
Asn	Phe	Ile	Tyr 260	Phe	Leu	Thr	Val	Gln 265	Arg	Glu	Thr	Leu	Asp 270	Ala	Gln
Thr	Phe	His 275	Thr	Arg	Ile	Ile	Arg 280		Сүз	Ser	Ile	Asn 285	Ser	Gly	Leu
His	Ser 290	Tyr	Met	Glu	Met	Pro 295	Leu	Glu	Cys	Ile	Leu 300	Thr	Glu	Lys	Arg
Lуз 305	ГЛа	Arg	Ser	Thr	Lys 310	Lya	Glu	Val	Phe	Asn 315	Ile	Leu	Gln	Ala	Ala 320
Tyr	Val	Ser	Lys	Pro 325	Gly	Ala	Gln	Leu	Ala 330	Arg	Gln	Ile	Gly	Ala 335	Ser
Leu	Asn	Asp	Asp 340	Ile	Leu	Phe	Gly	Val 345	Phe	Ala	Gln	Ser	Lys 350	Pro	Asp
Ser	Ala	Glu 355	Pro	Met	Asp	Arg	Ser 360	Ala	Met	Cya	Ala	Phe 365	Pro	Ile	ГЛа
Tyr	Val 370		Asp	Phe	Phe	Asn 375	-	Ile	Val	Asn	Lys 380	Asn	Asn	Val	Arg
Сув 385	Leu	Gln	His	Phe	Tyr 390			Asn	His	Glu 395		Сүз	Phe	Asn	Arg 400
	Leu	Leu	Arg	Asn 405		Ser	Gly	Суз	Glu 410		Arg	Arg	Asp	Glu 415	
Arg	Thr	Glu			Thr	Ala	Leu			Val	Asp	Leu			Gly
Gln	Phe		420 Glu	Val	Leu	Leu		425 Ser	Ile	Ser	Thr		430 Ile	Lys	Gly
Asp	Leu	435 Thr	Ile	Ala	Asn	Leu	440 Gly	Thr	Ser	Glu	Gly	445 Arg	Phe	Met	Gln
Val	450 Val	Val	Ser	Arq	Ser	455 Glv	Pro	Ser	Thr	Pro	460 His	Val	Asn	Phe	Leu
465	Asp			-	470	-				475					480
	-			485					490					495	
Asn	Gln	Asn	Gly 500	Tyr	Thr	Leu	Val	Ile 505	Thr	Gly	Lys	Lys	Ile 510	Thr	Гла
Ile	Pro	Leu 515	Asn	Gly	Leu	Gly	Суз 520	-	His	Phe	Gln	Ser 525	Суз	Ser	Gln
Суз	Leu 530	Ser	Ala	Pro	Pro	Phe 535	Val	Gln	Суз	Gly	Trp 540	CAa	His	Aab	ГЛа
Cys 545	Val	Arg	Ser	Glu	Glu 550	Cys	Leu	Ser	Gly	Thr 555	Trp	Thr	Gln	Gln	Ile 560
СЛа	Leu	Pro	Ala	Ile 565	Tyr	Lys	Val	Phe	Pro 570	Asn	Ser	Ala	Pro	Leu 575	Glu
Gly	Gly	Thr	Arg 580	Leu	Thr	Ile	Суз	Gly 585	Trp	Asp	Phe	Gly	Phe 590	Arg	Arg
Asn	Asn	Lys 595	Phe	Asp	Leu	ГÀа	Lys 600	Thr	Arg	Val	Leu	Leu 605	Gly	Asn	Glu
Ser	Cys 610	Thr	Leu	Thr	Leu	Ser 615	Glu	Ser	Thr	Met	Asn 620	Thr	Leu	Lys	Cys
	Val	Gly	Pro	Ala			Lys	His	Phe			Ser	Ile	Ile	
625					630					635					640

-	CC	nt	in	ue	d

Ser Asn Gly His Gly Thr Thr Gln Tyr Ser Thr Phe Ser Tyr Val Asp Pro Val Ile Thr Ser Ile Ser Pro Lys Tyr Gly Pro Met Ala Gly Gly Thr Leu Leu Thr Leu Thr Gly Asn Tyr Leu Asn Ser Gly Asn Ser Arg His Ile Ser Ile Gly Gly Lys Thr Cys Thr Leu Lys Ser Val Ser Asn Ser Ile Leu Glu Cys Tyr Thr Pro Ala Gln Thr Ile Ser Thr Glu Phe705710715720 Ala Val Lys Leu Lys Ile Asp Leu Ala Asn Arg Glu Thr Ser Ile Phe Ser Tyr Arg Glu Asp Pro Ile Val Tyr Glu Ile His Pro Thr Lys Ser 740 745 Phe Ile Ser Gly Gly Ser Thr Ile Thr Gly Val Gly Lys Asn Leu Asn Ser Val Ser Val Pro Arg Met Val Ile Asn Val His Glu Ala Gly Arg Asn Phe Thr Val Ala Cys Gln His Arg Ser Asn Ser Glu Ile Ile Cys Cys Thr Thr Pro Ser Leu Gln Gln Leu Asn Leu Gln Leu Pro Leu Lys Thr Lys Ala Phe Phe Met Leu Asp Gly Ile Leu Ser Lys Tyr Phe Asp Leu Ile Tyr Val His Asn Pro Val Phe Lys Pro Phe Glu Lys Pro Val Met Ile Ser Met Gly Asn Glu Asn Val Leu Glu Ile Lys Gly Asn Asp Ile Asp Pro Glu Ala Val Lys Gly Glu Val Leu Lys Val Gly Asn Lys Ser Cys Glu Asn Ile His Leu His Ser Glu Ala Val Leu Cys Thr Val Pro Asn Asp Leu Leu Lys Leu Asn Ser Glu Leu Asn Ile Glu Trp Lys Gln Ala Ile Ser Ser Thr Val Leu Gly Lys Val Ile Val Gln Pro Asp Gln Asn Phe Thr Ala Ser Gly Ala Ala Trp Ser His Pro Gln Phe Glu Lys Gly Ala Ala Trp Ser His Pro Gln Phe Glu Lys Gly Ala Ala Trp Ser His Pro Gln Phe Glu Lys Gly Ala Ala His His His His His His <210> SEQ ID NO 14 <211> LENGTH: 976 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE:

<223> OTHER INFORMATION: Decoy Met mutation K842E-TAGs

<400> SEQUENCE: 14

Met Lys Ala Pro Ala Val Leu Ala Pro Gly Ile Leu Val Leu Leu Phe 1 5 10 15

Thr	Leu	Val	Gln 20	Arg	Ser	Asn	Gly	Glu 25	Суз	Lys	Glu	Ala	Leu 30	Ala	Lys
Ser	Glu	Met 35	Asn	Val	Asn	Met	Lys 40	Tyr	Gln	Leu	Pro	Asn 45	Phe	Thr	Ala
Glu	Thr 50	Pro	Ile	Gln	Asn	Val 55	Ile	Leu	His	Glu	His 60	His	Ile	Phe	Leu
Gly 65	Ala	Thr	Asn	Tyr	Ile 70	Tyr	Val	Leu	Asn	Glu 75	Glu	Asp	Leu	Gln	Lys 80
Val	Ala	Glu	Tyr	Lys 85	Thr	Gly	Pro	Val	Leu 90	Glu	His	Pro	Asp	Суз 95	Phe
Pro	Суз	Gln	Asp 100	Суз	Ser	Ser	Lys	Ala 105	Asn	Leu	Ser	Gly	Gly 110	Val	Trp
rÀa	Asp	Asn 115	Ile	Asn	Met	Ala	Leu 120	Val	Val	Asp	Thr	Tyr 125	Tyr	Aab	Asp
Gln	Leu 130	Ile	Ser	СЛа	Gly	Ser 135	Val	Asn	Arg	Gly	Thr 140	СЛа	Gln	Arg	His
Val 145	Phe	Pro	His	Asn	His 150	Thr	Ala	Asp	Ile	Gln 155	Ser	Glu	Val	His	Cys 160
Ile	Phe	Ser	Pro	Gln 165	Ile	Glu	Glu	Pro	Ser 170	Gln	Сүз	Pro	Asp	Cys 175	Val
Val	Ser	Ala	Leu 180	Gly	Ala	Lys	Val	Leu 185	Ser	Ser	Val	Lys	Asp 190	Arg	Phe
Ile	Asn	Phe 195	Phe	Val	Gly	Asn	Thr 200	Ile	Asn	Ser	Ser	Tyr 205	Phe	Pro	Asp
His	Pro 210	Leu	His	Ser	Ile	Ser 215	Val	Arg	Arg	Leu	Lys 220	Glu	Thr	Lys	Asp
Gly 225	Phe	Met	Phe	Leu	Thr 230	Asp	Gln	Ser	Tyr	Ile 235	Asp	Val	Leu	Pro	Glu 240
Phe	Arg	Asp	Ser	Tyr 245	Pro	Ile	Lys	Tyr	Val 250	His	Ala	Phe	Glu	Ser 255	Asn
Asn	Phe	Ile	Tyr 260	Phe	Leu	Thr	Val	Gln 265	Arg	Glu	Thr	Leu	Asp 270	Ala	Gln
Thr	Phe	His 275	Thr	Arg	Ile	Ile	Arg 280	Phe	Суз	Ser	Ile	Asn 285	Ser	Gly	Leu
His	Ser 290	Tyr	Met	Glu	Met	Pro 295	Leu	Glu	Суз	Ile	Leu 300	Thr	Glu	Lys	Arg
Lys 305	Lys	Arg	Ser	Thr	Lys 310	Lys	Glu	Val	Phe	Asn 315	Ile	Leu	Gln	Ala	Ala 320
Tyr	Val	Ser	Lys	Pro 325	Gly	Ala	Gln	Leu	Ala 330	Arg	Gln	Ile	Gly	Ala 335	Ser
Leu	Asn	Asp	Asp 340	Ile	Leu	Phe	Gly	Val 345	Phe	Ala	Gln	Ser	Lys 350	Pro	Asp
Ser	Ala	Glu 355	Pro	Met	Asp	Arg	Ser 360	Ala	Met	Суз	Ala	Phe 365	Pro	Ile	Lys
Tyr	Val 370	Asn	Asp	Phe	Phe	Asn 375	Lys	Ile	Val	Asn	Lys 380	Asn	Asn	Val	Arg
Cys 385	Leu	Gln	His	Phe	Tyr 390	Gly	Pro	Asn	His	Glu 395	His	Суз	Phe	Asn	Arg 400
Thr	Leu	Leu	Arg	Asn 405	Ser	Ser	Gly	Суз	Glu 410	Ala	Arg	Arg	Asp	Glu 415	Tyr

											-	con	tin	ued	
Arg	Thr	Glu	Phe 420	Thr	Thr	Ala	Leu	Gln 425	Arg	Val	Asp	Leu	Phe 430	Met	Gly
Gln	Phe	Ser 435	Glu	Val	Leu	Leu	Thr 440	Ser	Ile	Ser	Thr	Phe 445	Ile	Lys	Gly
Asp	Leu 450	Thr	Ile	Ala	Asn	Leu 455		Thr	Ser	Glu	Gly 460	Arg	Phe	Met	Gln
Val 465	Val	Val	Ser	Arg	Ser 470	Gly	Pro	Ser	Thr	Pro 475	His	Val	Asn	Phe	Leu 480
Leu	Asp	Ser	His	Pro 485	Val	Ser	Pro	Glu	Val 490	Ile	Val	Glu	His	Thr 495	Leu
Asn	Gln	Asn	Gly 500		Thr	Leu	Val	Ile 505	Thr	Gly	Lys	Lys	Ile 510	Thr	Lys
Ile	Pro	Leu 515	Asn	Gly	Leu	Gly	Cys 520	Arg	His	Phe	Gln	Ser 525	Суз	Ser	Gln
Суз	Leu 530	Ser	Ala	Pro	Pro	Phe 535	Val	Gln	Суз	Gly	Trp 540	Суз	His	Asp	Lys
Cys 545	Val	Arg	Ser	Glu	Glu 550	-	Leu	Ser	Gly	Thr 555	_	Thr	Gln	Gln	Ile 560
Сүз	Leu	Pro	Ala	Ile 565	Tyr	Lys	Val	Phe	Pro 570	Asn	Ser	Ala	Pro	Leu 575	Glu
Gly	Gly	Thr	Arg 580	Leu	Thr	Ile	Сүз	Gly 585	Trp	Asp	Phe	Gly	Phe 590	Arg	Arg
Asn	Asn	Lys 595	Phe	Asp	Leu	Lys	Lys 600	Thr	Arg	Val	Leu	Leu 605	Gly	Asn	Glu
Ser	Cys 610	Thr	Leu	Thr	Leu	Ser 615	Glu	Ser	Thr	Met	Asn 620	Thr	Leu	Lys	Сүв
Thr 625	Val	Gly	Pro	Ala	Met 630	Asn	Lys	His	Phe	Asn 635	Met	Ser	Ile	Ile	Ile 640
	Asn	Gly	His	Gly 645	Thr	Thr	Gln	Tyr	Ser 650	Thr	Phe	Ser	Tyr	Val 655	Asp
Pro	Val	Ile	Thr 660			Ser	Pro	Lys 665		Gly	Pro	Met	Ala 670	Gly	Gly
Thr	Leu	Leu 675		Leu	Thr	Gly	Asn 680		Leu	Asn	Ser	Gly 685		Ser	Arg
His	Ile 690		Ile	Gly	Gly	Lys 695		Суз	Thr	Leu	Lys 700		Val	Ser	Asn
Ser 705		Leu	Glu	Суз	Tyr 710		Pro	Ala	Gln			Ser	Thr	Glu	Phe 720
	Val	Lys	Leu	-		Asp	Leu	Ala	Asn 730	715 Arg	Glu	Thr	Ser	Ile 735	
Ser	Tyr	Arg		725 Asp	Pro	Ile	Val	Tyr 745		Ile	His	Pro		Lys	Ser
Phe	Ile		740 Gly	Gly	Ser	Thr			Gly	Val	Gly		750 Asn	Leu	Asn
Ser		755 Ser	Val	Pro	Arg		760 Val	Ile	Asn	Val		765 Glu	Ala	Gly	Arg
Asn	770 Phe	Thr	Val	Ala	Cys	775 Gln	His	Arg	Ser	Asn	780 Ser	Glu	Ile	Ile	Cys
785					790					795				Leu	800
-				805					810					815	-
Thr	Lys	Ala	Phe	Phe	Met	Leu	Asp	Gly	Ile	Leu	Ser	Lys	Tyr	Phe	Asp

-continued

			820					825					830		
Leu	Ile	Tyr 835	Val	His	Asn	Pro	Val 840	Phe	Glu	Pro	Phe	Glu 845	Lys	Pro	Val
Met	Ile 850	Ser	Met	Gly	Asn	Glu 855	Asn	Val	Leu	Glu	Ile 860	Lys	Gly	Asn	Asp
Ile 865	Asp	Pro	Glu	Ala	Val 870	Lys	Gly	Glu	Val	Leu 875	Lys	Val	Gly	Asn	Lys 880
Ser	Cys	Glu	Asn	Ile 885	His	Leu	His	Ser	Glu 890	Ala	Val	Leu	Суз	Thr 895	Val
Pro	Asn	Asp	Leu 900	Leu	ГЛа	Leu	Asn	Ser 905	Glu	Leu	Asn	Ile	Glu 910	Trp	Lys
Gln	Ala	Ile 915	Ser	Ser	Thr	Val	Leu 920	Gly	Lys	Val	Ile	Val 925	Gln	Pro	Asp
Gln	Asn 930	Phe	Thr	Ala	Ser	Gly 935	Ala	Ala	Trp	Ser	His 940	Pro	Gln	Phe	Glu
Lys 945	Gly	Ala	Ala	Trp	Ser 950	His	Pro	Gln	Phe	Glu 955	ГЛа	Gly	Ala	Ala	Trp 960
Ser	His	Pro	Gln	Phe 965	Glu	Lys	Gly	Ala	Ala 970	His	His	His	His	His 975	His
<220 <223	3> OF D> FF 3> OT D> SF	CATUI THER	RE: INF(ORMA'			rine	VL							
Met 1	Glu	Thr	Asp	Thr 5	Ile	Leu	Leu	Trp	Val 10	Leu	Leu	Leu	Trp	Val 15	Pro
Gly	Ser	Thr	Gly 20	Asp	Ile	Val	Leu	Thr 25	Gln	Ser	Pro	Ala	Ser 30	Leu	Ala
Val	Ser	Leu 35	Gly	Gln	Arg	Ala	Thr 40	Ile	Ser	Суз	ГЛа	Ala 45	Ser	Gln	Ser
Val	Asp 50	Tyr	Asp	Gly	Gly	Ser 55	Tyr	Met	Ser	Trp	Phe 60	Gln	Gln	Arg	Pro
Gly 65	Gln	Pro	Pro	ГЛа	Leu 70	Leu	Ile	Ser	Ala	Ala 75	Ser	Asn	Leu	Glu	Ser 80
Gly	Ile	Pro	Ala	Arg 85	Phe	Ser	Gly	Ser	Gly 90	Ser	Gly	Thr	Asp	Phe 95	Thr
Leu	Asn	Ile	His 100	Pro	Val	Glu	Glu	Glu 105	Asp	Val	Ala	Thr	Tyr 110	Tyr	CÀa
Gln	Gln	Ser 115	Tyr	Glu	Asp	Pro	Leu 120	Thr	Phe	Gly	Ala	Gly 125	Thr	LÀa	Val
Glu	Ile 130	Гла													
<21: <21: <21: <22: <22:	0> SH 1> LH 2> TY 3> OH 0> FH 3> OT	ENGTH (PE : RGAN] EATUH CHER	H: 13 PRT ISM: RE: INFO	31 art: DRMA			rine	VH							
<400)> SH	sQUEI	NCE:	16											

-continued

													υIII	ueu	
Met G 1	ly	Trp	Ser	Tyr 5	Ile	Ile	Leu	Phe	Leu 10	Val	Ala	Thr	Ala	Thr 15	Asp
Gly H	lis	Ser	Gln 20	Val	Gln	Leu	Gln	Gln 25	Pro	Gly	Thr	Glu	Leu 30	Val	Lys
Pro G	-	Ala 35	Ser	Val	Lys	Leu	Ser 40	Суз	Lys	Ala	Ser	Gly 45	Tyr	Thr	Phe
Thr S 5	er 0	Tyr	Trp	Ile	His	Trp 55	Val	Lys	Gln	Arg	Pro 60	Gly	Gln	Gly	Leu
Glu T 65	rp	Ile	Gly	Glu	Ile 70	Asn	Pro	Ser	Ser	Gly 75	Arg	Thr	Asn	Tyr	Asn 80
Glu L	ya	Phe	Lys	Asn 85	ГЛа	Val	Thr	Val	Thr 90	Val	Asp	ГЛа	Ser	Ser 95	Thr
Thr A	la	Tyr	Met 100	Gln	Leu	Ser	Asn	Leu 105	Thr	Ser	Glu	Aap	Ser 110	Ala	Val
Tyr T	-	Cys 115	Ala	Ser	Arg	Gly	Tyr 120	Trp	Gly	Gln	Gly	Thr 125	Thr	Leu	Thr
Val S 1	er 30	Ser													
<210><211><211><212><212><213><220><223>	· LE · TY · OR · FE · OT	NGTH PE: GANI ATUR HER	H: 1: PRT ISM: RE: INFO	31 art: ORMA			mani:	zed N	/L-c]	103G	05				
<400>	SE	:QUEI	NCE:	17											
Met G 1	lu	Thr	Asb	Thr 5	Ile	Leu	Leu	Trp	Val 10	Leu	Leu	Leu	Trp	Val 15	Pro
Gly S	er	Thr	Gly 20	Asp	Ile	Val	Leu	Thr 25	Gln	Ser	Pro	Ala	Ser 30	Leu	Ala
Val S		Leu 35	Gly	Glu	Arg	Ala	Thr 40	Ile	Ser	Сүз	Lys	Ala 45	Ser	Gln	Ser
Val A 5	o 10	Tyr	Asp	Gly	Gly	Ser 55	Tyr	Met	Ser	Trp	Phe 60	Gln	Gln	Arg	Pro
Gly G 65	ln	Pro	Pro	ГЛа	Leu 70	Leu	Ile	Tyr	Ala	Ala 75	Ser	Asn	Leu	Glu	Ser 80
Gly V	al	Pro	Asp	Arg 85	Phe	Ser	Gly	Ser	Gly 90	Ser	Gly	Thr	Asp	Phe 95	Thr
Leu A	sn	Ile	Ser 100	Pro	Leu	Glu	Ala	Glu 105	Asp	Val	Ala	Val	Tyr 110	Tyr	СЛа
Gln G		Ser 115	Tyr	Glu	Asp	Pro	Leu 120	Thr	Phe	Gly	Gly	Gly 125	Thr	Lys	Val
Glu I 1	le 30	Lys													
<210> <211> <212> <213> <223>	· LE · TY · OR · FE	NGTH PE: GANI ATUR	H: 1: PRT ISM: RE:	31 art:			mani:	zed N	/H-c]	103G	05				
<400>	· SE	QUE	ICE :	18											
Met G 1	ly	Trp	Ser	Tyr 5	Ile	Ile	Leu	Phe	Leu 10	Val	Ala	Thr	Ala	Thr 15	Asp

```
-continued
```

Gly His Ser Gln Val Gln Leu Val Gln Pro Gly Thr Glu Val Lys Lys 25 20 30 Pro Gly Ala Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Thr Ser Tyr Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 60 50 55 Glu Trp Met Gly Glu Ile Asn Pro Ser Ser Gly Arg Thr Asn Tyr Asn 70 65 75 Glu Lys Phe Lys Asn Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser 85 90 Thr Ala Tyr Met Gln Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 105 110 100 Tyr Tyr Cys Ala Ser Arg Gly Tyr Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> SEQ ID NO 19 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL-cl03F04 <400> SEQUENCE: 19 Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala 20 25 30 Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser 35 40 45 Val Asp Tyr Asp Gly Gly Ser Tyr Met Ser Trp Tyr Gln Gln Lys Pro 55 50 60 Gly Gln Pro Pro Lys Leu Leu Ile Ser Ala Ala Ser Asn Leu Glu Ser 75 65 70 80 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 Leu Thr Ile His Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys 100 105 110 Gln Gln Ser Tyr Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Val - 120 115 125 Glu Ile Lys 130 <210> SEQ ID NO 20 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH-cl03F04 <400> SEQUENCE: 20 Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp 1 5 10 15 Gly His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Lys Lys

-continued

20 25 30 Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 40 35 45 Thr Ser Tyr Trp Ile His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp Ile Gly Glu Ile Asn Pro Ser Ser Gly Arg Thr Asn Tyr Asn 65 70 75 80 Glu Lys Phe Lys Asn Lys Val Thr Ile Thr Val Asp Lys Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ser Asn Leu Arg Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Ala Ser Arg Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr 115 120 125 Val Ser Ser 130 <210> SEQ ID NO 21 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL-cl03H08 <400> SEOUENCE: 21 Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Trp Val Pro 1 5 10 15 Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu Gly Glu Arg Ala Thr Ile Ser Cys Lys Ala Ser Gln Ser 35 40 45 Val Asp Tyr Asp Gly Gly Ser Tyr Met Ser Trp Tyr Gln Gln Lys Pro 50 55 60 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser 65 70 75 80 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95 Leu Asn Ile Ser Ser Val Gln Glu Glu Asp Val Ala Thr Tyr Tyr Cys 100 105 110 Gln Gln Ser Tyr Glu Asp Pro Leu Thr Phe Gly Ala Gly Thr Lys Val 115 120 125 Glu Ile Lys 130 <210> SEQ ID NO 22 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH-cl03H08 <400> SEQUENCE: 22 Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp 1 5 10 15 Gly His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys 25 20 30

\sim	\sim	n	.	п.	n	11	Δ	\sim
\sim	\sim	тт	L	_	11	u	\sim	u

Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45 Ser Ser Tyr Trp Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu 50 55 60 Glu Trp Met Gly Glu Ile Asn Pro Ser Ser Gly Arg Thr Asn Tyr Asn 65 70 75 80 Glu Lys Phe Lys Asn Arg Val Thr Ile Thr Ala Asp Lys Ser Thr Ser 85 90 Thr Ala Tyr Met Glu Leu Ser Asn Leu Arg Ser Glu Asp Ser Ala Val 100 105 110 Tyr Tyr Cys Ala Ser Arg Gly Tyr Trp Gly Gln Gly Thr Thr Leu Thr 115 120 125 Val Ser Ser 130 <210> SEQ ID NO 23 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL-cl04H08 <400> SEQUENCE: 23 Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Trp Val Pro 5 10 15 1 Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 20 25 30 Val Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser 35 40 45 Val Asp Tyr Asp Gly Gly Ser Tyr Met Ser Trp Tyr Gln Gln Arg Pro 50 55 60 Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu Glu Ser 65 70 75 80 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr 85 90 95 Leu Thr Ile His Ser Leu Gln Ala Glu Asp Val Ala Thr Tyr Tyr Cys 100 105 Gln Gln Ser Tyr Glu Asp Pro Leu Thr Phe Gly Gly Gly Thr Lys Val 115 120 125 Glu Ile Lys 130 <210> SEQ ID NO 24 <211> LENGTH: 131 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH-cl04H08 <400> SEQUENCE: 24 Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Asp 1 5 10 15 Gly His Ser Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Val Lys Lys 20 25 30 Pro Gly Ser Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe 35 40 45

Thr Ser Tyr Trp Ile His Trp Val Lys Gln Ala Pro Gly Gln Gly Leu 55 Glu Trp Ile Gly Glu Ile Asn Pro Ser Ser Gly Arg Thr Asn Tyr Asn 65 70 75 80 Glu Lys Phe Lys Asn Lys Val Thr Ile Thr Val Asp Lys Ser Thr Ser 85 90 95 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val 100 105 110 Tyr Tyr Cys Ala Ser Arg Gly Tyr Trp Gly Gln Gly Thr Thr Val Thr 115 120 125 Val Ser Ser 130 <210> SEQ ID NO 25 <211> LENGTH: 717 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL+CL-cl03E08 (nucleotides) <400> SEOUENCE: 25 atggagacag acacaateet getatgggtg etgetgetet gggtteeagg etceaetggt 60 120 gatattgtgc tgacccagag cccggacagc ctggcagtga gtctgggtca acgcgccacc attaactgca aagccagcca gagcgtggat tatgacggcg gtagctacat gagctggttt 180 cagcagaaac cgggtcagcc gccgaaactg ctgatttatg ccgccagcaa tctggaaagc 240 ggcgttccgg cccgttttag cggtagcggc agcggcaccg attttaccct gaccattagc 300 tegetgeagg eggaggatgt ggecacetat taetgecage agagetaega agateegetg 360 acctttggcg gcggtaccaa agtggagatt aaacgaactg tggctgcacc atctgtcttc 420 atetteeege catetgatga geagttgaaa tetggaaetg eetetgttgt gtgeetgetg 480 aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540 600 ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc 660 717 acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttaa <210> SEQ ID NO 26 <211> LENGTH: 717 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL+CL-cl03G05 (nucleotides) <400> SEQUENCE: 26 atggagacag acacaateet getatgggtg etgetgetet gggtteeagg etceaetggt 60 gacategtge tgacceagte ccetgettee etegetgtgt ccetgggega gagggetace 120 atctcctgta aggcctccca gtccgtggac tacgacggcg gctcctacat gtcctggttc 180 cagcagaggc ctggccagcc tcccaagctg ctgatctacg ctgcctccaa cctggagtcc 240 qqcqtqcctq ataqqttcaq cqqatccqqc tccqqcaccq acttcaccct qaatatctcc 300 cctctggagg ctgaggacgt ggccgtgtac tactgccagc agtcctacga ggaccctctg 360 420 accttcqqcq qcqqcaccaa qqtqqaqatc aaqaqaactq tcqcaqcacc ttccqtcttt

33

attttcccac catcagatga acagetgaaa teeggtaetg ceagtgtggt etgtetgete	480
aataatttet ateeeeggga ggetaaagte eagtggaaag tggataatge eetteagtee	540
ggcaactccc aggagagcgt gaccgagcag gattctaagg actcaacata ttcactgtca	600
tctactctca ccctgtctaa ggctgattac gaaaagcaca aggtgtacgc ttgcgaagtt	660
actcatcagg gcctctcttc ccctgtgacc aagagtttca accggggcga gtgctaa	717
<210> SEQ ID NO 27 <211> LENGTH: 717 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL+CL-cl03F04 (nucleotides)	
<400> SEQUENCE: 27	
atggagacag acacaateet getatgggtg etgetgetet gggtteeagg etceaetggt	60
gacatogtga tgaccoagto cootgactoo otggotgtgt cootgggoga aagggocaco	120
atcaactgca aggeeteeca gteegtggae taegaeggeg geteetaeat gteetggtae	180
cagcagaagc ccggccagcc tcccaagctg ctgatctccg ccgcttccaa tctggagtcc	240
ggcgtgcccg ataggttttc cggctccggc tccggcaccg actttaccct gaccatccac	300
teeetgeagg eegaggaegt ggetgtgtae taetgeeage agteetaega ggaeeetetg	360
accttcggcg ccggcaccaa ggtggagatc aagagaactg tcgcagcacc ttccgtcttt	420
attttcccac catcagatga acagctgaaa tccggtactg ccagtgtggt ctgtctgctc	480
aataatttet ateeeeggga ggetaaagte cagtggaaag tggataatge eetteagtee	540
ggcaactccc aggagagcgt gaccgagcag gattctaagg actcaacata ttcactgtca	600
tctactctca ccctgtctaa ggctgattac gaaaagcaca aggtgtacgc ttgcgaagtt	660
actcatcagg gcctctcttc ccctgtgacc aagagtttca accggggcga gtgctaa	717
<210> SEQ ID NO 28 <211> LENGTH: 717 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL+CL-cl03H08 (nucleotides)	
<400> SEQUENCE: 28	
atggagacag acacaateet getatgggtg etgetgetet gggtteeagg etceaetggt	60
gacategtge tgacceagte ecetgettee etggetgtgt ecetgggega gagggetaee	120
ateteetgea aggeeteeea gteegtggae taegaeggeg geteetaeat gteetggtae	180
cagcagaage eeggeeagee teecaagetg etgatetaeg eegeeteeaa eetggagtee	240
ggcgtgcccg ataggttete eggateegge teeggeaeeg aetteaeeet gaacatetee	300
teegtgeagg aggaggaegt ggeeacetae taetgeeage agteetatga ggaeeeetg	360
acetteggeg etggeaceaa ggtggagate aagagaaetg tegeageaee tteegtettt	420
attttcccac catcagatga acagetgaaa teeggtaetg eeagtgtggt etgtetgete	480
aataatttet ateeeeggga ggetaaagte eagtggaaag tggataatge eetteagtee	540
ggcaactccc aggagagcgt gaccgagcag gattctaagg actcaacata ttcactgtca	600
tctactctca ccctgtctaa ggctgattac gaaaagcaca aggtgtacgc ttgcgaagtt	660

actcatcagg gcctctcttc ccctgtgacc aagagtttca accggggcga gtgctaa 717 <210> SEQ ID NO 29 <211> LENGTH: 717 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VL+CL-cl04H08 (nucleotides) <400> SEQUENCE: 29 atggagacag acacaateet getatgggtg etgetgetet gggtteeagg etceaetggt 60 gacategtge tgacceagte ceetgettee etggetgtgt ceetgggaga gagggeeace 120 atcaactgca aggcctccca gtccgtggac tacgacggcg gctcctacat gtcctggtac 180 cagcagagge ceggacagee teccaagetg etgatetacg etgeetecaa cetggagtee 240 ggcgtgcctg ataggttttc cggctccggc tccggaaccg acttcaccct gaccatccac 300 tccctgcagg cggaggacgt ggccacctac tactgccagc agtcctacga ggaccccctg 360 acatteggeg geggaaceaa ggtggagate aagagaactg tegeageace tteegtettt 420 attttcccac catcagatga acagetgaaa teeggtaetg ceagtgtggt etgtetgete 480 aataatttct atccccggga ggctaaagtc cagtggaaag tggataatgc ccttcagtcc 540 ggcaactccc aggagagcgt gaccgagcag gattctaagg actcaacata ttcactgtca 600 tctactctca ccctgtctaa ggctgattac gaaaagcaca aggtgtacgc ttgcgaagtt 660 actcatcagg gcctctcttc ccctgtgacc aagagtttca accggggcga gtgctaa 717 <210> SEQ ID NO 30 <211> LENGTH: 717 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: chimeric VL+CL (nucleotides) <400> SEOUENCE: 30 atggagacag acacaatcct gctatgggtg ctgctgctct gggttccagg ctccactggt 60 gacattgtgc tgacccaatc tccagcttct ttggctgtgt ctctagggca gagggccacc 120 atctcctgca aggccagcca aagtgttgat tatgatggtg gtagttatat gagttggttc 180 caacagagac caggacagcc acccaaactc ctcatctctg ctgcatccaa ccttgaatct 240 ggcateceag ceaggtttag tggcagtgge tetgggaeag actteaceet caatatecat 300 cctgtggagg aggaggatgt tgcaacctat tactgtcagc aaagttatga agacccgctc 360 acgttcggtg ctggtaccaa ggtggagatc aaacgaactg tggctgcacc atctgtcttc 420 atcttccccqc catctqatqa qcaqttqaaa tctqqaactq cctctqttqt qtqcctqctq 480 aataacttct atcccagaga ggccaaagta cagtggaagg tggataacgc cctccaatcg 540 ggtaactccc aggagagtgt cacagagcag gacagcaagg acagcaccta cagcctcagc 600 agcaccctga cgctgagcaa agcagactac gagaaacaca aagtctacgc ctgcgaagtc 660 acccatcagg gcctgagctc gcccgtcaca aagagcttca acaggggaga gtgttaa 717

<210> SEQ ID NO 31 <211> LENGTH: 1386 <212> TYPE: DNA <213> ORGANISM: artificial

<pre><220> FEATURE: <223> OTHER INFORMATION: humanized VH+CH1+CH2+CH3-cl03E08, knob mutation, (nucleotides)</pre>										
<400> SEQUENCE: 31										
atgggatgga gctatatcat cctctttttg gtagcaaca	g ctacagatgg ccactcccag 60									
gtgcagctgc agcagtcggg tgccgaagtg aaaaaaccg	g gtgctagtgt gaaactgagc 120									
tgcaaagcca gcggctatac cttcaccagc tactggatc	c actgggtgcg tcaggcgcct 180									
ggccagggcc tggaatggat tggcgaaatc aatccgagc	a gcggtcgcac caattacaat 240									
gaaaaattta aaaatcgtgt gaccgttacc gtggataaa	a gcacctccac cgcctatatg 300									
gagetgagea geetgaeeag egaagatage geegtgtat	t attgegeeag eegeggttat 360									
tggggccagg gtaccaccct gaccgtgagc agcgctagc	a cgaagggccc atcggtcttc 420									
cccctggcac cctcctccaa gagcacctct ggggggcaca	g cggccctggg ctgcctggtc 480									
aaggactact teeeegaace ggtgaeggtg tegtggaac	t caggegeeet gaecagegge 540									
gtgcacacct teceggetgt ectacagtee teaggaete	t actccctcag cagcgtggtg 600									
accgtgccct ccagcagett gggcacccag acctacate	t gcaacgtgaa tcacaagccc 660									
agcaacacca aggtggacaa gaaagttgag cccaaatct	t gtgacaaaac tcacacatgc 720									
ccaccgtgcc cagcacctga actcctgggg ggaccgtca	g tetteetett eeceeaaaa 780									
cccaaggaca ccctcatgat ctcccggacc cctgaggtc	a catgcgtggt ggtggacgtg 840									
agccacgaag accctgaggt caagttcaac tggtacgtg	g acggcgtgga ggtgcataat 900									
gccaagacaa agccgcggga ggagcagtac aacagcacg	t accgtgtggt cagcgtcctc 960									
accgtcctgc accaggactg gctgaatggc aaggagtac	a agtgcaaggt ctccaacaaa 1020									
gccctcccag cccccatcga gaaaaccatc tccaaagcc	a aagggcagcc ccgagaacca 1080									
caggtgtaca ccctgccccc atcccgggat gagctgacc	a agaaccaggt cagcctgtgg 1140									
tgeetggtea aaggetteta teeeagegae ategeegtg	g agtgggagag caatgggcag 1200									
coggagaaca actacaagac cacgootooo gtgotggac	t ccgacggctc cttcttcctc 1260									
tacagcaagc tcaccgtgga caagagcagg tggcagcag	g ggaacgtett eteatgetee 1320									
gtgatgcatg aggetetgea caaceaetae aegeagaag	a gcctctccct gtctccgggt 1380									
aaatag	1386									
<210> SEQ ID NO 32 <211> LENGTH: 1386 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH+CH1+ mutation, (nucleotides) <400> SEQUENCE: 32	CH2+CH3-cl03G05, knob									
	a atagagatag gapatagasa (A									
atgggatgga gotatatoat cototttttg gtagcaaca										
gtgcagctgg tgcagcccgg cacagaggtg aagaagcct										
tgcaaggeet eeggetaeae etteaceage taetggate										
ggacagggcc tggagtggat gggcgagatc aaccoctco	t ccggcaggac caactacaac 240									
gagaagttca agaaccgggt gaccatcacc gccgacaag	t ccacctccac cgcctacatg 300									
cagetgteet ceetgaggte egaggacaee geegtgtae	t actgcgcctc caggggatat 360									

tggggccagg gcaccacagt gaccgtgagc tccgctagca cgaagggccc atcggtcttc	420
cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc	480
aaggactact teeecgaace ggtgaeggtg tegtggaact eaggegeeet gaecagegge	540
gtgcacacet teeeggetgt estacagtee teaggastet acteesteag cagegtggtg	600
accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc	660
agcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcacacatgc	720
ccaccgtgcc cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa	780
cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg	840
agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat	900
gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc	960
accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa	1020
geceteecag eccecatega gaaaaceate teeaaageea aagggeagee eegagaacea	1080
caggtgtaca cootgoocoo atooogggat gagotgacca agaaccaggt cagootgtgg	1140
tgeetggtea aaggetteta teecagegae ategeegtgg agtgggagag caatgggeag	1200
ccggagaaca actacaagac cacgceteee gtgetggaet cegaeggete ettetteete	1260
tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc	1320
gtgatgcatg aggetetgea caaceaetae aegeagaaga geeteteeet gteteegggt	1380
aaatag	1386
<pre><210> SEQ ID NO 33 <211> LENGTH: 1386 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH+CH1+CH2+CH3-cl03F04, knob mutation (nucleotides)</pre>	
<400> SEQUENCE: 33	
atgggatgga gctatatcat cctctttttg gtagcaacag ctacagatgg ccactcccag	60
gtgcagctgc agcagcccgg agccgaagtg aagaagcccg gctccagcgt gaagctgtcc	120
tgcaaggeet eeggetacae etteacetee taetggatee aetgggtgaa geaggeteet	180
	180 240
tgcaaggeet eeggetacae etteacetee taetggatee aetgggtgaa geaggeteet ggacagggee tggagtggat eggegagate aaceeeteet eeggeeggae caaetacaae gagaagttea agaacaaggt gaceateaee gtggacaagt ceaeeteeae egeetaeatg	
ggacagggee tggagtggat eggegagate aaceeeteet eeggeeggae caaetaeaae gagaagttea agaacaaggt gaccateaee gtggacaagt ceaeeteeae egeetaeatg	240
ggacagggee tggagtggat eggegagate aaeeeeteet eeggeeggae caaetaeaae gagaagttea agaacaaggt gaceateaee gtggacaagt eeaeeteeae egeetaeatg gagetgteea aeetgeggte egaggaetee geegtgtaet aetgtgeete eaggggetat	240 300
ggacagggcc tggagtggat cggcgagatc aaccecteet eeggeeggae caactaeaac gagaagttea agaacaaggt gaceateace gtggacaagt ceaeeteeae egeetaeatg gagetgteea acetgeggte egaggaetee geegtgtaet aetgtgeete eaggggetat tgggggeeagg geacaaeeet gaeegtgtee teegetagea egaagggeee ateggtette	240 300 360
ggacagggcc tggagtggat cggcgagatc aaccecteet eeggeeggae caactacaae gagaagttea agaacaaggt gaceateaee gtggacaagt eeaeeteee egeetaeatg gagetgteea acetgeggte egaggaetee geegtgtaet aetgtgeete eaggggeetat tgggggeeagg geacaaeeet gaeegtgtee teegetagea egaagggeee ateggtette eeeetggeae eeteeteeaa gageaeetet gggggeaeag eggeeetggg etgeetggte	240 300 360 420
ggacagggcc tggagtggat cggcgagatc aaccecteet eeggeeggae caactaeaae	240 300 360 420 480
ggacagggcc tggagtggat cggcgagatc aaccecteet eeggeeggae caactacaae gagaagttea agaacaaggt gaceateaee gtggacaagt eeaeeteee egeetg gagetgteea aeetgeggte egaggaetee geegtgtaet aetgtgeete eaggggeetat tggggeeagg geacaaeeet gaeegtgtee teegetagea egaagggeee ateggtette eeeetggeae eeteeteeaa gageaeetet gggggeaeag eggeeetggg etgeetggte aaggaetaet teeeegaaee ggtgaeggtg tegtggaaet eaggegeeet gaeeagege	240 300 360 420 480 540
ggacagggce tggagtggat eggegagate aaeceeteeteeteeteeteeteeteeteeteeteeteetee	240 300 360 420 480 540 600
ggacagggee tggagtggat eggegagate aaceeteet eeggeeggae eaactacaae gagaagttee agaacaaggt gaecateae gtggacaagt eeaecteeteeteeteeteeteeteeteeteeteeteeteete	240 300 420 480 540 600
ggacagggee tggagtggat eggegagate aaceeteet eeggeeggae eaactacaae gagaagttea agaacaaggt gaceateaee gtggacaagt eeaecteee egeetgtee gagetgteea aeetgeggte egaggaetee geegtgtaet aetgtgeete eaggggeetat tgggggeeagg geacaaeeet gaeegtgtee teegetagea egaagggeee ateggtette eeeetggeae eeteeteea gageaeetet gggggeaeag eggeeetggg etgeetggte aaggaetaet teeeegaaee ggtgaeggtg tegtggaaet eagegegeet gaeeggeg gtgeaeaeet teeeggetgt eetaeagtee teaggaetet aeteeteag eagegtggtg aeegtgeeet eeageaget gggeaeeeg aeetaeet gegageetet aeteeteag eagegtggtg acegtgeeet eeageaget gggeaeeeg aeetaeet geaaegtgaa teaeaageee aggaaaeaeee aggtggaeaa gaaagttgag eeeaaatett gtgaeaaaae teaeaateg	240 300 420 480 540 600 660 720

con	+	п.	n	11	Δ	\sim	

ccaqacaca ageogeogga ggacacata accagacata acc ccccccccq gccccccccq ggacacata agtotaca agtotaca agtotaca gcccccccc accccccccq gcccccccccq agagacata agtotaca agtotaca agtotaca gccggacaca adagacagat ccccccccq gccccccccc adagacagat cccccccq gcccgaca agtotaca ragacagat ccccccccq gcccgacacaga ggacacata agtotaca agtotacata agtotacataa agtotacataaa agtotacataa agtotacat agtotacat agtotac	-continued	
cectoccag ococcatega gamascate tecaages aggegtaes agtegrage eegagaaca 1020 cectoccag ococcatega gamascate tecaages aggegrage eegagaaca 1080 aggtgtaes ococgecatega gamascate tecaages aggegrage eaggegrage 1100 graggaase actaesaga caegettee grageggag gateggtee egagages 1100 cgagaases attaesaga caegettee grageggag gasegtet ettettee 1260 acagesage teaceate acegegaga gettetee grageggag gasegtet ettettee 1260 acagesage teaceate acegegaga gettetee grageggg gasegtet ettettee 1260 1100 SBO ID NO 34 2110 SBO ID NO 34 2125 STRE INA 2125 STRE INA 2126 SBO ID NO 34 2125 SBO ID NO 34 2125 STRE INA 2126 SBO ID NO 34 2126 SBO ID NO 34	agocacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat	900
cecteceag ceccetega generative tecangers anggerage eegagaaca 1080 aggtgtaca cecterega generative tecangers anggerage eegagaaca 1080 getggtea anggettet teceagegae ategeetigg agtgggagag caatgggeag 1200 ogggagaaca attacaagae caegeetee gtgetgga eigagaggg caetggged ettetteet 1260 acangeage teacegtiga caagageagg tggeageagg ggaegetet ettetteet 1260 acangeage teacegtiga caagageagg tggeageagg ggaegetet ettetteet 1260 acangeage teacegtiga caagageagg tggeageagg ggaegetet ettetteet 1280 ataag atag	gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc	960
aggigitate celigice according a decording agging aga gyac gat gyag ag agging aggin	accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa	1020
<pre>crdigtica aaggittica toocogac atogood atogood gaaag catiggaag 1200 cggagaaca actacaagac cacgootoc fgittiggact ocgacgitt cittitett 1240 acageaag toacogtigg caaggood ggicagag ggaagtett otcatgetee 1320 tgatgetig aggetetiga caaceactae acgragaaga geeteteet geteoggit 1380 aatag 1386 210- SED TD NO 34 211- SED TD NO 34 212- SED TD NO 34 213- SED TD NO 34 214- SED TD NO 34 215- SED TD NO 34</pre>	geeeteecag eeeceatega gaaaaceate teeaaageea aagggeagee eegagaacea	1080
constraints of the second s	caggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgtgg	1140
anagcaage teacogtggg caagageagg tggeaqage ggaacgtett eteatgetee 1120 tgatgeatg aggetetgea caaceactae acgeagaaga geeteteet gteetegggg aatag 1386 210- SEO ID NO 14 212- SEO ID NO 14 212- SEO ID NO 14 212- SEO ID NO 14 212- SEO ID NO 14 213- KENDTH: 1386 223- OTHER INFORMATION: humanized VH+CH1+CH2+CH3-e103H08, knob mutation (nucleotides) 400- SEQUENCE: 34 tgggatggg getatateat eteetteet teatggateg geoggeteet 180 geeagget tgggetggat gggeagate acceeteet eagggtag geoggeteet 180 gaeagget tgggatggat gggeagate acceeteet eagggtag geoggeteet 180 gaeagget tgggatggat gggeagate acceeteet eagggtag eagetteet 180 gggatggg gedeateet geoggeagate geoggeagg caaeteeae 240 aggetgtee agaecegg tgsceateae etteeteet actggateg caaetee 240 gaeagget tgeagteeg geogaagte geoggeagate acceeteet eagggtag teagetteet 180 gaeagget teeggetagte geoggeagate acceeteet eagggtag teagetteet 420 ecetggee eageacetet ggeggeagate acceeteet eagggteg tegeegtette 420 ecetggee eageagete teeggatget eageggee teggeggeag teagetgeet gaeeggeet 420 ecetggee eageacetet ggeggegaate eagegeete gaeeggeeteg 420 ecetggee eageacete ggeggeeag teggggaate acceeteg acaegtgee 640 geacaace teeggetg ceataace teeggatge teggggeaag teggegeeteg acaegtgeg 640 geacaace teeggegg gaacetee teggatget eategeggte gaeegtete 720 ecetggee eageacetga acceetggg geacegt acceetge geeggetga gegeetgg 94 ecetggee aageetgag teagttee teeggage acteet teggatget gaeegtete 720 ecetgee eageacetga acceetggg ggaeegte atggeegtg gggaagge 720 ecetgee aageetggg ggaeegtee acaegeet acceetge aggegetgg gggaeegt 720 ecetgee acceetga teeteggg gaacetee teggatge aggeegtgg ggaeegtet 900 ecetgee acceetga teeteggga ggaeegtee atgeetggg aggeegtet 900 ecetgee acceetga gaaaaceate teeaagee atgeetggg aggeettea 1000 ecetgee acceetga gaaaaceate teeaagee atgeetggg aggeeteta 900 ecetgee acceetga gaaaaceate teeaagee atgeetggg aggeetget 91 ecetgee acceetga gaaaceate teeaagee aggeegge eaged eageaceat 900 ecetgee acceetga gaaaceate teeaagee aggeegge eageaceat 900 ecetgee acceetga gaaaceate teeaagee aggeegge	tgeetggtea aaggetteta teecagegae ategeegtgg agtgggagag caatgggeag	1200
tadgodig aggototigae caaceadtae acgodagaag godetetee gitte 1380 atag 1386 210, SEO TD NO 34 211, SEO TD NO 34 211, SEO TD NO 34 213, SEO TD NO 34 214, SEO T	coggagaaca actacaagac cacgootooo gtgotggact cogaoggoto ottottooto	1260
atag 1386 210 SEQ ID NO 34 211 LENNOTH: 1386 212 TFE: DNA 213 ORANITAEN: artificial 220 FMARTURA: 223 OTHAR INFORMATION: humanized VH+CH1+CH2+CH3-cl03H08, knob mutation, (nucleotides) 400 SEQUENCE: 34 15ggatgga gotatatcat cototttttg gtagcaacag ctacagatgg ccactoccag 60 gcacaggot cggagtgcag cgccgaagtg aagaagccgg gotoctog gaagctggg 120 gcacaggot cggagtgagt ggccgaagta gagcagccg acctocag gaaggtgcc 180 gacaggot tggagtggat ggccgaagta gaccatcace gocgaagta caacgggtgg cacatcacaa 240 aggatgtca gacaccggt gaccatcace gocgacaagt cacaggatgg ccactacaa 240 aggatgtca gacaccggt gaccatcace gocgacaagt cacatcaca cgoctacatg 300 agottgtca acctgaggtc cgaggatce gocgtgtaa atgggcgca caggggtt 420 coctggoca cotoctocaa gagcacctt gggggcacag cgacgggcc tgggggtat 360 ggggccagg gcaccacce gacgatgt to togggaca caccocag cagggggt 540 tgcacacct toccggacg gggacggtg togtggaact accoccag cagggggg 540 tgcacacct toccggacg ggacaccace gacgatca actocaca gacggggg 540 tgcacacct toccggacg gggcaccaca gacgatca actocaca taccacacac 720 caccggace cagacctg actcacag gggcacgtag tottcottt cccccaaa 780 ccaaggaca cottagat tocccggac cotggggt a catggtgg tggggggg ggggggg 5 ccaaggaca acctagat tocccggac acagacgag acctacat ggaggacgt a aggaggacg 100 ccaaggaca cactagat tacccgggg gacgacga acagacgg fggggggg gggggggg 9 ccaaggaca acctagat tacccgggg gacgacga tactactt cccacacatg 720 ccaaggaca cottagat tacccgggg gacgacga tactact toccacacat 720 ccaaggaca acctagat tacccggg gacgacga acagacg acggtggg gatggatat 900 ccaaggaca acctagat tacccggga gagagacgac acagacga acggtgg gagggacgac 9 ccaaggaca acctagat gacgacat gaaggaga accgga aggagacgac aggaggacgac 1080 aggtgtaca ccctgccc atcccggga gagagacga acagacga aggagaga acggtggg gagagacgac 1080 aggtgtaca ccctgccc atcccggac atggcggg gagaggacg cagacgggg gagaggacg 1200 ccgtggaaga actacaga caggcgcga atggcggg ggacggtct ttcttctc 1260 aggagaca atacaaga cacgcctce gtggtggacgg ggacggtct ttcttctcc 1260 ccggagaaca atacaaga cacgcctce gtggtggacggg ggacggtct ttcttctcc 1260 aggagacac tacccgggg aaggacggt acacgggg ggacggtct ttcttctccc	tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtett eteatgetee	1320
210- SEV 215 LENNTH: 1386 212- TTFE: DNA 213- ORGANISM: artificial 220- FEATURE: 223- OTHER INFORMATION: humanized VH+CR1+CH2+CH3-cl03H08, knob mutation, (nucleotides) 400- SEQUENCE: 34 tgggatggg gctatatcat cotottttg gtagcaacag ctacagatgg coactoccag 60 gcaaggoot coggetacac ottotocto tactggatca atgggtgg gaaggtggd 120 gacaggoot coggetacac ottotocto tactggatca atgggtgg gaaggtcad 300 agactgoog tggatgggt gggcgagat accoctoct coggoagga caactacaa 240 agaagttca agaaccggg gcaccacce gacggatg accoctoct coggoagga caactacaa 240 agaagttca acctgagtg cacgatca gccgacagt caactocar cgootaatg 300 agctgtca acctgagtg cagagatce gcggtgata tactgogot acggtott 420 coctggaca cottocta gagaactet gggggecag cgacagt ggacctggg ctgottggt 480 aggactact toccogaace ggtgacggt togtgagat caccocta caggoctggt 540 tgcacacet taccgggtg cacacag ggcacatat gaggatta ataccoctag cagggggg 540 cogggeca aggtggacag acctacag gccacaat gaaggtga taccacage 660 goacacaca aggtggacag aactetggg ggaccgtag tottoott coccocaaa 780 ccaaggaa cottagat toccoggaa catagatg cacagcag aggecgtgg gtgggggg 840 gccaaggaa coctagat taccogggg ggaccgtag tottoott coccocaaa 780 ccaaggaa coctagat taccoggg gagacgta aaggacgat acggagg gggggatatat 900 ccaaggaa acctagat taccoggag aggacgata aaggacgag aggegtgg gggggg gggggacga 1020 ccottagaa agcogggg ggacgata aaagcacg aggecgtag tottoott coccocaaa 1020 ccaagaaa agcogggg ggaagata aaggacact tocaagaag aggacgaca 1080 aggttaa coctgocc atcocgga gaagcagta aggagaga aggagaga Cagacggg 1140 gcctggta aaggatta toccoggaa aggataa aggagaga cagaggg fagadga 1120 cggagaaca atacaagaa cacgctce gtgetggaa taggagag cagacggg 1220 cggagaaca atacaagaa cacgctce gtgetggaa taggagag cagaggg 1220 cggagaaca atacaagaa cacgctce gtgetggaat cagaggt cagaggg 1220 cggagaaca atacaagaa cacgctce gtgetggaat cagagget ttotottc toctagcaa 1020 cggagaaca atacaagaa cagctce gtgetggaat cagaggetce ttottotce 1260 aggagaaca atacaaga cacgctce gtgetggaat cagagget ttottottc toctagcaa 1020	ytgatgcatg aggetetgea caaceaetae aegeagaaga geeteteeet gteteegggt	1380
111- LEWOTH. 1366 212- YUE: NA 213- OKCANISM. artificial 223- OTHER INFORMATION: humanized VH+CH1+CH2+CH3-cl03H08, knob mutation, (nucleotides) 400- SEQUENCE: 34 tgggatgga gotatateat extetting gtageacag etacagatgg ceaeteega 60 tgcagetgg tgeagteegg egeegaagtg aagaageeeg geteeteegt gaagetgage 120 geaaggeet egggetgaag egeegaagt aaceeteete eeggeagaa eaactacaae 240 agaaggtee agaaceggg gaecateee geegacaagt eeaeetee egeetaaat 240 agaagtee agaaceggg gaecateee geegacaagt eeaeetee egeetaaet 240 agaagtee agaacegggt gaecateee geegacaagt eeaeetee egeetaaet 300 agetgteea acetgaggte egaggaete teegetgaea deeggeee ateggeetee 420 eeetggeae eeteetee geegacaagt eeaeetee geegacaagt eeaeetee egeetaaet 360 ggggeeagg geaceaeeet gaeggtgte teegegeeag egeeetggee taeegggee 540 tgeaeeet teeeggeeg egeecaagt eeteetee geaggeeteet eaeegtggg 600 eegtgeeet eeaeggeeg eaeeteet egaggeeteet teeetgeaa teeeeagee 540 tgeaeeet teeeggee etacage gegeeetag eeteeteet eaeegtggg 600 eegtgeeet eeaeggeeg eetaeaete teagggeete geaeggeeteet eeeee 720 eaeeggee eagaeetg gggeeega acetaeet geaegtgga teeeeage 720 eaeegtgee eageaeetg aceteeggg ggaeegtea tetteeteet eeeeaaa 780 eeaaggaea eeetaagt eteeeggge gaeegteeg tetteetet eeeeaaa 780 eeaaggaae eeetagagt eaagtegae aaegtagg aeggegtgg ggtgeadaat 900 eeaagaeaa ageeegagag gageagtae aaeggeegt aeegtggg gegeegtee 960 eegteete eeeeagaet geegaaega acetaegge aeegtggg deaggeetee 960 eegteete eeeeagaet geegaaegd eaaggaegae aeegtggg eaeggeegt 960 eegteete eeeeagaet geegaaegg aagagtae aaegeegg eeeggaeggeegg ggaeagtee 960 eegteete eeeeagaet geegaaegae aaegeegg eaeggeegge gaeegteet 960 eegteete eeeegaaeg eeeaagtee eeggaeedee eeeggeegaeg eaeggeegge gaeegeegg 960 eegteete eeeeagaet geegaaege eaeggaegae aeegtggg eaeggeegee 1080 aggtgtaea eeetgeag gaaaeeete teeeaggeeg aaggeegee eeggaeaag 1080 eggaaaaea aetaeaagae eaegeetee gtgeeggaeg gaaegeete teteetgeegg 1200 eggaaaeae aetaeaagae eaegeetee gtgeeggaeg gaaegeete teteetgeegg 1200 eggaaaeae aetaeaagae eaegeetee gtgeeggaeg gaaeggeete teteetgeege 1200 eggaaaeae etaeegtgge eaagaegge tgeeegee	aaatag	1386
tgggatgga getatatea ectettig gtageacag etacagatgg ecaeteecag geaagget gegategg egegaagt aagaageeg geteeteeg gaagetgae 120 geaagget eggategae etteeteete teatggate aaceeteete eeggaagga eaagtaeaa 240 agaaggte agaaceggg gaeetaee geegaaga eeaaetaeaa 240 aggatgtea agaaceggg gaeetaee geegaaga eeaaetaeaa 240 aggatgtea aeetgagt eggagate geegaaag eeaeteeae egeetaeat 360 ggggeeggg geaeeaeet gaeagtge teegetaa eegaeggee aeegaeat 420 eeetggea eeteetee ggggaate gaeggee eggeeteg etgeetig 420 eeetggea eeteetee ggggaeggt teggggaat eaggeetee gaeeagge 540 tgeeaeet teeegaeg ggaaetge teeggaat eagegeet gaeeagge 540 tgeeaeet teeegaeg gggaeete teaggaeta eegaeggaa eagegeet gaeeageg 540 tgeeaeet teeegaeg ggaaetge teaggaeta eeteetee gaeeageg 540 eeetggee eageaeetg gggaeegte teaggaeta eteeteete gaeeagege 540 tgeeaeet teeegaag gaaaetteg gegaeette teaggaeta eegeeggaa teaeaagee eage gaeaaeea aggtggaea gaagttgg eeetaga etaeatt geaagtgaa teaeaagee eage geaeaeet aegeaget gggaeege eeetaet geaagtee eagegeet gaeeaageg 720 eaeegtgee eageaeetg geaegtee eetaggg aeegteeg teteetett eeeeeaaa 780 eeeaggaa aeeetgag eeagtee eetaggaeea aegeeggg gggeegteeg 940 geeaegaag aeeetgag eagteeae etgaggee aaggeegge gggeegtee 960 eegteega aeeeggag ggaegata aaegeegg aegeegteg geggaaeta 900 eeeacgaag aeeetgag gegaagtae aaggeegge aegeegteg geggaaeaa 1020 eeeteeag eeeeaggae gaaaeeae teeeaaage aegeeggg aggeegtee eegaaaea 1020 eeeteecag eeeeata aeeegga gaaegee eegagaae aaggeegee eegagaaea 1080 aggtgtaa eeetgeegga gaaaeeat teeeaagea aggeeggee eegagaaea 1080 aggtgtaa eeetgeeceag aeeeeeag aaeeeagg ageggag eaatggeeg 1140 geetggea aaggettea teeeegga taggeegga gaeggee eegagaae eetggeeg 1140	<210> SEQ ID NO 34 <211> LENGTH: 1386 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH+CH1+CH2+CH3-cl03H08, knob mutation, (nucleotides)	
tgcagetg tgcagtcog cgcgaagtg aagaagcog geteetegg gaagetgag 120 geaaggoet egggtaga eggeggage aaceeetee eeggaaga eaceetee 180 gacagggee tggagtgg ggeggage aaceeetee eeggaaga eaceetee 240 agaagtte agaacegg gaceatee geegacaag eecaeetee egggagat 360 ggggeeagg geaecaeet gacagtgee teegetgae ateggeete eaggggat 360 ggggeeagg geaecaeet gacagtgee teegetaga eggaggee ateggteet 420 eeetggee eeteetee gggggeggg teggggaag eggeeetgg etgeetgge 480 aggaatet teeeggeet eetaeagg gggeaegg tgetgggaa eaggeeetg eagetgge 540 tgeaacaeet teeeggeet eetaagg ggaeetee teegaga eggeeetgg etgeetgge 660 geaacaee aggtggaea gaagttgg geaecaet gegagete teeteetee gaagggee ategagge 720 eeetggee eageaeget gggeaege eetaete gegggeg ggeeggg ggeeggg ggeegge g840 geaacaea aggeggaa gaagttgg eetaagge tetteette eeetaag eggeggee 960 eeetaagaa aeeetgag teeeggg ggaeegte atgegegg ggeggga ggeggetg 9840 geeaagaa ageeegga ggaegata aacgeegg aeegtegg eeteetgg ggeggaegg 9840 geeaagaa ageeegga ggaegata aacgeeg aeegtggg eetgetggt eggggaegg 9840 geeaagaaa ageeegga ggaegata aacageeg aeegtggg eggeggag ggegataa 900 eeetaagaaa ageeegga gagaatae aacgeeg aaggeegga eeggeggg eeteet 960 eeetee acegeegg ggaagaate aacageeg aaggeegga eggeggg eegaaed 1020 eeetee acegeegg gaaagtee teeeagaa aggeegge eegagae 1020 eeetee aaggetta teeeagga gaagetge atgeegga gageagge eegagaeg 1200 eggagaaaa aeetaeaga eaceecg gtgetgga gtgegaag eataggeeg 1200	<400> SEQUENCE: 34	
gcaaggeet eeggetaaca etteeeggaate teeeggaag eeggetaat eegaeggaa eaagtaate teeeggaag eeggetaat eeggeeggaa eeggeeggaate teeegaagaa eeggeggaate teeegaagaa eeggeggaate eegaeggaa eeggeetaateee eegaeggaatee eegaegaetee eegaateee eegaateee eegaateee eegaateee eegaateee eegaateee eegaateee eegaegaetee eegaegaetee eegaateee eegaateee eegaateee eegaateee eegaateee eegaateee eegaateee eegaateee eegaegeee eegaateee eegaegeee eegaateee eegaegae eesaateee eegaegae eesaateee eegaegeee eesaateee eegaegeee eesaateee eegaegeee eesaateee eesaateeee eesaateeee eesaateee eesaateee eesaateeeesee eesaateee eesaateeee eesaateee eesaateeee eesaateee eesaateee eesaateeee eesaateeee eesaateeee eesaateeee eesaateee eesaateee eesaateeee eesaateeeee eesaateeeee eesaateeeeeee eesaateeeee eesaateeeeeeee eesaateeeeeee eesaeggeeeee eesaaa	atgggatgga gctatatcat cctctttttg gtagcaacag ctacagatgg ccactcccag	60
gacagggee tggagtggat gggegagate accectee ceggeaggae caactacaac 240 agaagttea agaacegggt gaceateae geegacaagt ecaecteeae egeetaagt 300 agetgteea acetgaggte egaggatee deegtagae egagggeee ateggtette 420 eeetggeae eteeceeag gggaeeggt tegtggaaet eaggegeeet gaeeagegge 540 tgeacaeet teeeggaee gggaeeggt tegtggaaet eaggegeeet gaeeagegge 540 eeetggeee teeeggetg eetaaegtee teeggaeet geaeggtggt 600 eeetggeee teeeggetg eetaaegtee teeggaeet geaeggtggt 600 eeetggeee teeeggetg gggeaeegg aceaaett geaaegtgaa teaeaagee 660 geaacaeea aggtggaeag agaegteg tegteggaeet geaeagegtggt 840 geaeaeea aggtggaea gaagttga eeetaatet geaaegtggt gggggaeggt 840 geeeeggae eeetaag teeeeggae eatggeget ggggaeegg aeeegggg gggeegteg 960 eeeggaea eeetagat eeetaggae aaeggeegg ageeggtg eaggegtgg agegegte 960 eeeggeeg accetegag geaegate aaeggeegg aeeggtggg gggeegte 960 eeegaagaa ageegggga ggaegataa aaeggeeg aeeggtggg eagegetee 960 eeegteet aceeggaee gegaaaeate teeeaagee eeegagae aaggeegee eeegaa 1020 eeeteega accetegag gaaaaeeta teeeaagee aaggeegee eeegagaaeaa 1020 eeeteega aeeeggae gaaaaeeta teeeaagee aggeegee eeegagae 1140 geetggtea aaggetteta teeeaggaa ategeegg ggtggaag eatagggeag 1200 eggagaaea aetaeaagae eacgeetee gtgetggae teegaegge ettetteete 1260 aaageeaag teeeegtga eaagaegg tggeageag gggeegte ettetteete 1260	ytgcagctgg tgcagtccgg cgccgaagtg aagaagcccg gctcctccgt gaagctgagc	120
agaagtta agaaccggg gacatcac geegacaag eecactcac egeetacat 300 agetgtee acetgagge gacacace geeggtata actgegeet eaggggata 360 ggggeeag geaceacet gacagtgte teegetgae eggegetgg etgetgget 420 ceetggea eeteeta gagaegtg tegtggaat eaggeeet gaceagege 540 tgeacacet teeeggetg eetaagtee teaggaetet acteetag eagetggg 600 eegtgeeet eageagetg gggeaccag acetacate geaegtgaa teacaagee 660 geaacacea aggtggacaa gaaagttga eecaaatet gtgaeaaaa teacaagee 720 eacegtgee eageaceta aceeggag ggaeegteag tetteett eegaggge 378 eecaaggaa aceteaggg ggaeegteag tetteett eegaggetg 984 geeacacaa ageegggg gagegtaa aacageegg acetgegg ggaeggtg ggtggaegt 984 geeacacaa ageegggg ggaeggta aagagtaea aggeggtga eggegggg ggtggaat 900 eeegtgeet aceaggaet geeggaate aacageeg acetgegg eeegge 984 geeacagaa ageegggg geeggaa aggagtaea aggeggtga eeggegtgg eeggegteg 984 eeegtgeeta eeeggaetg eeeggaate aacageeg acetgegg eeeggetge eeegaace eeegtgeeta aceeggaet geeggagta aaggagtaea agtgeaggt eeggegtga eeggegtee 960 eeegteeta aceeggaet geeggaatge aaggagtaea agtgeagge eeegaacea 1020 eeeteeta aaggetteta teeeggaa aggetgae aggeegtga gatgegagg 1200 eeggagaaca actacaaga eeegeette gtgetggaet eegaegget eetteetteeta 1260 aggtgtaa actacaaga eaegeette gtgetggaet eegaegget eetteetteeta 1220	tgcaaggeet eeggetacae etteteetee taetggatee aetgggtgag geaggeteet	180
agetgteca acetgaggte egaggaetee geegtgtaet actgegeete eaggggatat 360 ggggeeagg geaceaceet gaeagtgtee teegetagea egaagggeee ateggtette 420 ceetggeae eeteeteeteeteeteeteeteeteeteeteeteetee	ggacagggcc tggagtggat gggcgagatc aacceeteet eeggeaggae caaetaeaae	240
ggggccagg gcacacct gacagtgte teegetage eggecetage eggecetage ateggtet 420 ceetageae ceteteeaa gagacactt gggggcaca eggegecag eggegecetag etgeetage 440 aggactaet teecegaace ggggacggg tegtggaact caggegecet gacacgggg 540 tgeacacet teeeggegt etaeagtee teaggactet actoecteag 600 cegtggeet ceageaget gggacacae gaggtgaeag eactacatet geaacgtgga 600 ceaggaget ceageaget gggacacae actoecteag eacaagtee feaaagte 600 ceaggaget ceageaget gggacacae gaggtgaeag eacaatet geaacgtgga feaaagtee ggeacaccac aggtggacag gaactteegggg teaggactae teacaagtee feaaagteg feaaagteg gecaeggace eaggagata acteetaggg ggtacgtgg ggtacgteg feaaagteg feaaagtegg feaaagtegg ggeacaccaca aggtggacag gaacgtegg ggtacgteg teaggacgtegg ggtggacggg feaaagtegg feaaagtegg caacgtge cadgeaget cacaagteg ggtgacgtgg ggtggacggg ggtggacggg ggtggacggg feaaagtegg ggeacaccaa aggtggacag cacagtggg ggtggacggg ggtggacggg ggtggacggg ggtggacggg feaaagtegg caaggaca accetaggag caceteggag ggacgacga acggggggggggggg gggggggggggggggggggggggggggggggggggg	gagaagttca agaaccgggt gaccatcacc gccgacaagt ccacctccac cgcctacatg	300
cectggeae etcecteaa gageaeette gggggeaeag eggeeetggg etgeetggte 480 aggaetaet teeeggetg eetaeagtee teaggaetet aeteeteag eagegtggtg 600 eegtgeeet eeggegtg eetaeagtee teaggaetet aeteeteag eagegtggtg 600 geaaeaeea aggtggaeaa gaaagttgag eeeaaatett geaaegtgaa teaeaageee 660 geaaeaeea aggtggaeaa gaaagttgag eeeaaatett gtgaeaaaae teaeaageee 660 geaaeaeea aggtggaeaa gaaagttgag eeeaaatett gtgaeaaaae teaeaageee 720 eaeegtgee eageaeetg aeteetgggg ggaeegteag tetteetett eeeeaaaa 780 geeaegaea eeetagaat eteeegggg ggaeegteag tetteetett eeeeeaaaa 780 geeaegaea eeetagagt eaagtteaae teggaeegt ggtggaegtg ggtggaegtg 840 geeaegaeaa ageegegga ggageagtae aaeageegg aeeggetggt eagegteete 960 eegteete aeeggaeeg getgaatgge aaggagtaea agtgeaaggt eteeaaaaa 1020 eeeteeea aeeggaeeg geegaaaeea eaeggeegg aggeegteag teeesaaaa 1020 eeeteeea eeesaa eeesaaeae teeeaageea agagegaee eeggaaeea 1080 aggtgtaea eeetgeeee ateeeggaa aaggeegge aggeggaeg eagegeegg 1140 geetggtea aaggetteta teeeaggaa ategeeggg agtgggaag eaatgggeag 1200 eggagaaea aetaeaagae eaegeetee gtgetggaet eegaeggee etteetteete 1260 aeageaage teaeegtgga eaagageagg tggeageagg ggaacgtett eteatgetee 1320	gagetgteea acetgaggte egaggaetee geegtgtaet aetgegeete eaggggatat	360
aggactact teeeggace ggtgaeggtg tegtggaact eaggegeet gaeeagege 540 tgeaeaeet teeeggetg eetaeagtee teaggaetet acteeetag eagegtggtg 600 eegtgeeet eeggagetg gggeaeeegg acetaeatet geaaegtgaa teaeaageee 660 geaaeaeea aggtggaeaa gaaagttgag eeeaaatett gtgaeaaaae teaeaatge 720 eaeegtgee eageaeetga acteetgggg ggaeegteag tetteettet eeeeaaa 780 eeaaggaea eeetaagat eteeegggg ggaeegteag tetteettet eeeeaaaa 780 geeaegaag aceetgaggt eaagtteaa tggtaegtgg aeggegtgg ggtggaegtg 840 geeaegaaa ageegeggga ggageagtae aaeageaegt aeegtggg ggtggaegtg 840 eeeaagaeaa ageegeggga ggageagtae aaeageaegt aeegtggg eggegteet 960 eeegteetge aceaggaetg getgaatgge aaggagtaea agtgeeaaggt eteeaaeaa 1020 eeetgeeega eeesgaaetg getgaatgge gagetgaeea agageegge eaggeeggg 1140 geetggtea aaggetteta teeeagega ategeeggg agtggaagg eaatgggeag 1200 eggagaaea actaeaagae eacgeetee gtgetggaet eegaeggete ettetteete 1260 aeageaage teaeegtgga eaagageagg tggeageagg ggaaegtett eteatgetee 1320	tggggccagg gcaccaccct gacagtgtcc tccgctagca cgaagggccc atcggtcttc	420
tgeacacet teeeggetgi octacagtee teaggaetet acteeteag eagegtggtg 600 eegtgeeet eageagett gggeaceeag acetacatet geaaegtgaa teaeaageee 660 geaacacea aggtggaeaa gaaagttgag eeeaaatett gtgaeaaaae teaeaageee 720 eaeegtgee eageaeetga aceeegggg ggaeegteag tetteetett eeeceaaaa 780 eeaaggaea eeeteagagt eaagtteaae tggtaegtgg aeggegtggt ggtggaegtg 840 geeaaggaea eeeteagagt eaagtteaae tggtaegtgg aeggegtgga ggtggaegtg 840 geeaagaaa ageegggga ggaeegtea eatgegtgg aeggegtgga ggtgeataat 900 eeegteetge aceaggaetg getgaatgge aaggagtaea aaeageaegt acegtgtggt eagegteete 960 eegteetge aceaggaetg getgaatgge aaggagtaea agtgeaaggt eteeaaaaa 1020 eeeteeeg eeeeeaa aaeageeeg aaggagtaea aggageagee eegagaaeea 1080 aggtgtaea eeetgeeee ateeeggaa gagetgaeea agaaeeaggt eageetgtgg 1140 geetggtea aaggetteta teeeagega ategeeggg agtgggagag eaatgggeag 1200 eggagaaea actaeaagae eaegeetee gtgetggaet eegaeggete ettetteete 1260 aeageeage teaeegtgga eaagageagg tggeageagg ggaaegtett eteatgetee 1320	cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc	480
ccgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc 660 gcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcacacatgc 720 caccgtgcc cagcacctga actcctgggg ggaccgtcag tcttcctctt ccccccaaaa 780 ccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg 840 gccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat 900 ccaaggacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc 960 ccgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020 ccctccccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080 aggtgtaca ccctgcccc atcccgggat gagctgacca agaaccaggt cagcctgtgg 1140 gcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200 cggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc 1260 acagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320	aaggactact teeeegaace ggtgaeggtg tegtggaaet eaggegeeet gaeeagegge	540
gcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcaccatgc 720 caccgtgcc cagcacctga actoctgggg ggaccgtcag totteetett ecececaaaa 780 ccaaggaca coeteatgat eteeceggace eetgaggtea eatgegtggt ggtggacgtg 840 gecacgaag aceetgaggt eaagtteaae tggtaegtgg aeggegtgga ggtgeataat 900 eceaagacaa ageegeggga ggageagtae aacageaegt acegtgtggt eagegteete 960 eegteetge aceaggaetg getgaatgge aaggagtaea agtgeaaggt eteeaaeaa 1020 eeeteeeg eeeeeega gaaaaceate teeaaageea agtgeaaggt eteeaaeaa 1020 eeeteeega eeeega gaaaaceate teeaaageea aagggeagee eegagaacea 1080 aggtgtaea eeetgeeee ateeeggaa gagetgaeea agaaceaggt eageetgtgg 1140 geetggtea aaggetteta teeeagegaa ategeegtgg agtggaagg eaatgggeag 1200 eeggagaaca actaeaagae eaegeeteee gtgetggaet eegaeggete ettetteete 1260 acageeage teaeegtgga eaagageagg tggeageagg ggaaegtett eteatgetee 1320	gtgcacacct teeeggetgt eetacagtee teaggaetet acteeeteag eagegtggtg	600
caccgtgcccagcacctgaactectggggggaccgtcagtettectettcececcaaaa780ccaaggacacectcatgateteecggacecetgaggtcacatgegtggtggtggacgtg840gecaegaagaccetgaggtcaagtteaatggtaegtggacggegtggaggtgcataat900ccaaggacaageegegggaggageagtaeaacageaegtacegtgtggtcagegteete960ccgteetegaccaggactggetgaatggeaaggagtaeaagtgcaaggtctecaaaaaa1020cecteetegaccetgeeteggaaaaccatetecaaageeaagagetgggcageetgggg1140geetggteaaaggettetateceaggaagagtgetggaeggatgggaggg1200eggagaacaactacaagaacacgeetegegtgetggaetcegaeggete1260acagcaageteacegtggatggeageaggtettettettettettettettettettettettettet	accgtgccct ccagcagctt gggcacccag acctacatct gcaacgtgaa tcacaagccc	660
ccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg 840 gccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat 900 ccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc 960 ccgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020 ccctcccag ccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080 aggtgtaca ccctgcccc atccgggat gagctgatca agtgcaggt cagcgtgtgg 1140 gcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200 cggagaaca actacaagac cacgcctcc gtgctggact ccgacggctc cttcttcctc 1260 acagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320	agcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcacacatgc	720
gccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat 900 ccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtctc 960 ccgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020 ccctcccag ccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080 aggtgtaca ccctgcccc atcccgggat gagctgacca agaaccaggt cagcctgtgg 1140 gcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200 cggagaaca actacaagac cacgcctcc gtgctggact ccgacggctc cttcttcctc 1260 acagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320	ccaccgtgcc cagcacctga actectgggg ggaccgteag tetteetett ecceccaaaa	780
ccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtctc 960 ccgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020 ccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080 aggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgtgg 1140 gcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200 cggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc 1260 acagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320	cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg	840
ccgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa 1020 ccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca 1080 aggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgtgg 1140 gcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag 1200 cggagaaca actacaagac cacgcctccc gtgctggact ccgacggctc cttcttcctc 1260 acagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc 1320	agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat	900
coctoccag cocccatega gaaaaccate tecaaageea aagggeagee eegagaacea 1080 aggtgtaca eeetgeeee ateeeggat gagetgacea agaaccaggt eageetgtgg 1140 geetggtea aaggetteta teeeagegae ategeegtgg agtgggagag eaatgggeag 1200 eggagaaca actacaagae eaegeeteee gtgetggaet eegaeggete ettetteete 1260 acageeage teaeegtgga eaagageagg tggeageagg ggaaegtett eteatgetee 1320	gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc	960
aggtgtaca cootgococo atocogggat gagotgacoa agaacoaggt cagootgtgg 1140 gootggtoa aaggottota tocoagogac atogoogtgg agtgggagag caatgggoag 1200 oggagaaca actacaagac caegootoco gtgotggact cogaoggoto ottottooto 1260 acagoaago toacogtgga caagagcagg tggoagcagg ggaacgtott otoatgotoo 1320	accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa	1020
gcetggtea aaggetteta teecagegae ategeegtgg agtgggagag caatgggeag 1200 eggagaaca aetaeaagae caegeeteee gtgetggaet eegaeggete ettetteete 1260 acageaage teacegtgga caagageagg tggeageagg ggaaegtett eteatgetee 1320	gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca	1080
cggagaaca actacaagac cacgceteee gtgetggaet eegaeggete ettetteete 1260 acageaage teacegtgga caagageagg tggeageagg ggaaegtett eteatgetee 1320	caggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgtgg	1140
acagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtett etcatgetee 1320	tgeetggtea aaggetteta teecagegae ategeegtgg agtgggagag caatgggeag	1200
	coggagaaca actacaagac cacgceteee gtgetggaet eegaeggete ettetteete	1260
tgatgcatg aggetetgea caaceaetae aegeagaaga geeteteeet gteteegggt 1380	tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtctt ctcatgctcc	1320
	gtgatgcatg aggetetgea caaceactae acgeaqaaga geeteteeet gteteegggt	1380

aaatag	1386
<210> SEQ ID NO 35 <211> LENGTH: 1386 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: humanized VH+CH1+CH2+CH3-cl04H08, knob mutation, (nucleotides)	
<400> SEQUENCE: 35	
atgggatgga gctatatcat cctctttttg gtagcaacag ctacagatgg ccactcccag	60
gtgcagctgc agcagcctgg agccgaggtg aagaagcccg gctcctccgt gaagctgtcc	120
tgcaaggeet eeggetacae etteacetee taetggatee aetgggtgaa geaggeeeet	180
ggacagggcc tggagtggat cggcgagatc aacccctcct ccggcaggac caactacaac	240
gagaagttca agaacaaggt gaccatcacc gtggacaagt ccacctccac cgcctacatg	300
gagetgteet eeetgaggte egaggacaee geegtgtaet aetgtgeete eaggggetat	360
tggggccagg gcacaaccgt gaccgtgtcc tccgctagca cgaagggccc atcggtcttc	420
cccctggcac cctcctccaa gagcacctct gggggcacag cggccctggg ctgcctggtc	480
aaggactact teecegaace ggtgaeggtg tegtggaaet eaggegeeet gaecagegge	540
gtgcacacct teeeggetgt ectacagtee teaggaetet acteeeteag eagegtggtg	600
accgtgccct ccagcagett gggcacccag acctacatet gcaacgtgaa teacaageee	660
agcaacacca aggtggacaa gaaagttgag cccaaatctt gtgacaaaac tcacacatgc	720
ccaccgtgcc cagcacctga actectgggg ggacegteag tetteetett ecceecaaaa	780
cccaaggaca ccctcatgat ctcccggacc cctgaggtca catgcgtggt ggtggacgtg	840
agccacgaag accctgaggt caagttcaac tggtacgtgg acggcgtgga ggtgcataat	900
gccaagacaa agccgcggga ggagcagtac aacagcacgt accgtgtggt cagcgtcctc	960
accgtcctgc accaggactg gctgaatggc aaggagtaca agtgcaaggt ctccaacaaa	1020
gccctcccag cccccatcga gaaaaccatc tccaaagcca aagggcagcc ccgagaacca	1080
caggtgtaca ccctgccccc atcccgggat gagctgacca agaaccaggt cagcctgtgg	1140
tgcctggtca aaggcttcta tcccagcgac atcgccgtgg agtgggagag caatgggcag	1200
ccggagaaca actacaagac cacgceteee gtgetggaet eegaeggete ettetteete	1260
tacagcaagc tcaccgtgga caagagcagg tggcagcagg ggaacgtott ctcatgotcc	1320
gtgatgcatg aggetetgea caaceaetae aegeagaaga geeteteeet gteteegggt	1380
aaatag	1386
<210> SEQ ID NO 36 <211> LENGTH: 1386 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: chimeric VH+CH1+CH2+CH3, knob mutation, (nucleotides)	
<400> SEQUENCE: 36	
atgggatgga gctatatcat cctcttttg gtagcaacag ctacagatgg ccactcccag	60
gtccaactgc aacagcctgg gactgaactg gtgaagcctg gggcttcagt gaagctgtcc	120

tgcaaggctt c	ctggctacac	cttcaccagt	tactggatac	actgggtgaa	gcagaggcct	180
ggacaaggcc t	tgagtggat	tggagagatt	aatcctagca	gcggtcgtac	taactacaac	240
gagaaattca a	agaacaaggt	cacagtgact	gtagacaaat	cttccaccac	agcctacatg	300
caactcagca a	acctgacatc	tgaggactct	gcggtctatt	actgtgcaag	taggggctac	360
tggggccaag g	gcaccactct	cacagtctcc	tcagctagca	cgaagggccc	atcggtcttc	420
cccctggcac c	cctcctccaa	gagcacctct	gggggcacag	cggccctggg	ctgcctggtc	480
aaggactact t	ccccgaacc	ggtgacggtg	tcgtggaact	caggcgccct	gaccagcggc	540
gtgcacacct t	cccggctgt	cctacagtcc	tcaggactct	actccctcag	cagcgtggtg	600
accgtgccct c	ccagcagctt	gggcacccag	acctacatct	gcaacgtgaa	tcacaagccc	660
agcaacacca a	aggtggacaa	gaaagttgag	cccaaatctt	gtgacaaaac	tcacacatgc	720
ccaccgtgcc c	cagcacctga	actcctgggg	ggaccgtcag	tcttcctctt	ccccccaaaa	780
cccaaggaca c	ccctcatgat	ctcccggacc	cctgaggtca	catgcgtggt	ggtggacgtg	840
agccacgaag a	accctgaggt	caagttcaac	tggtacgtgg	acggcgtgga	ggtgcataat	900
gccaagacaa a	agccgcggga	ggagcagtac	aacagcacgt	accgtgtggt	cagcgtcctc	960
accgtcctgc a	accaggactg	gctgaatggc	aaggagtaca	agtgcaaggt	ctccaacaaa	1020
geceteccag c	cccccatcga	gaaaaccatc	tccaaagcca	aagggcagcc	ccgagaacca	1080
caggtgtaca c	ccetgeccec	atcccgggat	gagctgacca	agaaccaggt	cagcctgtgg	1140
tgcctggtca a	aaggetteta	tcccagcgac	atcgccgtgg	agtgggagag	caatgggcag	1200
ccggagaaca a	actacaagac	cacgcctccc	gtgctggact	ccgacggctc	cttcttcctc	1260
tacagcaagc t	caccgtgga	caagagcagg	tggcagcagg	ggaacgtctt	ctcatgctcc	1320
gtgatgcatg a	aggctctgca	caaccactac	acgcagaaga	gcctctccct	gtctccgggt	1380
aaatag						1386
<pre><210> SEQ II <211> LENGTH <212> TYPE: <213> ORGANI <220> FEATUF <223> OTHER <400> SEQUEN</pre>	H: 741 DNA ISM: artifi RE: INFORMATIC		H2+CH3, Hold	e mutations,	, (nucleotić	les)
atgggatgga g		catatttta	atagaagaa	ateaaetaa	ccactoccac	60
aaaactcaca c	-	-			-	120
ctcttccccc c	-		-			120
gtggtggtgg a						240
gtggaggtgc a						300
						360
gtggtcagcg t						
aaggtctcca a						420
cagccccgag a						480
caggtcagcc t	cgagttgege	ggtcaaaggc	ttctatccca	gcgacatcgc	cgtggagtgg	540
gagagcaatg g	ggcagccgga	gaacaactac	aagaccacgc	ctcccgtgct	ggactccgac	600
			******	agagatagaa	gcaggggaac	660

gtetteteat geteegtgat geatgagget etgeacaaee actaeaegea gaagageete	720
tccctgtctc cgggtaaata g	741
<210> SEQ ID NO 38 <211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: His-TAG (nucleotide)	
<400> SEQUENCE: 38	
caccatcacc atcaccat	18
<210> SEQ ID NO 39 <211> LENGTH: 6 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: His-TAG	
<400> SEQUENCE: 39	
His His His His His 1 5	
<pre><210> SEQ ID NO 40 <211> LENGTH: 108 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Strep-TAG (nucleotide)</pre>	
<400> SEQUENCE: 40	
ggtgccgcat ggagccaccc ccagttcgaa aaaggggccg catggagcca cccccagttc	60
gaaaaagggg ccgcatggag ccacccccag ttcgaaaaag gggccgca	108
<210> SEQ ID NO 41 <211> LENGTH: 36 <212> TYPE: PRT <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: Strep-TAG	
<400> SEQUENCE: 41	
Gly Ala Ala Trp Ser His Pro Gln Phe Glu Lys Gly Ala Ala Trp Ser 1 5 10 15	
His Pro Gln Phe Glu Lys Gly Ala Ala Trp Ser His Pro Gln Phe Glu 20 25 30	
Lys Gly Ala Ala 35	
<210> SEQ ID NO 42 <211> LENGTH: 39 <212> TYPE: DNA <213> ORGANISM: artificial <220> FEATURE: <223> OTHER INFORMATION: K842E sense nucleotide	
<400> SEQUENCE: 42	
gtacataatc ctgtgtttga gccttttgaa aagccagtg	39

210> SEQ ID NO 43		
211> LENGTH: 39		
212> TYPE: DNA		
213> ORGANISM: artificial		
220> FEATURE:		
223> OTHER INFORMATION: K842E antisense nucleotide		
400> SEQUENCE: 43		
actqqcttt tcaaaaqqct caaacacaqq attatqtac	39	
actygette teaaaayyet taaacacayy attatytat	39	

1. An anti-Met antibody fragment comprising a single antigen binding arm and an Fc region (that increases stability of said antibody fragment compared to a Fab molecule comprising said antigen binding arm), wherein the Fc region comprises a complex of a first and a second Fc polypeptide, wherein the antibody fragment comprises:

- (i) a first polypeptide comprising one humanized light chain variable (VL) domain, and one human light chain constant (CL) domain, wherein the humanized VL domain is fused to the human CL domain in the N- to C-term direction, and wherein the humanized VL domain contains three complementary determining regions (CDRs) having amino acid sequences as set forth in SEQ ID No.: 1, 2 and 3, and wherein the humanized VL domain has an amino acid sequence as set forth in SEQ ID No.: 7;
- (ii) a second polypeptide comprising one humanized heavy chain variable (VH) domain, one human heavy chain constant CH1 domain and the first Fc polypeptide, wherein the first Fc polypeptide comprises one hinge region, one human constant CH2 domain and one human CH3 constant domain, wherein the humanized VH domain is fused to the human CH1 domain, that is fused to the human hinge region, that is fused to the human CH2 domain, that is fused to the human CH3 domain in the N- to C-term direction, and wherein the humanized VH domain contains three complementary determining regions (CDRs) having amino acid sequences as set forth in SEQ ID No.: 4, 5 and 6, and wherein the humanized VH domain has an amino acid sequence as set forth in SEQ ID No.: 8; and
- (iii) a third polypeptide comprising the second human Fc polypeptide, wherein the second human Fc polypeptide comprises one human hinge region, one human constant CH2 domain and one human CH3 constant domain, wherein the human hinge region is fused to the CH2 domain that is fused to the human CH3 domain in the N- to C-term direction, wherein the human hinge region is truncated at the N-terminus.

2. The anti-Met antibody fragment according to claim **1**, wherein the human CL domain is a human light kappa type domain.

3. The anti-Met antibody fragment according to claim **1**, wherein the human hinge region and the human constant domains CH1, CH2 and CH3 are from a human IgG1.

4. The anti-Met antibody fragment according to claim **1**, wherein the two Fc polypeptides are linked through intermolecular disulfide bonds at the hinge region.

5. The anti-Met antibody fragment according to claim **1**, wherein the first Fc polypeptide and the second Fc polypeptide meet at an interface, and one between the first and the

second Fc polypeptide comprises a knob at the interface, and the other between the first and the second Fc polypeptide comprises a hole at the interface, wherein the knob is positionable into the hole.

6. The anti-Met antibody fragment according to claim **5**, wherein one between the first and the second Fc polypeptide comprises a mutated CH3 constant domain, wherein the mutated CH3 constant domain carries an amino acid mutation at position 389, wherein the original amino acid at position 389 has been mutated to import an amino acid having a larger side chain volume than the original amino acid; and wherein the other between the first and the second Fc polypeptide comprises a mutated CH3 constant domain, wherein the mutated CH3 constant domain, wherein the mutated CH3 constant domain, wherein the mutated CH3 constant domain carries three amino acid mutations at positions 389, 391 and 438, wherein the original amino acids have been mutated to import amino acids, wherein the amino acid numbering is according to the EU numbering scheme of Kabat.

7. The anti-Met antibody fragment according to claim 6, wherein the original amino acids at positions 389, 391 and 438 are threenine, leucine and tyrosine respectively; and wherein in one between the first and the second Fc polypeptide the threenine in position 389 has been mutated to tryptophan; and wherein in the other between the first and the second Fc polypeptide the threenine at position 389 has been mutated to serine, the leucine at position 391 has been mutated to alanine and the tyrosine at position 438 has been mutated to valine.

8. The anti-Met fragment according to claim **1**, wherein the human CL domain has an amino acid sequence as set forth in SEQ ID No.: 9 and the human CH1 domain has an amino acid sequence as set forth in SEQ ID No.: 10.

9. The anti-Met antibody fragment according to claim **1**, wherein the first human Fc polypeptide has an amino acid sequence as set forth in SEQ ID No.: 11, and the second human Fc polypeptide has an amino acid sequence as set forth in SEQ ID No.: 12.

10. The anti-Met antibody fragment according to claim **1**, wherein the anti-Met antibody fragment when bound to Met induces shedding of an extracellular domain of Met.

11. Isolated nucleic acid encoding the anti-Met antibody fragment of claim **1**.

12. A composition comprising two or more recombinant nucleic acids which collectively encode the anti-Met antibody fragment of claim **1**.

13. A product comprising, in a single bottle or in two bottles, (a) an anti-Met antibody fragment according to claim **1**, and a pharmaceutically acceptable vehicle, and (b) an extracellular portion of human Met and a pharmaceutically acceptable vehicle, wherein the extracellular portion of human Met is capable of binding to Hepatocyte Growth

Factor (HGF) in a stable manner and contains at least one amino acid mutation within the epitope recognized by the anti-Met antibody fragment to prevent binding of the anti-Met antibody fragment thereto.

14. The product according to claim 13, wherein the extracellular portion of human Met contains SEMA, PSI, IPT-1, IPT-2, IPT-3 and IPT-4 domains.

15. The product according to claim **13**, wherein the extracellular portion of human Met has an amino acid sequence as set forth in SEQ ID No.: 13, wherein at least one of the amino acids between position 797 and position 875 of SEQ ID No.: 13 is mutated in order to prevent binding of the anti-Met antibody fragment thereto.

16. The product according to claim 13, wherein the extracellular portion of human Met has an amino acid sequence as set forth in SEQ ID No.: 14.

17. A method for treatment of a patient suffering from a tumor and/or metastasis, comprising administering to the patient in need thereof an anti-Met antibody fragment according to claim 1, wherein the patient carries genetic alterations of the MET gene.

18. A method for treatment of a patient suffering from a tumor and/or metastasis, comprising administering to the patient in need thereof an product according to claim **13**, wherein the patient carries a wild-type MET gene.

19. Process for the manufacturing of an anti-Met antibody fragment according to claim **1**, the process comprising the following steps: (i) synthesis of cDNA sequences of the first, second and third polypeptides constituting the anti-Met antibody fragment, (ii) insertion of the three cDNA sequences into one or more plasmids, wherein the plasmid (s) is(are) suitable for expression in a mammalian cell line, (iii) transient or stable co-transfection of a mammalian cell line with the plasmid(s), (iv) collection of the culture supernatant, (v) purification by affinity chromatography of the anti-Met antibody fragment.

20. A method for treatment of a patient suffering from a tumor and/or metastasis, comprising administering to the patient in need thereof a product according to claim **13**, wherein the patient carries genetic alterations of the MET gene.

* * * * *